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Alzheimer’s disease (AD) is the major cause of dementia among patients 
over the age of 65, aecting around 50 million people worldwide 18% of 
persons above the age of 65 and approximately 25% of persons above the 
age of 85 will develop AD. In the Netherlands 280.000 patients currently 
suer from dementia and the number is expected to double in 2040. 
Dementia is the most expensive chronic disease costing our society
annually approximately 9 billion euros, which accounts for 9.5% of our total 
health costs. 70% of patients with dementia live at home with help from 
their caregivers. More than 50% of caregivers experience stress or are at 
increased risk to experience stress in the future. At present, there is no 
cure available. Results of clinical trials in AD dementia patients have been 
disappointing. This is, at least in part, due to the fact that treatment of AD
at the dementia stage is too late. Disease modifying therapy is probably 
most eective when given early in the course of the disease when neuro-
degeneration and cognitive impairment are limited. 
In the past years major advancements have been made in the develop-
ment of AD biomarkers that can be used to assess the key pathologies of 
AD in-vivo. These biomarkers will have a major impact on clinical practice 
and the design of trials for disease modifying treatments.  In this thesis we 
will investigate the implications of the availability of AD biomarkers for the 
design of AD prevention trials and management in clinical practice. Our 
focus is on the role of biomarkers in the diagnosis, prognosis, and disease 
tracking of non-demented subjects. 
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La vida no es la que uno vivió, sino la que uno recuerda, y cómo la recuerda para 
contarla. 
Gabriel García Márquez.
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Introduction
Alzheimer’s disease (AD) is the major cause of dementia among patients over the age 
of 65, affecting around 50 million people worldwide, 8% of persons above the age 
of 65 and approximately 25% of persons above the age of 85 will develop AD [1]. In 
the Netherlands 280.000 patients currently suffer from dementia and the number is 
expected to double in 2040. Dementia is the most expensive chronic disease costing 
our society annually approximately 9 billion euros, which accounts for 9.5% of our 
total health costs. 70% of patients with dementia live at home with help from their 
caregivers. More than 50% of caregivers experience stress or are at increased risk to 
experience stress in the future [2]. At present, there is no cure available. Results of 
clinical trials in AD dementia patients have been disappointing. This is, at least in part, 
due to the fact that treatment of AD at the dementia stage is too late. Disease modifying 
therapy is probably most effective when given early in the course of the disease when 
neurodegeneration and cognitive impairment are limited.
In the past years major advancements have been made in the development of 
AD biomarkers that can be used to assess the key pathologies of AD in-vivo. These 
biomarkers will have a major impact on clinical practice and the design of trials for 
disease modifying treatments. In this thesis we will investigate the implications of the 
availability of AD biomarkers for the design of AD prevention trials and management 
in clinical practice. Our focus is on the role of biomarkers in the diagnosis, prognosis, 
and disease tracking of non-demented patients.
Alzheimer’s disease, AD pathology and biomarkers
AD is a neurodegenerative disease with a gradual onset and progression of cognitive 
deficits, ultimately leading to dementia. Memory impairment is the most common 
feature of AD, but AD can also have a non-amnestic presentation with language, 
visuospatial or executive dysfunction [3]. AD is sporadic in the majority of cases. 
The most common and most studied risk factors for sporadic AD are older age and 
APOE-ε4 genotype [4-7]. In 1% of cases AD is the result of a genetic mutation in the 
amyloid precursor protein (APP), presiniline 1 or presiniline 2 (PSEN 1 or PSEN2) [8-
CHAPTER 1
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10]. Neuropathological hallmarks of AD include extracellular deposits of amyloid 
(senile plaques) and intracellular accumulation of tau (neurofibrillary tangles) [11,12]. 
Pathophysiologically, AD is hypothesized to be initiated by abnormal amyloid processing, 
followed by neuronal dysfunction and structural brain changes, which ultimately lead 
to cognitive impairment and dementia (see figure 1) [13,14]. These pathophysiological 
changes are thought to be present many years before clinical symptoms of disease 
emerge and can be measured in vivo with biomarkers [15,16]. Biomarkers for AD can 
be subdivided into markers that measure abnormal amyloid processing and biomarkers 
that measure downstream neurodegeneration. Abnormal amyloid can be measured in 
cerebrospinal fluid (CSF) or on positron emission tomography (PET). The best-studied 
markers for neurodegerenation are tau in CSF, hypometabolism on fludeoxyglucose 
PET (FDG PET) and atrophy on structural brain scans.
Figure 1: hypothetical cascade of biomarkers in Alzheimer’s disease
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With the use of these biomarkers the diagnosis of AD moved from a clinicopathological 
diagnosis to a clinicobiological diagnosis and enabled researchers to study AD from the 
asymptomatic to the most severe stages of dementia in vivo. These biomarkers are mainly 
intended for research purposes but are also increasingly used in clinical practice [17].
Treatment of AD
Currently only cholinesterase inhibitors are available for the treatment of AD- dementia. 
These drugs relieve symptoms but do not stop the underlying disease process. Given 
the central role of amyloid aggregation in the disease, novel treatments mainly focus on 
preventing or clearing amyloid aggregates in the brain [18,19]. As amyloid aggregation 
is present many years before dementia onset these treatments may be most effective 
in non-demented patients. For clinical trials to be successful it is crucial to identify 
the appropriate population of non-demented patients with underlying AD such that 
progression to dementia can be prevented. Also, outcome measures are necessary 
to measure the effect of treatment. While trials in demented patients used cognitive 
function as an outcome, this is less useful in non-demented patients because decline 
in cognition is slow [20]. This complicates clinical trials as large sample sizes or a long 
follow up are needed to demonstrate effects. Biomarkers may facilitate trial design in 
two ways. First, biomarkers can be used to select non-demented patients with evidence 
of AD pathology. Second, they may be good surrogate markers for disease progression 
and therefore can be used as outcome measure.
Biomarkers in novel AD research criteria
The availability of amyloid and neuronal injury markers has led to the development of 
two sets of research criteria for AD that can be used for selection of patients in trials, 
one by an International Working Group (IWG) and one by National Institute on Aging-
Alzheimer’s Association (NIA-AA). Both include biomarkers and can also be used to 
diagnose AD in non-demented patients. According to the research criteria AD can be 
subdivided into three stages; 1) an asymptomatic or preclinical stage, 2) a stage of mild 
cognitive impairment (prodromal AD or MCI due to AD), and 3) a dementia stage (AD 
dementia or dementia due to AD)[3,21-24] (figure 2). The International working group-
2 (IWG-2) criteria use a single set of criteria to classify patients in the MCI or dementia 
stage. It requires evidence of abnormal amyloid pathology on PET or a combination 
of abnormal amyloid beta and abnormal tau in CSF (figure 3). With these criteria AD 
pathophysiological markers are indicators of AD pathology rather than markers linked to 
disease stages [21]. The NIA-AA criteria proposed three distinct sets of criteria for AD, one 
1
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for individuals with preclinical AD, one for MCI due to AD, and one for dementia due to AD 
[3,23,25]. These sets of criteria make a hierarchical distinction between amyloidosis and 
neurodegeneration markers. Based on the biomarker hierarchy, individuals with preclinical 
AD, can be subdivided into one of three stages. Stage 1 is characterized by individuals 
with normal cognition and signs of amyloidosis. At stage 2 neurodegeneration is also 
present. At stage 3 individuals have a combination of amyloidosis, neurodegeneration 
and subjective cognitive decline (SCD), but do not meet the clinical criteria for MCI (figure 
2). Hypothesized is that individuals at stage 3 have a higher risk to convert to MCI or 
AD, compared to stage 2 and stage 2 individuals have an increased conversion risk 
compared to stage 1 individuals [26]. Later, two additional categories were proposed to 
the NIA-AA criteria for preclinical AD; stage 0 in cognitively normal individuals without 
signs of amyloidosis or neurodegeneration, and suspected non-Alzheimer pathology 
(SNAP) in individuals with neurodegeneration without amyloidosis [27].
The criteria for MCI due to AD and dementia due to AD require evidence for the 
presence of abnormal amyloid and neuronal injury markers to diagnose AD with high 
likelihood. If only amyloid or injury markers are measured, AD can be diagnosed with 
intermediate likelihood. The presence of an abnormal amyloid marker with a normal 
neuronal injury marker or a normal amyloid marker with an abnormal neuronal injury 
marker is considered uninformative (figure 4).
Figure 2: AD stages according to the IWG-2 and NIA-AA criteria as published by Visser et al.24
AD stages Prepathology AD Asymptomatic AD Symptomatic AD
SCD MCI Dementia
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Figure 4: : NIA-AA criteria for MCI and dementia due to AD with likelihood estimate according to 
biomarkers 3,23
Amyloid marker abnormal Injury marker abnormal
High likelihood + +




Use of biomarkers in trial design and clinical practice
While biomarkers have found their way into novel research criteria there are a number 
of major challenges that need to be addressed in order to better understand the role 
of biomarkers in trial design and clinical practice. For instance, the pattern of disease 
progression in each stage of AD is not fully understood yet. Also, the definition of 
abnormal amyloid is not clear and it is poorly understood how combinations of different 
biomarkers of the research criteria influence outcome. Finally, it is unknown whether 
clinicians perceive the research criteria as useful for clinical practice.
Thesis outline
The aim of this thesis was to investigate the use of biomarkers in non-demented AD 
patients for trial design and clinical practice. The thesis has two main topics. First, we will 
investigate the pattern of disease progression and the assessment of AD biomarkers. 
Second, we will study the use of AD biomarkers for clinical trials and will assess how 
clinicians perceive the use of biomarkers in clinical practice.
I. Course of AD and assessment of amyloid biomarkers
In this part we will answer the following questions.
· What is the temporal evolution of biomarkers in different stages of AD?
· Are amyloid levels within the normal range predictive for cognitive decline?
· How can the cutoff for beta amyloid 1-42 (aß1-42) in CSF be determined?
First, in chapter 2.1 we investigated biomarker and cognitive changes in the 
asymptomatic stage, MCI stage and dementia stage of AD. We also investigated whether 
these changes differed from patients with normal cognition, MCI or dementia without 
AD pathology. In chapter 2.2 we assessed the predictive value of normal CSF aß1-42 
1
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levels for future prodromal AD or AD-type dementia. In chapter 2.3 we defined a cutoff 
for CSF aß1-42 with the use of Gaussian mixture modelling and investigated whether 
cutoff was dependent of different factors.
II. Use of AD biomarkers for clinical trials and clinical practice.
In the second part we will answer the following questions.
· How have biomarkers been used in clinical trials for inclusion and as outcome 
measure?
· How does the definition of AD, based on different combinations of AD biomarkers, 
influence outcome and impact sample size estimates for trials?
· How do clinicians perceive the clinical utility of the MCI concept and the novel 
research criteria based on AD biomarkers in clinical practice?
In chapter 3.1 we reviewed how AD biomarkers have been used to select non-demented 
patients for AD trials and as outcome measure. In chapter 3.2 we studied whether 
changes in outcome measures depend on the inclusion criteria used for preclinical and 
prodromal AD. To study the effects of different combinations of inclusion criteria and 
outcome measures on trial design, we calculated sample size for a hypothetical 3-year 
placebo-controlled trial in patients at the pre-dementia AD stage. In chapter 3.3 we 
assessed the view of European clinicians towards the use of the clinical concept of MCI 
and of the novel research criteria for prodromal AD or MCI due to AD in clinical practice.
In the last chapter of this thesis we give a summary of our main findings and answer 
the questions described above. We discuss methodological issues and provide 
recommendations for use of biomarkers in trials and clinical practice and for future 
research.
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PART I
COURSE OF AD AND ASSESSMENT 
OF AMYLOID BIOMARKERS
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CHAPTER 2.1
TEMPORAL EVOLUTION OF 
BIOMARKERS AND COGNITIVE 
MARKERS IN THE ASYMPTOMATIC, 
MCI AND DEMENTIA STAGE OF 
ALZHEIMER’S DISEASE
Daniela Bertens, Dirk L. Knol, Philip Scheltens, Pieter Jelle Visser for the 
Alzheimer’s Disease Neuroimaging Initiative.
Alzheimer’s and Dementia 2015 May; 11(5): 511-522
Abstract
Background: We investigated the pattern of disease progression in the 
asymptomatic, mild cognitive impairment (MCI) and dementia stage of 
Alzheimer’s Disease (AD).
Methods: We selected 284 subjects with AD pathology, defined as abnormal 
levels of amyloid beta 1-42 (Aß1-42) in cerebrospinal fluid (CSF). Disease 
outcome measures included six biomarkers and five cognitive markers. We 
compared differences in baseline measures and decline over 4 years between 
the AD stages and tested whether these changes differed from subjects, 
without AD pathology (N=132).
Results: CSF Aß1-42 reached the maximum abnormality level in the 
asymptomatic stage and tau in the MCI stage. The imaging and cognitive 
markers started to decline in the asymptomatic stage, and decline accelerated 
with advancing clinical stage.
Conclusion: This study provides further evidence for a temporal evolution 
of AD biomarkers. Our findings may be helpful to determine stage specific 
outcome measures for clinical trials.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease, hypothesized to be initiated 
by abnormal amyloid processing, followed by neuronal dysfunction and structural brain 
changes which ultimately lead to cognitive impairment and dementia [1]. According 
to the new NIA-AA/IWG research criteria, AD can be subdivided in three stages: an 
asymptomatic or preclinical stage, a stage of mild cognitive impairment (MCI) and the 
dementia stage [2-4]. The pattern of disease progression in each of these stages is not 
fully understood yet. This limits trial design, in particular in the predementia stage where 
intervention is believed to be most effective because neuronal injury and cognitive 
impairment are still limited. The aim of the present study is to investigate biomarker and 
cognitive changes in the asymptomatic stage, MCI stage and dementia stage of AD. We 
also investigated whether these changes differed from subjects with normal cognition, 
MCI or dementia but without AD pathology. We selected subjects from Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) with AD pathology, defined as abnormal amyloid 
beta 1-42 (Aß1-42) in cerebrospinal fluid (CSF), who had normal cognition, MCI or 
dementia. We examined change for up to four years on six key biomarkers for AD 
(CSF Aß1-42, CSF tau, Fludeoxyglucose Positron Emission Tomography (FDG-PET) and 
hippocampal, whole brain and ventricular volume on Magnetic Resonance Imaging 
(MRI), and five cognitive markers (Clinical Dementia Rating scale sum of boxes (CDR-SOB) 
[5], Mini-mental state examination (MMSE) [6], Alzheimer’s Disease Assessment Scale-
cognitive (ADAS-Cog) [7], and composite scores for executive function and composite 
scores for memory [8, 9]. We compared baseline scores and slope of decline on each 
measure between the AD stages and with subjects who had normal cognition, MCI or 
dementia but no AD pathology.
Methods
ADNI study
We selected subjects from ADNI (adni.loni.ucla.edu). ADNI was initiated by the National 
Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering 
(NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and 
non-profit organizations and launched in 2003. The initial goal of ADNI was to recruit 
800 adults, ages 55 to 90, to participate in the research, approximately 200 cognitively 
normal older individuals to be followed for three years, 400 people with MCI to be 
followed for three years and 200 people with early AD to be followed for two years. 
For up-to-date information, see www.adni-info.org. The institutional review boards of 
all participating institutions approved the procedures for this study. Written informed 
consent was obtained from all participants or surrogates.
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Participants
The ADNI inclusion criteria for participants with normal cognition were absence of memory 
complaints, a MMSE score of 24-30, a CDR score of 0 and no MCI or dementia diagnosis. The 
inclusion criteria for subjects with MCI were memory complaints, objective memory loss, a 
MMSE score between 24 and 30 and a CDR of 0.5. The inclusion criteria for subjects with AD 
were memory complaints, objective memory loss, a MMSE score between 20-26, a CDR of 
0.5-1.0 and a diagnosis of probable AD according to NINCDS-ADRDA criteria [10]. Exclusion 
criteria were absence of an informant, a score of >4 on the modified Hachinski scale [11] and 
score of >5 on the Geriatric Depression Scale [12], diseases expected to interfere with the 
study, use of investigational agents, neurological disease, psychiatric disorders, alcohol abuse 
and neuroimaging abnormalities showing other reasons for cognitive problems. Permitted 
medication had to be stable for at least four weeks prior to screening. We downloaded ADNI 
data on May 2012. Of the 800 subjects included in ADNI-1 we selected all cognitively normal, 
MCI and demented participants (N=416) with available baseline CSF Aß1-42.
Definition of diagnostic groups
We defined AD pathology as a CSF Aß1-42 level below 192 pg/ml. Subjects were classified 
as AD-asymptomatic (n=44) if cognition was normal, AD-MCI (n=148) if subjects had MCI, 
and AD-dementia (n=92) if subjects were demented. Subjects with CSF Aß1-42 levels 
>192 pg/ml were classified as control (n=72) if cognition was normal, MCI-other (n=51) 
if subjects had MCI, or dementia-other (n=9) if subjects were demented.
Baseline assessment and longitudinal assessment
At baseline all subjects underwent a standardized assessment, which included 
neurological examination, physical examination and neuropsychological assessments. 
Furthermore, CSF and blood samples were taken and MRI and FDG-PET scans were 
obtained. The protocols for cognitive testing, CSF, MRI and PET are described in detail 
at http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml. Assessments were repeated 
at six or twelve months intervals up to six years. For the present study we used results 
from the baseline and annually assessments for up to four years for cognitive measures, 
CSF Aß1-42 and tau, FDG-PET and MRI volumetric measures.
Cognitive assessment
We used the MMSE, ADAS Cog, CDR-SOB, and composite scores for executive function 
and memory. The composite executive function measure consisted of seven subtests 
and the memory composite measure of eight subtests as described in detail elsewhere 
[8, 9]. We selected scores from the annual assessment up to four years.
2.1
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CSF analyses
CSF was collected by lumbar puncture and shipped on dry ice to the Penn ADNI Biomarker 
Core Laboratory at the University of Pennsylvania, Philadelphia for storage until further 
analysis. CSF was analysed using a multiplex xMAP Luminex platform (Luminex Corp) 
with immunoassay kit-based reagents (INNO-BIA Alzbio3; Innogenetics; www.adni-info.
org) as described elsewhere [13]. Follow-up was performed annually up to four years.
MRI analyses
We used scans made on a 1.5 Tesla MRI scanner. We selected measures for whole brain, 
ventricular and hippocampal volume. For measurement of whole brain and ventricular volume 
boundary shift integral (BSI) was used [14, 15]. Whole brain and ventricles were first semi-
automatically delineated from T1-weighted MRI. The repeat scans were then registered to the 
baseline scans using 9-degree-of-freedom registration. The intensity inhomogeneity between 
baseline and registered repeat scans was corrected using the differential bias correction. 
Hippocampal volumes were measured, using FreeSurfer version 4.3 on T1 weighted images 
which were pre-processed (gradient warping, scaling, B1 correction and N3 inhomogeneity 
correction)[16]. For measurements, an unbiased within-subject template space and average 
image was created using robust, inverse consistent registration. Information from each 
subject’s template was used to initialize the longitudinal image processing in several locations 
to increase reliability and statistical power when measuring brain change over time [17]. 
Hippocampal volume was measured bilateral and averaged. We used BSI data from baseline 
and the first two annual visits and FreeSurfer of the annual visits up to four years. To correct 
for intracranial volume (ICV), we used the estimated ICV measure from FreeSurver.
FDG-PET analyses
FDG-PET was available in a subgroup of 207 subjects. FDG image data were acquired 
30 to 60 minutes post-injection. After pre-processing (frames were averaged, spatially 
aligned, interpolated to a standard voxel size, and smoothed to a common resolution of 
8 mm full width at half maximum) images were spatially normalized in SPM5 to MNI PET 
template. MetaROI’s were calculated that includes FDG uptake in bilateral angular gyrus, 
posterior cingular and bilateral inferior temporal gyrus. Each MetaROI was normalised to 
a reference region composed of the pons and vermis. Total FDG uptake was calculated 
as a mean of the five individual MetaROI’s [18]. Follow-up was annually for four years for 
cognitively normal subjects and MCI subjects for two years for subjects with dementia.
Statistical analyses
Analyses were performed with SPSS version 19.0 for the Macintosh. In order to compare 
cognitive markers and biomarkers at baseline and over time, raw scores were converted 
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into z-scores, relative to the baseline scores of the cognitively normal controls. The z-score 
is the number of standard deviations from which the score deviates from the expected 
score given age, sex, education, and apolipoprotein E (APOE) genotype. In the control 
group we performed multiple linear regression with age, sex, education, APOE genotype, 
and ICV (MRI measurements only) entered in the first step, using P<.05 as the criterion 
for remaining in the model. On the basis of the resulting model, an expected test score 
for each subject was calculated. This score was subtracted from the observed score. The 
residual was divided by the standard deviation of the residual in the reference population 
to give the z-score. Z-scores were expressed such that a negative score indicated a 
performance worse than the control group at baseline. For each variable and assessment 
z-scores were calculated relative to the control group at baseline.
Change in biomarkers and cognitive scores over time were assessed by slope 
analyses with mixed models using an unstructured covariance matrix (which assumes 
a random intercept and random slope), with age, education and gender as covariates 
and follow-up time as repeated measure. We assumed a linear change in time, as time 
coded with a quadratic term was not a statistically significant predictor. Analyses were 
performed in the total group using contrasts to calculate baseline differences and 
slopes for individual groups and to compare them between groups. The analyses of 
the slopes included baseline score and available follow-up scores. We tested whether 
slopes were different from 0 and whether they differed between groups. A difference 
with a p-value <0.05, without correction for multiple testing, was considered statistically 
significant. In table 2 we indicate which differences would not be statistically significant 
after correction for multiple testing according to Benjamini-Hochberg [19].
Results
Baseline characteristics
Table 1 shows the baseline characteristics according to diagnostic groups. Age, gender and 
APOE-ε4 status differed between groups. Age was higher in subjects with dementia-other 
compared to the other subjects, except for subjects with AD-asymptomatic, and subjects 
were more often female in the dementia-other group compared to the MCI-other group. 
APOE-ε4 was more frequently positive in subjects with abnormal amyloid levels than in 
subjects with normal amyloid, regardless of clinical status. AD-asymptomatic subjects were 
less often APOE-ε4 positive (45%) than subjects with AD-MCI (65 %) and APOE-ε4 carriership 
tended to be lower in AD-MCI compared to AD-dementia (77%). Among ε4 carriers, ε4 
homozygosity was least common in AD-asymptomatic (10%) and highest in AD-dementia 
(32%). The unadjusted biomarker and cognitive scores are shown in table 1 and the z-scores 
relative to controls in table 2 and in figures 1, 2 and 3 and will be discussed below.
2.1
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Figure 1. Estimated change in z-scores of the biomarkers according to clinical stage and AD 
biomarker status
Change over time for biomarkers. CSF= cerebrospinal fluid; aß 1-42= amyloid beta 1-42; FDG-
PET= Fludeoxyglucose Positron Emission Tomography; MRI= Magnetic Resonance Imaging; NC=normal 
cognition; MCI= Mild Cognitive Impairment. Slopes for change on FDG-PET could not be estimated in the 
dementia other group. A negative z-score indicates that the score is worse than that of the control group 
at baseline. Error bar indicates standard error of the mean.
    Subjects with AD pathology
    Subjects without AD pathology
2.1
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Figure 2. Estimated change in z-scores of the cognitive markers according to clinical stage and 
AD biomarker status
 
   
  
Change over time for cognitive markers. CDR-SOB= Clinical Dementia Rating scale sum of boxes; 
MMSE= Mini-Mental State Examination; ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cognitive; 
NC=normal cognition; MCI= Mild Cognitive Impairment. Slopes for change on memory and executive 
scores could not be estimated in the dementia other group. A negative z-score indicates that the score 
is worse than that of the control group at baseline. Error bar indicates standard error of the mean.
    Subjects with AD pathology
    Subjects without AD pathology
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Figure 3. Temporal evolution of biomarkers and cognitive markers from in AD from the 
asymptomatic to dementia stage
Aß 1-42= amyloid beta 1-42; FDG-PET= Fludeoxyglucose Positron Emission Tomography; MRI= Magnetic 
Resonance Imaging; ADAS-Cog= Alzheimer’s Disease Assessment Scale-Cognitive; NC= normal cognition; 
MCI= Mild Cognitive Impairment. A negative z-score indicates a score worse than that of the control.
AD-asymptomatic stage
At baseline, AD-asymptomatic subjects had, by definition, more abnormal CSF 
Aß1-42 compared to controls. In addition, they had more abnormal CSF tau levels, 
ventricular volume, ADAS-Cog scores and composite executive scores. At follow-up, 
AD-asymptomatic subjects tended to decline on CSF Aß1-42 (p=0.09) and significantly 
declined on CSF tau (p=0.0001), FDG-PET (p=0.046), hippocampal volume (p= 0.0001) 
ventricular volume (p=0.0001), whole brain volume (p=0.0001) and CDR-SOB (p=0.0001). 
Only the decline in ventricular volume (p=0.05) exceeded the decline observed in the 
controls.
AD-MCI stage
AD-MCI subjects differed at baseline from controls on all measures. They also differed 
from MCI-other on all cognitive markers and biomarkers, except for whole brain volume. 
Subjects with AD-MCI declined on all biomarkers and cognitive markers, except on CSF 
Aß1-42. Decline on all these markers was larger than observed in MCI-other.
AD-dementia stage
At baseline subjects with AD-dementia were impaired on all biomarkers and cognitive 
markers compared to controls. Compared to the nine subjects with dementia-other, 
only CSF tau and ventricular volume were more abnormal, in addition to CSF Aß1-42. 
AD-dementia subjects showed decline on all measures except CSF Aß1-42, CSF tau 
2.1
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and the composite executive score. The decline was similar to that of dementia-other 
subjects, although in the latter group slopes for some markers could not be estimated, 
probably due to the small sample size.
Differences between AD stages
Baseline scores
AD-asymptomatic subjects had at baseline less abnormal CSF Aß1-42 and tau and 
less abnormal imaging markers and cognitive scores compared to AD-MCI and AD 
dementia subjects. AD-MCI differed from AD-dementia on all imaging markers and 
cognitive scores.
Rate of decline
Decline in CSF Aß1-42 levels was larger in AD-asymptomatic than in AD-dementia. 
Decline in CSF tau was larger in AD-asymptomatic and AD-MCI subjects than in AD-
dementia subjects. All imaging markers showed more decline with advancing clinical 
stage. The increase in decline between stages was largest for FDG-PET and hippocampal 
volume on MRI. Decline in CDR-SOB, ADAS-cog and in composite score for memory was 
larger in subjects with AD-MCI and AD-dementia than in AD-asymptomatic subjects. 
Decline on the MMSE and composite executive score was larger in AD-dementia than 
in AD-MCI and larger in AD-MCI than in AD-asymptomatic.
Figure 3 summarizes the baseline values and slopes according to clinical stage for 
CSF Aß1-42, CSF tau, FDG-PET, hippocampal volume and ADAS-Cog score.
Differences between controls, MCI-other and dementia-other
Baseline scores
Hippocampal atrophy and whole brain volume were more severe in MCI-other 
and dementia-other subjects compared to controls. Ventricular enlargement was 
significantly more abnormal in MCI-other subjects compared to controls and FDG 
uptake on PET more abnormal in demented-other subjects compared to controls and 
MCI-other subjects. Cognitive performance differed between the groups with worst 
performance in the demented group, as expected.
Rate of decline
CSF tau declined faster in controls and hippocampal volume less compared to MCI-
other subjects. Other differences were not statistically significant or could not be tested 
(table 2).
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Discussion
We found that CSF, imaging and cognitive markers show different rates of decline in 
subjects with AD-asymptomatic, AD-MCI and AD-dementia. The pattern of decline was 
distinct from that of subject without amyloid pathology.
Our observation that subjects in the AD-asymptomatic stage had abnormal CSF 
tau is in line with previous studies [20, 21]. Ventricular volume was abnormal in AD-
asymptomatic subjects, indicating that this is a sensitive measure [22]. The finding of 
normal hippocampal volume, whole brain volume and FDG PET in AD-asymptomatic, is 
in line with previous studies [23, 24]. Other studies, however, reported cortical thinning 
in several cortical regions [25], and reduced whole brain and hippocampal volume 
[26, 27]. These discrepancies may be explained by differences in subject selection or 
image analysis techniques. All imaging measures showed decline at follow-up but only 
the increase of ventricular volume exceeded that of the control group. This finding is 
consistent with earlier studies [23, 28] and supports the observation that change in 
ventricular volume is better correlated with amyloid pathology in cognitively normal 
subjects than change in brain volume and hippocampal volume [22]. Subjects with AD-
asymptomatic had impairments on the ADAS-Cog and executive functioning relative to 
controls. Only the CDR-SOB declined at follow-up although it did not exceed that of the 
control group. Previous studies yielded conflicting results with some studies showing a 
relation between amyloid pathology and impairments or decline in memory, executive 
function, or global function, while others did not [27, 29-32]. These differences might, 
again, be explained by differences in tests used and in subject selection.
Subjects with AD-MCI differed at baseline from controls on all markers and from MCI-
other on all markers, except whole brain volume. This finding, together with other 
studies, indicates that cross-sectionally measured whole brain volume, is not specific 
or sensitive for early AD in MCI subjects [33-35]. AD-MCI subjects declined more than 
MCI-other on CSF tau, imaging and cognitive markers, illustrating that AD pathology 
drives neurodegeneration in these subjects.
In AD-dementia subjects baseline cognitive scores and biomarkers did not differ 
from the dementia-other group, except for the CSF measures and ventricular volume. 
Over time, AD-demented subjects showed the same rate of decline as dementia-other 
subjects on CSF, MRI (except for ventricular volume) and cognitive markers, although 
the interpretation of these findings is limited by the small sample size of the dementia-
other group.
We summarized the trajectory of change on five key markers for AD in figure 3 to 
make a comparison with previous modelling studies that hypothesized trajectories for 
2.1
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these markers [32, 36]. As regards the rate of order of decline, our findings support 
the assumption that CSF Aß1-42 declines first, followed by tau, which is followed by 
the other markers. Unlike the proposed models, hippocampal volume, FDG PET and 
ADAS-Cog declined simultaneously in our analysis. As regards the form of the curves, 
our findings support the proposed flattening of the curves of Aß1-42 and tau in the 
AD-asymptomatic or AD-MCI stage. It also suggests that impairments on the imaging 
and cognitive markers will continue to increase in more advanced stages, as we did not 
observe flattening of these markers in the dementia stage. Because we used z-scores 
relative to controls rather than relative to end-stage dementia, we could also compare 
the severity of the impairments on each marker. We found that in the dementia stage 
impairment for CSF Aß1-42, FDG-PET, hippocampal volume and ADAS-Cog were similar 
and more severe than for tau. This would suggest that CSF tau levels reach a balance 
between tau release and tau metabolism, despite increasing neuronal cell death [37-39]. 
However, there are also other explanations such as the variability of the SD between 
measures which affected z-scores (see below), the possibility that tau is also abnormal 
in controls [40-42] or selective dropout of subjects with high tau, although this then 
would also apply to the other injury markers.
As regards the markers that were not taken into account in the summarized figure, 
whole brain volume followed the same pattern as FDG PET and hippocampal volume. 
Ventricular volume, was already abnormal in the asymptomatic stage. Besides ADAS–
Cog, executive function was impaired in AD-asymptomatic but decline was observed 
only for the CDR-SOB. In the MCI and AD stage all markers were abnormal and showed 
further decline, and the rate of decline further increased in the dementia stage.
The APOE-ε4 allele distribution was lowest in AD-asymptomatic and highest in 
AD-dementia. Since the APOE-ε4 allele is strongly associated with age of onset, the 
difference in APOE-ε4 carriership between the AD stages could explain why subjects 
in each stage had a similar age despite differences in disease severity.
Although the control group did not have amyloid pathology they still showed 
decline on the biomarkers. This decline may result from normal aging, no-AD related 
neurodegeneration, or very early stage AD. Post-hoc analyses, however, made it less 
likely that in controls decline was driven by latent AD pathology because decline on the 
cognitive and biomarkers was very similar between subjects with a ‘low-normal’ CSF 
Aß1-42 (CSF Aß1-142 193- 250 pg/ml) and ‘high-normal’ CSF Aß1-42 levels (CSF Aß1-42 
> 250 pg/ml).
Subjects with MCI-other had normal CSF Aß1-42 and tau at baseline and did not 
change over time in these measures. Relative to the control group, MCI-other subjects 
only showed increased decline in hippocampal volume, while change in other imaging 
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markers was comparable to that of controls. Cognition was remarkably stable in MCI-
other subjects suggesting a relatively benign underlying process [23, 31, 43-45].
Our data contained very few subjects with a clinical diagnosis of AD with normal 
CSF Aß, which were labelled as dementia-other. They were older and had less abnormal 
CSF tau levels than AD-dementia subjects. They were all APOE-ε4 negative and had CSF 
tau levels marginally increased compared to controls. These findings suggest non-AD 
pathology, but further studies with a larger sample size are needed to confirm this.
Our analyses expand those reported from other ADNI studies and other cohorts 
in several ways. We stratified clinical groups according to amyloid status, tested 
simultaneously a wide range of biomarkers and clinical markers and presented follow-
up data for up to four years [32, 38, 46-50]. This enabled us to study trajectories of 
different markers in different AD stages and relative to amyloid negative subjects. 
We used z-scores, relative to control subjects, which enabled us to compare scores 
between different diagnostic groups and also between markers despite different 
units of measurements. A limitation of z-scores for comparison across different tests, 
however, is that the standard deviation (SD) could vary between different markers, 
which may influence the absolute z-scores. Variability in SD may be caused by biological 
variability, test characteristics and selection of subjects. For example, the CDR was 
used to define normal cognition, which resulted in a small SD in controls and large 
z-scores for diseased subjects. Still, when we repeated all analyses with raw scores 
similar results were obtained.
A possible limitation of our study is that our cognitive markers might not be sensitive 
enough to find abnormalities in the AD-asymptomatic stage although the tests used 
are well known and typically used in trials. FDG-PET was performed in only 50% of 
the subjects. This reduced statistical power to find changes compared to the other 
markers tested. Our subjects were relatively old and since rate of decline may depend 
on age, this might have resulted in an underestimation of decline in biomarkers and 
cognition and our findings may not apply to younger subjects [41]. We selected subjects 
with different AD stages cross-sectionally. Although our findings suggest a continuum 
between the stages (figure 3) findings need to be replicated in studies that follow 
subjects with asymptomatic AD until the dementia stage. A number of our findings 
were not statistically significant after correction for multiple testing.
Our study provided further evidence for a temporal evolution of AD. Our findings 
might be helpful to determine which marker can be used in each clinical stage of AD, 
for inclusion or outcome measure in clinical trials. For instance in AD-asymptomatic 
individuals, CSF Aß1-42, ventricular volume on MRI and CDR-SOB appear to be candidate 
outcome markers.
2.1
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LOW NORMAL CEREBROSPINAL 
FLUID AΒ42 LEVELS PREDICT 
CLINICAL PROGRESSION IN NON-
DEMENTED SUBJECTS
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Teunissen, Philip Scheltens, Wiesje M. van der Flier, Pieter Jelle Visser.
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Abstract
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid 
β 1-42 (≥640 pg/ml) levels related with rate of clinical progression in a sample 
of 393 non-demented memory clinic patients. Lower normal levels were 
associated with faster clinical progression and this depended on baseline 
cognitive status (subjective cognitive decline: HR = 0.57, p <.05; mild cognitive 
impairment: HR=0.19, p <.001), indicating that normal CSF amyloid levels do not 
exclude incident Alzheimer’s disease. These findings suggest that research on 
preclinical markers for Alzheimer’s disease should take the continuum of CSF 
amyloid β 1-42 levels within the normal range into account.
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Introduction
Amyloid can be measured in cerebrospinal fluid (CSF) and decreased CSF amyloid β 
1-42 (Aβ 1-42) levels indicate abnormal amyloid plaque aggregation in the brain [1,2]. 
Abnormally low CSF Aβ 1-42 levels in non-demented subjects are robustly associated 
with clinical progression [3]. As such, patients with mild cognitive impairment (MCI, i.e., 
subjects without dementia, who have impairment in memory and/or another cognitive 
domain) and abnormal amyloid markers have prodromal Alzheimer’s disease (AD) [4]. 
However, 15-35% of MCI subjects with normal amyloid markers develop an AD-type 
dementia [5,6]. Although their amyloid levels are normal, it has been shown that for at 
least a subset of subjects these levels are near the cut-point for abnormality [6]. Using 
a cut-point implies that amyloid accumulation is an on-off phenomenon. However, 
recent longitudinal CSF studies showed in non-demented subjects that lower, normal 
amyloid levels can become abnormally low over time [7-9]. Such lower normal amyloid 
levels have also been associated with a decline in cognitive functioning as measured 
with neuropsychological test scores [7,10]. This suggests that part of the normal range 
of Aβ 1-42 values reflects the start of the process of amyloid accumulation. Being able 
to identify such a range would provide novel opportunities to intervene in the process 
of amyloid accumulation at a very early stage.
The objective of this study was to investigate, in non-demented memory clinic subjects, 
the relationship between lower normal CSF Aβ 1-42 levels and rate of clinical progression. 
We also tested whether Aβ 1-42 levels had additive value over the injury markers tau and 
tau phosphorylated at threonine 181 (p-tau), which have been robustly associated with 
disease progression in non-demented subjects with abnormal CSF Aβ 1-42 levels [11].
Methods
Subjects
Non-demented subjects (n=393) with either subjective cognitive decline (SCD: i.e., 
subjects who present with cognitive complaints, but cognitive functioning was normal 
and criteria for MCI or dementia were not met) or MCI from the Amsterdam Dementia 
cohort [12] who visited our memory clinic at the VU University Medical centre between 
2000 and 2014 and had CSF samples at baseline, and at least 1 follow up assessment 
available (mean number of visits = 2.8, SD = 1.07). At their first visit, most subjects 
received standard dementia screening that included their medical history, physical 
and neurological examination, global and extensive cognitive functioning examination, 
screening laboratory tests, an electroencephalogram (EEG) and a structural magnetic 
resonance imaging (MRI) scan. Subjects were labelled as SCD in accordance to 
international research criteria for SCD [13] or as MCI when they fulfilled international 
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consensus criteria for MCI [4,14]. The primary outcome in the present study was time 
to clinical progression to MCI or AD-type dementia, defined as the time between the 
first visit and the time that a new diagnosis was made. For most subjects, follow up 
visits were scheduled at about 1-year intervals as part of their regular clinical care, 
which included a medical history, neurological and neuropsychological work up. A 
follow up diagnosis of AD was based on the criteria proposed by the National Institute 
of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) [15] for patients seen before 2011, or 
National Institute on Aging and the Alzheimer’s Association (NIA-AA)[16] workgroup for 
patients seen after 2011. The Ethical Review Board of the VU University Medical Center 
Amsterdam approved the study. All participants provided written informed consent to 
use their data for research purposes.
Cerebrospinal fluid analysis
CSF samples were obtained with a lumbar puncture between the L3/L4, L4/L5 or 
L5/S1 intervertebral space using a 25-gauge needle and syringe, and collected in 
polypropylene tubes. Aβ 1-42, total tau, and p-tau concentrations were determined 
with sandwich ELISAs (Innotest, Innogenetics, Belgium). Several methods exist to 
determine amyloid positivity, and we have previously shown that a cut-point based on 
clinical diagnosis can lead to an underestimation of amyloid pathology detection [17]. A 
higher cut-point of <640 pg/mL improved concordance with amyloid positron emission 
tomography (PET) [17], suggesting this cut-point is more appropriate to detect amyloid 
pathology in the brain. Therefore, we have labelled subjects as having normal amyloid 
using this strict threshold of ≧ 640 pg/mL.
Statistical analyses
Demographical and clinical characteristics were compared between subjects who did 
and who did not progress to MCI or AD-type dementia with t-tests, Kruskal-Wallis 
tests or chi-square tests where appropriate. CSF data was log or Box Cox transformed 
to approximate normality, and subsequently Z-transformed. Associations between 
continuous CSF values (predictor variable) and time to progression to AD-type dementia 
or MCI (outcome variables) were analysed with Cox proportional hazard models. These 
models included an interaction term of baseline cognitive status * CSF Aβ 1-42 levels to 
test the influence of baseline cognitive status on time to clinical progression. We further 
explored whether hazard ratios (HRs) increased for lower values of CSF Aβ 1-42 levels 
by defining quintiles, such that progressive subjects were equally distributed across 
the strata. All analyses included potential confounders age, gender and the number of 
visits as covariates and were performed in R version 3.2.3.
2.2
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Results
During a median follow-up period of 2.3 years (interquartile range = 1.1-4.1), 31 (8%) 
subjects showed clinical progression to either MCI (n = 14) or AD-type dementia (n = 16; 
of whom 2 with SCD at baseline, table 1). SCD subjects who progressed were older 
and had lower, but still normal CSF Aβ 1-42 levels. MCI subjects who progressed had, 
lower, but still normal, CSF Aβ 1-42 levels and increased tau and p-tau levels (table 1).
Table 1. Baseline characteristics by clinical outcome (absence or presence of MCI or AD-type of 
dementia at follow up) in N = 393 non-demented memory clinic subjects, stratified for baseline 
cognitive status: subjective cognitive decline (SCD) or mild cognitive impairment (MCI).
Total sample (n=393) SCD (n=237) MCI (n=156)
Absence Presence Absence Presence Absence Presence
N (% of total sample) 362 (92%) 31 (8%) 220 (56%) 17 (4%) 142 (36%) 14 (4%)
Female 128 (35%) 10 (32%) 87 (40%) 3 (18%) 41 (29%) 7 (50%)
Age years 61.24 (8.52) 66.53 (8.64)** 59.95 (8.49) 64.76 (7.53) * 63.37 (8.13) 68.67 (9.67)
Education 5 (4-6) 5 (4-6) 5 (4-6) 5 (4-6) 5 (4-6) 5 (4-6)
MMSE 28 (27-29) 28 (26-29) 28 (28-30) 28 (26-29) 27 (25-29) 28 (26-29)
APOE-ε4 positive ‘ 104 (28%) 14 (45%) * 64 (31%) 14 (53%) 40 (29%) 6 (50%)
























CSF tau > 375 pg/ml 60 (17%) 16 (52%)**** 28 (13%) 5 (29%) 32 (23%) 11 (79%)****
CSF p-tau’’ 44 (35-54) 53 (40-83) ** 44 (34-53) 48 (32-54) 46 (35-58) 77 (50-114)***
CSF p-tau > 52 pg/ml 103 (29%) 17 (55%)** 59 (27%) 7 (41%) 44 (31%) 10 (71%)**














Follow-up visits 2.5 (2-3) 3 (2-4) 2 (2-3) 3 (3-4) ** 3 (2-4) 3 (2-3.25)
MCI at follow up n.a. 15 (48%) n.a. 15 (88%) n.a. n.a.
AD at follow up n.a. 16 (52%) n.a. 2 (12%) n.a. 14 (100%)
Data are presented as N (% of subgroup), mean (SD) or median (first quartile- third quartile). Tau and p-tau cut-
points were based on Mulder et al., 2005.21 MCI is mild cognitive impairment; AD is Alzheimer’s disease; n.a. is not 
applicable; IQR is interquartile range; CSF is cerebrospinal fluid, ‘ value missing for n=9, ‘’ value missing for n=1; 
Comparison of no AD-type dementia or MCI at follow up (i.e., absence) versus AD-type dementia/MCI at follow up 
(i.e., presence): * is p <.05; ** is p < .01; *** is p <.001; **** is p < .0001.
Cox proportional hazard models showed significant interaction effects of baseline 
cognitive status and biomarker values on the time to clinical progression (all pinteraction 
< .05), and so all further analyses were stratified for baseline cognitive status. Table 
2 shows that in SCD, lower, normal Aβ 1-42 levels were associated with faster clinical 
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progression (HR = 0.57, p = .04). In these subjects, tau and p-tau did not predict time to 
progression (table 2). In MCI subjects, lower normal levels of Aβ 1-42 were associated 
with faster time to clinical progression (HR = 0.19, p = .002), which was faster than seen 
for SCD. In these subjects, injury markers tau and p-tau also predicted time to clinical 
progression, but less strongly than Aβ 1-42 (HRtau = 2.47, p =.01; HRptau = 1.87, p = .04).
Table 2. Cox proportional hazards ratios (95% confidence interval) for clinical progression to MCI 
or AD-type dementia.
Biomarker Total sample SCD MCI
Aβ 1-42 (per SD) 0.38 (0.24 - 0.62) *** 0.57 (0.34 - 0.96) * 0.19 (0.07 - 0.56) **
Tau (per SD) 2.19 (1.42 – 3.38) *** 1.23 (0.67 - 2.27) 2.47 (1.20 - 5.06) *
P-tau (per SD) 1.73 (1.15 – 2.58) ** 0.86 (0.49 - 1.51) 1.87 (1.04 - 3.35) *
SCD is subjective cognitive decline, MCI is mild cognitive impairment. Predictors were Z transformed before analyses 
and so Hazard ratios represent faster time to progression per standard deviation decreased amyloid or increased 
tau or p-tau. For each predictor the interaction term of biomarker * baseline cognitive status was significant (p < 
.05), thus all analyses were stratified for baseline cognitive status. All models included age, gender and number of 
visits as covariates, analyses for the total group additionally included baseline cognitive status as covariate. * is p 
< .05, ** is p < .01, *** is p < .001.
We further explored whether the association of low Aβ 1-42 levels was driven by the 
values near the cut-point, or whether HR values would show a relationship according to 
quintiles of the Aβ 1-42 levels. When subjects were stratified according to quintiles of Aβ 
1-42 levels, there was no interaction effect of baseline cognitive status (pinteraction >.05). 
We repeated analyses including baseline cognitive status as an additional covariate. 
Figure 1 illustrates that compared to the highest quintile of CSF Aβ 1-42 levels, HR 
ratios increased for subsequently lower quintiles. Relative to the highest quintile (Aβ 
1-42: 953 – 1332 pg/mL) the HR increased from 1.27 (0.40 – 3.99; p = .68) for Aβ 1-42 
levels between 765-952 pg/mL, to 2.79 (0.82 – 9.43; p = .10) for Aβ 1-42 levels between 
686-764 pg/mL, to 7.58 (2.51 – 22.87; p < .001) for Aβ 1-42 levels between 661-685 pg/
mL, up to 21.60 (6.84 -68.22, p < .0001) for Aβ 1-42 levels between 644-660 pg/mL.
2.2
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Figure 1. Survival curves for the time to clinical progression in non-demented subjects
 pSCD is subjects with subjective cognitive decline who showed clinical progression, pMCI is subjects with 
mild cognitive impairment who showed clinical progression. Separate lines indicate progression according 
to quintiles of cerebrospinal fluid (CSF) Aβ 1-42 (Aβ42) levels.
Discussion
We found that lower CSF Aβ 1-42 levels within the normal range are predictive for 
faster clinical progression in non-demented memory clinic subjects. This effect was 
more evident in MCI subjects. For both SCD and MCI subjects, the predictive value of 
CSF Aβ 1-42 levels was stronger than CSF tau or p-tau levels.
Previous studies reported that at least some non-demented subjects with normal 
amyloid who showed incident clinical progression had Aβ 1-42 levels just above the 
cutoff value [6]. Other studies have reported in cognitively normal older adults that low, 
normal Aβ 1-42 levels predicted decline in cognitive test scores [7,10], and that low CSF 
levels were predictive for future worsening of Aβ 1-42 levels [7,9,10]. Our results are in 
line with those studies, and further extend these by showing that such lower, but still 
normal Aβ 1-42 levels are also associated with time to incident clinical progression and 
are not limited to concentrations just above the cutoff.
For SCD subjects, low Aβ 1-42 levels were the only predictor for clinical progression, 
and this is in line with the amyloid cascade hypothesis that proposes that tau levels 
would rise during later stages of the disease [18]. In our sample two SCD subjects 
progressed to AD-type dementia, and we observed in these subjects abnormal tau 
levels. A possibility is that CSF measures of tau levels might not be sensitive enough 
to pick up the earliest changes in SCD subjects who progressed to MCI. The predictive 
value of low normal Aβ 1-42 levels in MCI subjects seems to deviate from the amyloid 
cascade hypothesis, because at this stage amyloid should be saturated [19]. Possibly 
for these subjects the threshold for amyloid to become toxic is lower. An alternative 
explanation could be that some of these subjects have increased processing of 
amyloid precursor protein (APP), which subsequently results in the presence of more 
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soluble amyloid in CSF [10]. Such higher levels of CSF amyloid might obscure the initial 
decreases in CSF due to plaque formation in the brain.
Decreasing quintiles of CSF Aβ 1-42 levels were gradually associated with increasing 
hazard ratios for clinical progression. This leads us to consider that variability of normal 
amyloid from a certain point onwards reflects a dynamic range during which amyloid 
plaque deposition has started, but has yet to reach plateau levels. The ability to 
identify such a range during which amyloid is still in the process of aggregation, makes 
it possible to study the earliest pathological changes in the brain that are related to 
the development of AD. This has implications for research that focuses on preclinical 
markers for AD, and provides opportunities for amyloid targeted therapies at very 
early stages of the disease. For clinical practice our results imply that AD should not 
be excluded when CSF Aβ 1-42 level are normal, and future research should aim to 
determine risk estimates that also take normal amyloid levels into account.
A potential limitation of the present study is that our outcome measure was defined 
as progression to a clinical diagnosis of MCI or AD-type dementia, which might not 
accurately reflect the underlying pathology [20]. Although two of the SCD subjects 
developed an AD-type dementia, for the other subjects it cannot be ruled out that 
some of the SCD subjects who progressed to MCI might in time develop another type 
of dementia, or remain cognitively stable. Similarly, MCI subjects who progressed to 
clinical AD-type dementia might have been misdiagnosed. Unfortunately, no autopsy 
data was available for this sample, and so the possibility that they might have been 
misdiagnosed cannot be ruled out. Another potential limitation of the present study is 
that follow-up visits were part of regular patient care, and so the number of visits and 
the time period between visits can vary between subjects. Although we have adjusted 
our analyses for the variability in the number of visits, we cannot exclude the possibility 
that this might still have influenced the results. The present results were based on initial 
CSF Aβ 1-42 levels and so it is possible that amyloid levels had become abnormal at the 
time of diagnosis. Longitudinal studies to assess whether CSF Aβ 1-42 levels will also 
become abnormal are necessary to further investigate this question.
In conclusion, we have demonstrated that in non-demented subjects, low normal CSF 
Aβ42 is associated with time to clinical progression. These results suggest that the 
continuum of normal CSF Aβ 1-42 levels should be taken into account when investigating 
the earliest changes in the brain that are relevant for AD.
2.2
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Abstract
Background: We sought to define a cutoff for ß-amyloid 1-42 in cerebrospinal 
fluid (CSF), a key marker for Alzheimer’s disease (AD), with data driven Gaussian 
mixture modeling in a memory clinic population. 
Methods: We performed a combined cross-sectional and prospective cohort study. 
We selected 2462 subjects with subjective cognitive decline (SCD), mild cognitive 
impairment (MCI), AD-type dementia, and dementia other than AD from the 
Amsterdam Dementia Cohort. We defined CSF amyloid beta 1-42 cutoffs by data-
driven Gaussian mixture modeling in the total population and in subgroups based 
on clinical diagnosis, age, and apolipoproteine E (APOE) genotype. We investigated 
whether abnormal ß-amyloid 1-42 as defined by the data-driven cutoff could better 
predict progression to AD type dementia than abnormal ß-amyloid 1-42 defined by 
a clinical diagnosis-based cutoff using Cox proportional hazard regression.
Results: In the total group of patients we found a cutoff for abnormal CSF 
amyloid beta 1-42 of 680 pg/ml (95% CI 660-705). Similar cutoffs were found 
within diagnostic and APOE genotype subgroups. The cutoff was higher in 
elderly subjects than in younger subjects. The data-driven cutoff was higher 
than our clinical diagnosis based cutoff and had a better predictive accuracy 
for progression to AD-type dementia in non-demented subjects (hazard ratio 
(HR) 7.6 versus 5.2, p<0.01).
Conclusion: Mixture modeling is a robust method to determine cutoffs for CSF 
ß-amyloid 1-42. It might better capture biological changes that are related to 
AD than cutoffs based on clinical diagnosis.  
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Introduction 
Decreased β-amyloid 1–42 (Aβ1-42) in cerebrospinal fluid (CSF) is indicative of Alzheimer’s 
disease (AD) pathology and part of research criteria for AD [1–4]. However, there is no 
universal cutoff value to define abnormal CSF Aβ1-42. This is in part due to the variability 
of Aβ1-42 measurements across laboratories [5, 6]. In addition, clinical centers have 
used different methods to define a cutoff [7]. Often, a cutoff value is determined by 
comparing CSF Aβ1-42 levels of cognitively normal subjects with those of patients with 
a clinical diagnosis of AD- type dementia. However, about 10% of the subjects with 
clinical AD-type dementia do not have amyloid pathology [8], and 25% of subjects 
with normal cognition can have amyloid pathology [9], which biases the cutoff value. 
Data-driven Gaussian mixture modeling provides an alternative approach that does not 
rely on clinical diagnosis [10]. With this approach, CSF Aβ1-42 levels showed a bimodal 
distribution representing a normal and an abnormal population. However, it is unclear 
whether this method is influenced by clinical diagnosis and risk factors for AD.
We aimed to define a cutoff for CSF Aβ1-42 with mixture modeling and to investigate 
whether this cutoff was dependent on clinical diagnosis, age, and apolipoprotein E 
(APOE) genotype. We compared the diagnostic accuracy and the predictive accuracy 
for AD-type dementia progression of the new cutoff value with our previous clinically 
based cutoff [11]. We also performed a simulation analysis to determine the minimum 
sample size needed to reliably estimate the cutoff with mixture modeling.
Methods
Participants 
We selected 2462 subjects from the Amsterdam Dementia Cohort (ADC) [12] with 
subjective cognitive decline (SCD; n = 448), mild cognitive impairment (MCI; n = 490), AD 
dementia (n = 1031), and dementia other than AD (n = 493) who had CSF measurements 
available at the time of their first visit at the memory clinic between August 1997 and 
July 2015. All patients underwent standardized dementia screening at baseline, including 
physical and neurological examinations, electroencephalograms, magnetic resonance 
imaging, and laboratory tests. Cognitive screening included the Mini Mental State 
Examination and, in over 90% of the subjects, a comprehensive neuropsychological test 
battery. Diagnoses were made by consensus among a multidisciplinary team that did not 
have knowledge of the CSF results, and they were based on the following clinical criteria. 
Subjects were diagnosed with SCD when cognitive complaints were present but criteria 
for MCI, dementia, or any other neurological or psychiatric disorders were not met and all 
other examinations were normal [13]. Subjects were diagnosed with MCI according to the 
established MCI criteria [14]. Subjects with AD-type dementia were diagnosed according 
to the criteria of the National Institute of  Neurological and Communicative Disorders and 
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Stroke-Alzheimer’s Disease and Related Disorders Association [4, 15]. Subjects with non-
AD-type dementia included subjects with behavioral variants of  frontotemporal dementia 
(n = 204)  [16, 17], dementia with Lewy bodies (n = 113) [18], vascular dementia (n = 66) [19], 
corticobasal degeneration or syndrome (n = 31 or n = 10, respectively) [20], progressive 
supranuclear palsy (n = 44) [21], alcohol-related dementia (n = 3), Huntington’s disease (n 
= 3), Parkinson’s disease (n = 1), normal pressure hydrocephalus (n = 3), CADASIL (cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; n 
= 1), Creutzfeldt-Jakob disease (n = 3), tauopathy (n = 2), and dementia without a known 
cause (n = 9). All subjects gave written informed consent for the use of their clinical and 
biomarker data for research purposes, and the ethical review board of the VU University 
Medical Center approved the study.
Follow-up assessment
Subjects were followed according to clinical needs. The standard follow-up procedure 
included a 6-month follow-up examination for subjects with dementia and a 12-month 
follow-up visit for subjects without dementia [12]. Neuropsychological tests were 
repeated every 12 months. Diagnoses at follow-up were made on the basis of clinical 
criteria listed above by consensus among a multidisciplinary team.
CSF Aβ1–42 analyses
CSF was collected from 67% of the subjects in the ADC [12]. Reasons for not collecting 
CSF were refusal, contra- indications, technical failure, or CSF having been collected 
elsewhere. CSF was obtained by lumbar puncture using a 25-gauge needle with a 
syringe into 10-ml poly- propylene tubes (Sarstedt, Nümbrecht, Germany). Within two 
hours, CSF samples were centrifuged at 1800 × g for 10 minutes at 4 °C. The CSF 
supernatant was transferred to new polypropylene tubes and stored at −20 °C until 
further analysis (within 2 months). Baseline Aβ1–42 was measured using a commercially 
available enzyme- linked immunosorbent assay (Innotest β-amyloid(1-42; Innogenetics, 
Ghent, Belgium) on a routine basis as de- scribed before [11]. The intra-assay coefficient 
of variation (mean ± SD) for Aβ1–42 was 2.0 ± 0.5%, calculated by averaging the coefficient 
of variation of duplicates from five runs randomly selected over 2 years. The inter-assay 
coefficient of variation (mean ± SD) was 10.9 ± 1.8%, as analyzed in a high and low pool 
from 13 consecutive pool preparations used in total in 189 runs. The team performing 
the CSF analysis was unaware of the clinical diagnoses.
Statistical analyses
Baseline characteristics were compared between diagnostic groups with analysis of 
variance and Kruskal- Wallis or chi-square tests, where appropriate, using IBM SPSS 
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Statistics version 20.0 software (IBM, Armonk, NY, USA). A difference with a p value less 
than 0.05 was considered significant. Gaussian mixture modeling was used to define 
a cutoff for abnormal CSF Aβ1-42 using the R statistical software program version 3.2.1 
mixtools package. First, the number of distributions that best de- scribed the data 
was determined with the R boot.comp function. Next, we defined a data-driven cutoff 
as the point where the lines of two fitted normal distributions crossed each other. 
The main analyses included all subjects. We repeated mixture modeling in subgroups 
based on diagnosis, age (dichotomized based on the median age of 66.5 years), and 
APOE-ε4 allele carriership. Boot- strap sampling was used to determine 95% CIs of the 
cutoff. Cutoffs were considered to be statistically different between subgroups when 
their 95% CIs did not overlap. 
New cutoff values were compared with our previously clinically defined cutoff of 550 
pg/ml, which was based on subjects seen between 2001 and 2007 (n = 1070) [11]. For 
this comparison, we repeated mixture modeling in a subset of data including subjects 
from this time period. Using this subset, we further tested differences between the 
clinical and new cutoff values in discrimination between nondemented subjects with 
or without AD-type dementia at follow-up. In addition, using Cox proportional hazard 
models, we compared the association of the old cutoff and new cutoff with time to AD-
type dementia progression, including age and sex as covariates. For these analyses, 
nondemented patients were included when they had at least 6 months of follow-up 
available. We compared both models with chi-square tests of the log-likelihood ratio. A 
difference with a p value less than 0.05 was considered significant. Statistical analyses 
for multivariate Cox regression were performed using R version 3.2.3 software. Finally, 
we studied the minimum number of subjects per clinical population necessary to 
reliably estimate the cutoff in a data-driven way. To this end, we simulated CSF Aβ1-42 
values from a bimodal distribution with mean and SD values as estimated from our 
dataset. We recalculated the cutoffs and 95% CIs for sample sizes with varying numbers 
starting from n = 300 to 3000 with steps of 100. The minimum sample size required to 
obtain a reliable cutoff was determined as the sample size for which 95% CI lines were 
larger than the mean cutoff ±10%, which is currently used as a rule-of-thumb indication 
of acceptable variability in CSF Aβ1-42 levels.
Results 
Baseline characteristics
Table 1 shows the baseline characteristics according to diagnostic group. Briefly, 
patients with AD and patients with MCI were older and included a higher percentage 
of APOE-ε4 allele carriers than the other groups. CSF Aβ1-42 42 levels were highest 
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for SCD, followed by non-AD type dementia, MCI and AD-type dementia. Of the non-
demented subjects, over an average follow-up period of 3.2 (2.04 SD) years, 21 (9%) 
of the subjects with SCD progressed to MCI and 13 (5%) to AD-type dementia and 146 
(39%) of the subjects with MCI progressed to AD-type dementia. 













Age, years 66.8 (7.0) 64.4 (6.2)b,c,d 68.2 (6.9)a,c,d 67.3 (7.2)a,b 66.9 (6.8)a,b
Female sex, n (%) 1049 (43) 170 (38)c 181 (37)c 528 (51)a,b,d 170 (34)c
Years of education 11.1 (3.0) 11.9 (3.1)b,c,d 11.4 (3.2)a,c,d 10.8 (2.8)a,b 10.5 (2.9)a,b
MMSE score 23.6 (5.2) 28.3 (1.7)b,c,d 26.5 (2.5)a,c,d 20.4 (5.0)a,b,d 23.0 (5.2)a,b,c,
APOE ε4 allele carriers, n (%) 1186 (54) 158 (35)b,c 242 (49)a,c,d 615 (60)a,b,d 171 (35)b,c
CSF Aβ1–42, pg/ml 667 (289) 906 (277)
b,c,d 676 (295)a,c,d 504 (174)a,b,d 781 (278)a,b,c
CSF tau, pg/ml 527 (401) 317 (205)b,c,d 486 (313)a,c,d 705 (406)a,b,d 394 (443)a,b,c
CSF p-tau, pg/ml 70 (37) 52 (25)b,c 70 (35)a,c,d 88 (39)a,b,d 50 (25)b,c
Outcome at follow-up AD-type/no
AD-type dementia (% AD-type dementia)
– 13/235 (5) 146/224 (61) – –
Average follow-up duration, years – 2.93 (1.99) 2.41 (1.46) – –
Data are mean (SD), unless otherwise specified. Superscript letters indicate that this group shows a statistically 
significant difference (p < .05) with other groups as labelled with a,b,c,d or e in the column headers Abbreviations: 
SCD,  Subjective cognitive decline;  MCI, Mild cognitive impairment; AD, Alzheimer’s Disease; APOE Apolipoprotein 
E;  CSF,  Cerebrospinal fluid;  Aβ1–42,  β-Amyloid 1–42;  - Not applicable
CSF aß 1-42 cutoff based on mixture modeling 
In the total sample and all subgroups, a bimodal distribution best fitted the data (table 
2). In the total sample this yielded a cutoff of 680 pg/ml (95% CI 660-705 pg/ml) (figure 
1a). With this cutoff 55% of our population fell into the abnormal amyloid distribution. 
Similar cutoffs were found when we repeated mixture modeling within the dementia 
group (694 pg/ml [95% CI 670-721]), the pooled sample of subjects with SCD and MCI 
(664 pg/ml [95% CI 621-712]), subjects with SCD (621 pg/ml (95% CI 526-901)) and 
subjects with MCI (696 pg/ml [95% CI 654-758]) (figure 1b-e). 
A lower cutoff was found for subjects younger than 66.5 years (645 pg/ml [95% CI 
617-678]) than subjects older than 66.5 years (723 pg/ml [95% CI 691-762]) (figure 1f 
and 1g). The cutoff for CSF Aβ1-42 was higher in APOE-ε4 carriers than in non-carriers 
(resp. 716 pg/ml [95% CI 684-756]; 650 pg/ml [95% CI 611-689]), but this did not reach 
statistical significance (figure 1h and 1i). 
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Figure 1: CSF Aβ1-42 cutoff values based on mixture modeling  
a) Total sample, b) Demented subjects, c) Non demented subjects, d) Subjects with SCD, e) Subjects with 
MCI, f) Subjects >66,5 years, g) Subjects <=66,5 years, h) APOE-ε4 allele carriers i) APOE-ε4 allele non-
carriers. Subjects with a clinical diagnosis of AD-type dementia at baseline or at follow-up (non-demented 
subjects) are shown in grey.
Abbreviations: SCD, subjective cognitive decline; MCI, Mild Cognitive Impairment; APOE, Apolipoprotein 
E; AD, Alzheimer’s disease
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Table 2: Fit statistics from bootstrap tot test the null hypothesis of a K-component fit versus 
(K+1)-component fit for total sample. 
Log-likelihood 1 versus 2 
components
Log-likelihood 2 versus 3 
components
Observed Bootstrap (95% CI) p Value Observed Bootstrap (95% CI) p Value
All subjects 653.98 6.51 (1.65–15.69) <0.001 2.16 16.67 (0.78–11.15) 0.77
Subjective 
cognitive decline
15.64 6.12 (1.72–13.25) 0.03 2.45 5.8 (0.94–17) 0.74
Mild cognitive 
impairment
124.50 5.79 (1.91–12.63) <0.001 9.95 5.55 (0.54–10.82) 0.08
Nondemented 132.93 6.44 (1.5–13.1) <0.001 10.41 4.34 (0.73–11.3) 0.07
Dementia 471.81 6.01 (1.49–13.21) <0.001 3.61 4.34 (0.53–9.56) 0.55
Younger than 66.5 
years old
261.16 5.86 (1.4–12.82) <0.001 2.02 4.64 (0.65–9.83) 0.79
Older than 66.5 
years old
397.49 6.42 (1.82–14.46) <0.001 9.39 4.82 (0.68–11.64) 0.11
APOE ε4 
noncarrier
138.75 6 (1.77–13.01) <0.001 4.19 6.91 (0.79–11.26) 0.41
APOE ε4 carrier 367.29 5.83 (1.89–11.50) <0.001 10.49 7.25 (0.6–11.79) 0.07
APOE Apolipoprotein E
Comparison to previously defined cutoff  
The cutoff of 680 pg/ml based on mixture modeling was substantially higher than our 
previously clinically defined cutoff of 550 pg/ml (95% CI 531–570 pg/ml) [11]. Repeated 
mixture modeling in the subset of subjects with CSF analysis in the 2001–2007 period (in 
which subjects were selected for the clinically based cutoff calculation) also resulted in a 
higher cutoff (615 pg/ml, 95% CI 573– 673 pg/ml) (Fig. 2) than the clinically defined cutoff.
Figure 2: CSF Aβ1-42 cutoff values based on mixture modeling in subjects seen between 2001-2007
Subjects with a clinical diagnosis of AD-type dementia at baseline or at follow-up are shown in grey. 
Abbreviation: AD, Alzheimer’s disease.
2.3
Daniela_VolledigBinnenwerk_final.indd   57 15-3-2021   10:08:22
58 Chapter 2.3
In this subset, using a cutoff value of 615 pg/ml, 439 subjects were classified as having 
abnormal amyloid, which was a 13% increase compared with the 390 subjects classified 
by the clinically defined cutoff. The sensitivity of the cutoff of 615 pg/ml for AD-type 
dementia was 0.89 with a specificity of 0.62. The clinically defined cutoff of 550 pg/ml 
resulted in a sensitivity of 0.86 with a specificity of 0.65. Of the nondemented subjects 
who later progressed to AD-type dementia, 87% had CSF Aβ1-42 levels less than 615 pg/
ml, compared with 76% with CSF Aβ1-42 levels less than 550 pg/ml. For nondemented 
subjects who did not progress to AD-type dementia, these proportions were 30% 
versus 21%, respectively (Table 3). Survival analyses showed that both cutoffs were 
predictive of the time to development of AD-type dementia (550 pg/ml cutoff HR = 5.14, 
95% CI 2.96–8.93; pg/ml; versus 615 pg/ml cutoff HR 7.44, 95% CI 3.74–14.79) (Table 4). 
The HR for the development of AD-type dementia was significantly greater for the new 
cutoff of 615 pg/ml than for the cutoff of 550 pg/ml (p < 0.001).
Table 3: Number of subjects of subsample between 2001-2007 according to diagnosis at baseline, 
outcome at follow-up and CSF Aβ1-42 cutoff score. 
Total group 
(n = 688)
CSF Aβ42 cutoff 
<550 pg/ml
CSF Aβ 42 cutoff 
<615 pg/ml
AD-type dementia, n (%) 288 (42) 236 (82) 255 (89)
Non-AD-type dementia, n (%) 143 (21) 49 (34) 55 (38)
SCD with follow-up available
Converted to AD-type dementia, n (%) 7 (7) 5 (71) 6 (86)
Not converted to AD-type dementia, n (%) 91 (93) 16 (18) 20 (22)
MCI with follow-up available
Converted to AD-type dementia, n (%) 69 (53) 53 (77) 60 (87)
Not converted to AD-type dementia, n (%) 60 (47) 16 (27) 26 (43)
Data are from the subsample of patients seen between 2001 and 2007. For this time period the cutoff for CSF 
Aβ1-42 determined with Gaussian mixture modeling was 615 pg/ml.  Abbrevations: CSF, cerebrospinal fluid; Aβ1-42 , 
amyloid beta 1-42; SCD, subjective cognitive decline; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease.
Table 4: Cox proportional hazards ratios (95% confidence interval) for clinical progression to AD-
type dementia in non-demented subjects.
CSF Aβ4 cutoff Hazard Ratio (95% CI) Log likelihood Chi2
<550 (pg/ml) 5.14 [2.96-8.93]*** -327.85 n.a.
<615 (pg/ml) 7.44 [3.74-14.79]*** -324.66 6.38^
Data are from the subsample of patients seen between 2001 and 2007, and for non-demented sample with at least 
6 months follow-up available. *** p=0.0001. ̂  Decrease in Chi-2 p<0.01. Abbrevations: CSF, cerebrospinal fluid; aß 
1-42, amyloid beta 1-42. N.a. is not applicable. Analyses were adjusted for age and gender.
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We further explored why the data-driven cutpoint was somewhat lower in the 
subset of subjects with CSF analysis in the 2001–2007 period than in the total sample. 
Additional file 1: Figure S1 shows that the peaks of CSF Aβ1-42 level distributions seem 
to shift over subsequent years. This could not be explained by a difference in patient 
population, because the distribution of diagnoses remained comparable over time (χ2 
(45) = 61.32, p > 0.05) (Additional file 1: Table S1). We further explored whether this shift 
was due to an assay drift, and we repeated all subgroup analyses stratified for the time 
period when the lumbar puncture was obtained (2001–2007 versus 2008–2015) (see 
Additional file 1: Table S2 for baseline characteristics). Briefly, the cutpoint in the total 
group was higher in the 2008–2015 subsample (697 pg/ml [675–723 pg/ml]) than in the 
2001–2007 subsample (615 pg/ml [573–673 pg/ml]) (additional file 1: table S3 and figure 
S2 and S3). Subgroup analyses showed that the cutpoint for the dementia group and for 
APOE-ε4 allele carriers was also higher in the 2008-2015 group than in the 2001-2007. 
Cutpoints for the subgroups did not differ between time periods.
Minimum sample size required
Additional file 1: Figure S4 shows the mean and SD values for different sample sizes, 
varying from 300 to 3000 subjects with steps of 100. The average CSF Aβ1-42 cutoff 
was 679 pg/ml and remained similar with increasing sample size, whereas the 95% 
CI became narrower. Accepting a maximum deviation from the cutoff of ±10%, a 
minimum sample size of 800 is required for an acceptable 95% CI of 637–744 pg/ml. 
Our determined cutoff of 680 pg/ml and 95% CI fell within this range.
Discussion
Using a data-driven Gaussian mixture modeling approach, we determined a cutoff of 
680 pg/ml for abnormal CSF Aβ1-42 levels. This cutoff was independent of the cognitive 
stage and APOE genotype. The cutoff was higher in older than in younger subjects. 
With this new cutoff, a good classification of subjects with underlying AD pathology 
was achieved because 88% of nondemented subjects who later developed AD-type 
dementia had CSF Aβ1-42 levels below our new cutoff. Our results suggest that mixture 
modeling is a robust method to determine cutoff values for CSF Aβ1-42.
In the total sample, we found that subjects with AD- related characteristics 
(dementia, MCI, older age, and APOE ε4 carriers) fell mainly within the abnormal amyloid 
distribution and that subjects without AD-related characteristics (SCD, younger age, and 
APOE ε4 noncarriers) fell mainly within the normal amyloid distribution. This supports 
the idea that a bimodal distribution of amyloid levels represents normal and abnormal 
distributions of amyloid. When comparing cutoffs based on age and APOE ε4 groups, 
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the data-driven cutoff was higher in older than in younger subjects and tended to be 
higher in APOE ε4 allele carriers than in noncarriers. One explanation for the higher 
cutoff in these groups is that it reflects a difference in amyloid processing. However, this 
is unlikely, because a previous study showed that CSF Aβ1-42 levels were not dependent 
on APOE ε4 genotype after correction for Aβ deposition as measured by amyloid 
positron emission tomography (PET) [22]. Furthermore, researchers in another study 
found a similar cutoff for CSF Aβ1-42 across age groups [23]. A more likely explanation 
for the higher cutoff is that, within the old and APOE ε4 groups, relatively few subjects 
had normal CSF Aβ1-42 levels. As a consequence, the distribution of values reflecting 
normal Aβ1-42 levels was relatively wide, which resulted in a shift to a higher cutoff 
that separated the abnormal and normal CSF Aβ1-42 distribution. Thus, the variability 
in cutoffs is more likely to result from different sampling frequencies of normal and 
abnormal Aβ1-42 populations rather than from differences in amyloid processing. This 
suggests that, in order to determine a cutoff with this data-driven approach, the data 
need to contain a sufficient sample from both the normal and abnormal populations. 
For example, for the SCD group, which had few subjects who had abnormal CSF Aβ1-42, 
the 95% CI was wide, so the resulting cut- point should be considered with caution.
The cutoff of 680 pg/ml defined by Gaussian mixture modeling is higher than our 
previous clinically defined cutoff of 550 pg/ml. This indicates that clinically based cutoffs 
may underestimate the presence of abnormal CSF Aβ1-42. Still, the difference in cutoffs 
may also have resulted from drift in CSF Aβ1-42 levels over time, owing to variability in 
batches used for the biomarker analysis [6]. To test this possibility, we repeated our 
analyses based on data obtained in a time period similar to the previously clinically 
defined cutoff (2001–2007). Indeed, the cutpoint in the 2001–2007 subsample (615 pg/
ml) was lower than that in the 2007–2015 subsample (697 pg/ml). Nevertheless, the data-
driven cutoff derived for the 2007–2015 subsample was still higher than the clinically 
defined cutoff of 550 pg/ml, suggesting that our higher cutoff value was not due simply 
to a change in assay performance over time. Our data-driven cutoff is within the same 
range as the CSF Aβ1-42 cutoff that shows the best concordance with amyloid PET (640 
pg/ml) in our cohort [24] and in other cohorts (616–647 pg/ml) in which CSF Aβ1-42 was 
assessed with the Innotest assay [25–27]. This similarity between the amyloid PET derived 
cutoff for CSF Aβ1-42 and our new cutoff suggests that Gaussian mixture modeling is 
better able than a cutoff based on clinical diagnosis to capture and differentiate subjects 
from a memory clinic sample in terms of amyloid pathology. The higher cutoff led to 
an increased sensitivity to detect subjects with AD-type dementia at baseline and an 
increased sensitivity to predict future AD-type dementia in subjects with SCD or MCI. 
This increase in sensitivity could at least in part explain the results of a recent study that 
demonstrated an increased risk for cognitive decline in subjects with low normal CSF 
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Aβ1-42 values, based on a classical clinically defined cutoff [28]. However, subjects with a 
non-AD type dementia and subjects with SCD and MCI who did not convert to AD-type 
dementia also more often had abnormal CSF Aβ1-42 with the new cutoff. Some of these 
subjects may have low normal scores, but it could also mean that amyloid positivity is 
typically underestimated in these populations. For example, it is possible that some 
of the subjects with SCD and MCI might have developed AD-type dementia after the 
period in which they were followed. A strength of our study is the availability of a large, 
clinically well-characterized cohort with longitudinal data. This made it possible to analyze 
cutoffs for CSF Aβ1-42 for different subgroups of patients and to assess the ability of the 
new cutoff to detect future AD-type dementia before cognitive impairment becomes 
evident. A limitation of the Cox regression analysis was that the time to dementia was an 
approximation because the event occurred at an unknown time between two visits. The 
best gold standard currently available to measure amyloid pathology in vivo is amyloid 
PET because this correlates strongly with amyloid status determined post- mortem 
[29]. The similarity in cutoffs between our approach and amyloid PET indicates that 
centers that do not have PET techniques available can improve the accuracy of detecting 
abnormal amyloid with mixture modeling. A possible limitation of the method, however, 
is that the sample used for the cutoff definition should contain a sufficient number of 
subjects with normal and abnormal amyloid. We found that at least 800 subjects are 
needed to obtain a sufficiently reliable cutoff for CSF Aβ1-42. This number was calculated 
under the assumption that, in a memory clinic (as in ours), 55% of patients have abnormal 
CSF Aβ1-42 levels and 45% have normal levels. However, these distribution parameters 
might not apply to all memory clinics, because they are dependent on the type of patients 
seen and their age. For example, if 60% of patients in a population had abnormal CSF 
Aβ1-42 levels and 40% had normal CSF Aβ1-42 levels, a sample size of at least 450 subjects 
would be needed to determine a reliable cutoff (data not shown).
Conclusions
Using a data-driven mixture method, we found a new cutoff for abnormal CSF Aβ1-42 
levels that was higher and was better able to predict future AD-type dementia than 
our clinically determined cutoff. The increase in cutoff for CSF Aβ1-42 has implications 
for clinical practice be- cause more patients will be labeled as having AD path- ology 
than were so labeled using the old cutoff. This is likely to impact communication with 
and management of patients [30]. Still, regardless of the cutoff used at this time, 
the decision whether to communicate abnormal Aβ1-42 values with patients will be 
challenging because no therapy is yet available. Disclosure of pathological diagnosis 
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will probably depend on the AD stage, the wish of patients to know, and the view of the 











MMSE=Mini Mental State Examination
MRI=magnetic resonance 
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Supplementary data
Table S1. Distribution of diagnosis per year of CSF collection
Year Subjective complaints MCI Probable AD Dementia other
2001 4 (11.76%) 12 (35.29%) 11 (32.35%) 7 (20.59%)
2002 8 (13.33%) 17 (28.33%) 26 (43.33%) 9 (15%)
2003 11 (13.10%) 24 (28.57%) 37 (44.05%) 12 (14.29%)
2004 17 (20%) 18 (21.18%) 30 (35.29%) 20 (23.53%)
2005 10 (10.42%) 20 (20.83%) 39 (40.63%) 27 (28.13%)
2006 20 (13.70%) 32 (21.92%) 62 (42.47%) 32 (21.92%)
2007 38 (20.77%) 26 (14.21%) 83 (45.36%) 36 (19.67%)
2008 37 (17.79%) 40 (19.23%) 95 (45.67%) 36 (17.31%)
2009 50 (19.46%) 51 (19.84%) 100 (38.91%) 56 (21.79%)
2010 38 (20%) 35 (18.42%) 79 (41.58%) 38 (20%)
2011 68 (25.56%) 58 (21.80%) 98 (36.84%) 42 (15.79%)
2012 37 (14.98%) 51 (20.65%) 101 (40.89%) 58 (23.48%)
2013 50 (19.08%) 54 (20.61%) 112 (42.75%) 46 (17.56%)
2014 40 (19.23%) 31 (14.90%) 88 (42.31%) 49 (23.56%)
2015 19 (14.84%) 21 (16.41%) 66 (51.56%) 22 (17.19%)
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Table S2. Baseline characteristics according to time of CSF collection






Age (years) 68.3 (8.0) 64.8 (7.5) 70.1 (7.4) 68.9 (8.1) 68 (7.8)
Females (%) 360 (55%) 64 (62%) 82 (60%) 133 (48%) 81 (60%)
Years of education 4.8 (1.4) 5.3 (1.4) 4.8 (1.4) 4.7 (1.4) 4.6 (1.5)
MMSE score 23.7 (5.2) 28.4 (1.8) 26.5 (2.7) 21.1 (4.9) 22.8 (5.8)
APOE-ε4 allele carriers, n (%) 308 (47%) 36 (35%) 59 (43%) 174 (63%) 39 (29%)
CSF aß 1-42 (pg/ml) 592 (257) 796 (237) 581 (251) 463 (169) 711 (274)
CSF tau (pg/ml) 563(397) 327 (236) 546 (398) 728 (418) 429 (295)
CSF ptau (pg/ml) 74 (39) 52 (23) 75 (40) 92 (39) 55.15 (27)






Age (years) 66.3 (6.5) 64.2 (5.8) 67.4 (6.5) 66.8 (6.6) 66.5 (6.3)
Females (%) 1029 (58%) 211 (62%) 222 (65%) 362 (49%) 234 (67%)
Years of education 5.0 (1.3) 5.4 (1.2) 5.2(1.4) 4.9 (1.3) 4.7 (1.4)
MMSE score 23.5 (5.3) 28.2 (1.7) 26.6 (2.4) 20.2 (5.0) 23.1 (5.0)
APOE-ε4 allele carriers, n (%) 853 (48%) 120 (35%) 175 (51%) 430 (58%) 128 (37%)
CSF aß 1-42 (pg/ml) 700 (294) 942 (280) 722 (301) 525 (172) 815 (273)
CSF tau (pg/ml) 513 (401) 313 (194) 456 (265) 698 (400) 380 (493)
CSF ptau (pg/ml) 69 (37) 52 (25) 67 (33) 87 (39) 49 (24)
Abbrevations: SCD, subjective cognitive decline; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; APOE, 
Apolipoprotein E; CSF, cerebrospinal fluid; aß 1-42, amyloid beta 1-42, n.a. not applicable. Data are mean (SD), 
unless otherwise specified.
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Table S3. Cut-point according to period of CSF collection
Year All (n=2462) 2001-2007 (n=654) 2008-2015 (n=1766)
a. All 680 (661-706) 615 (573-673) 697 (675-723)*
b. No dementia 664 (623-712) 696 (578-863) 672 (628-731)
c. Dementia 694 (670-723) 610 (567-657)§ 715 (687-743)*
d. SCD 621 (526-821) 761 (549-1015) 638 (538-1136)
e. MCI 696 (653-754) 724 (593-834) 698 (653-773)
f. Age <= 66.5 645 (618-676) 644 (567-732) 666 (661-706)
g. Age >66.5 723 (691-761)# 651 (584-724) 737 (702-781)
h. APOE-ε4 non-carrier 650 (614-695) 597 (529-697) 672 (633-712)
i. APOE-ε4 carrier 716 (684-780) 586 (529-672)§ 734 (696-780)*
* Statistically significantly different between 2001-2007 and 2008-2015 cutoff.
§ Statistically significantly different between 2001-2007 and All cutoff.
# Statistically significantly different from Age <66.5 subgroup.
Figure S1. Distribution of CSF Aß42 values according to year of visit
Colours represent the year that CSF samples were obtained.
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Figure S2. CSF Aß42 cutoff values based on mixture modeling in 2001-2007 subsample
a) Total sample, b) Demented subjects, c) Non demented subjects, d) Subjects with SCD, e) Subjects 
with MCI, f) Subjects <= 66.5 years, g) Subjects > 66.5 years, h) APOE-ε4 allele non-carriers i) APOE-ε4 
allele carriers. Subjects with a clinical diagnosis of AD-type dementia at baseline or at follow-up (non-
demented subjects) are shown in grey. Abbreviations: SCD, subjective cognitive decline; MCI, Mild Cognitive 
Impairment; APOE, Apolipoprotein E; AD, Alzheimer’s disease.
2.3
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Figure S3. CSF Aß42 cutoff values based on mixture modeling in 2008-2015 subsample
a) Total sample, b) Demented subjects, c) Non demented subjects, d) Subjects with SCD, e) Subjects 
with MCI, f) Subjects <= 66.5 years, g) Subjects > 66.5 years, h) APOE-ε4 allele non-carriers i) APOE-ε4 
allele carriers. Subjects with a clinical diagnosis of AD-type dementia at baseline or at follow-up (non-
demented subjects) are shown in grey. Abbreviations: SCD, subjective cognitive decline; MCI, Mild Cognitive 
Impairment; APOE, Apolipoprotein E; AD, Alzheimer’s disease.
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Figure S4. Effect of sample size on CSF Aß 42 cutoff and 95% CI
The solid black line represents the mean CSF Aß 1-42 cutoff per sample size and the grey area represents 
the 95% CI for that CSF aß 1-42 cutoff. The dotted lines represent the mean cutoff + or - 10%. The place 
were the 95% CI crosses the dotted line represents the minimum sample size required (here n=800) to 
obtain a cutoff of which the 95% CI is within 10% of the mean cutoff. Our data-driven cutoff with 95% CI is 
represented in red. The modeling was performed in population of which 55% had abnormal CSF aß 1-42 
and 45% normal levels. Abbreviations: aß 1-42, amyloid beta 1-42.
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Abstract
Introduction: The aim of the present review is to give an overview on 
how biomarkers have been used to select individuals without dementia for 
prevention trials and as endpoint. Furthermore, we present a conceptual 
framework for prevention trials and discuss terminology, the pathophysiology, 
biomarkers, and treatment opportunities of AD.
Methods: We searched for AD phase II and III intervention trials on PubMED 
and trials registers published in the period January and July 2019. We included 
trials that included individuals with normal cognition or MCI and used a 
biomarker selection criterion and/or endpoint.
Results: In total 69 trials met our criteria. Of these trials 28 used biomarkers 
for inclusion and 66 as outcome measure. Sample size varied between 25 and 
2200 participants, with 57% of the studies having less than 150 participants. 
Biomarkers have been used for inclusion of since 2009 and these were typically 
amyloid markers. Biomarkers as outcome measure have been used since 1998 
and the most common outcome measures were neuronal injury markers. Over 
time, the use of biomarkers for both inclusion and outcome increased.
Discussion: Biomarkers for inclusion and as endpoint are increasingly used in 
prevention studies. Longitudinal modeling studies are needed across different 
clinical stages of AD to determine how biomarkers for inclusion and as endpoint 
impact sample size estimates.
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Introduction
Alzheimer’s disease (AD) is a slowly progressive disorder. After the first appearance 
of amyloid plaques in the brain it can take more than 20 years before an individual 
develops dementia [1–4]. Start of treatment of non-demented individuals is warranted 
as this likely prevents irreversible brain damage and cognitive loss. The design of such 
prevention trials in non-demented patients, however, is challenging [5,6]. clinical 
measures in prevention trials are less useful to select individuals and to measure 
treatment effects compared to AD trials in patients with dementia because non-
demented individuals with AD have no or limited cognitive impairments and show no 
or limited cognitive change over time. The design of prevention trials may be facilitated 
by the use of AD biomarkers. Biomarkers can select non-demented individuals with 
underlying AD pathology more accurately than clinical measures. This will help to select 
participants that are likely to have the disease, to respond to therapy and to show 
disease progression. Biomarkers can also be used as an outcome measure. That will 
allow to measure the effect of the intervention on key pathophysiological processes, and 
thereby determine target engagement of the compound. Both the use of biomarkers 
for inclusion and as outcome measure are likely to reduce sample size and length of 
the trial compared to prevention trials that do not make use of biomarkers[7,8].
The aim of the present review is to give an overview on how biomarkers have been 
used to select participants for prevention trials and as endpoint. In the first part of 
this review we will present a conceptual framework for prevention trials and discuss 
terminology, the pathophysiology, biomarkers, and treatment opportunities of AD. The 
second part of the review is on the use of AD biomarkers in previous prevention trials 
in non-demented individuals. We conclude with a discussion and future perspectives.
Conceptual framework for prevention trials
Terminology
Three types of prevention can be distinguished: primary, secondary, and tertiary 
prevention. We will explain these concepts using the 3 clinical stages of AD. AD has 
a pre-pathology stage in which individuals are at risk of developing AD pathology, an 
asymptomatic or preclinical stage in which brain pathology is present but cognition is 
not impaired, and a symptomatic or clinical stage with brain pathology and cognitive 
impairment (figure 1). The symptomatic stage can be subdivided into mild cognitive 
impairment, with objectified cognitive impairment on cognitive tests, without 
functional impairment (AD-MCI or prodromal AD), and a dementia stage in which 
functional impairment is also present (AD-dementia). Predementia AD refers to the 
asymptomatic and MCI stage of AD. Primary prevention aims to prevent the preclinical 
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stage, secondary prevention aims to prevent the progression from the preclinical stage 
to the symptomatic stage, and tertiary prevention aims to prevent further cognitive 
decline in symptomatic AD. The opportunities for prevention in each stage are shown 
in figure 1. Most AD trials so far have been tertiary prevention trials in subjects with 
AD-dementia and were typically referred to as AD treatment trials.
Figure 1. Stages of Alzheimer’s disease and opportunities for prevention
Pathophysiology of AD
Prevention trials aim to interfere with the underlying pathophysiology of AD in order 
to prevent the disease, prevent onset of symptoms or prevent clinical progression. 
According to the amyloid hypothesis, the primary event of AD is abnormal processing 
of the beta amyloid protein[9]. This leads to beta amyloid aggregates, which can be 
soluble (oligomeric beta amyloid) or insoluble (fibrils and plaques). Beta amyloid is 
generated from the amyloid precursor protein (APP) and is present in many isoforms. 
The beta amyloid 1-42 (aß1-42) peptide is in particular prone to aggregation and is 
thought to be one of the most toxic species. The cause of the abnormal beta amyloid 
processing is yet unknown, except for a number of familial cases in which it results 
from mutations in genes that code for APP or for peptides that process APP. In sporadic 
cases of AD, abnormal beta amyloid processing is likely the result from an interaction 
between aging, genetic risk factors, environmental risk factors and comorbid disorders. 
Abnormal beta amyloid processing leads to a cascade of secondary events including 
hyperphosphorylation of the tau protein, oxidative stress, inflammation, changes in 
lipid metabolism, synapse loss, and metabolic changes. These changes cause neuronal 
network dysfunction, neuronal loss and eventually cognitive impairment. This chain 
of events is referred to as the amyloid cascade and is shown in figure 2. The cascade 
may have positive feedback loops in which events downstream enhance upstream 
neuropathological events (as indicated by orange arrows in figure 2) [10–12].
3.1
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Figure 2. Hypothetical cascade of biomarkers in Alzheimer’s disease
AD biomarkers
For each of the risk factors and pathophysiological processes shown in figure 2, in-
vivo biomarkers are available. Examples of AD risk factors are the APOE-ε4 allele and 
increased homocysteine. Biomarkers for abnormal beta amyloid processing (referred 
to as amyloid biomarkers) are the aß1-42 peptide in cerebrospinal fluid (CSF), blood 
and PET-tracers that bind to fibrillar beta amyloid. Biomarkers for downstream events 
(referred to as injury biomarkers) include tau in CSF, medial temporal lobe atrophy, and 
hypometabolism or hypoperfusion on PET or SPECT scans [13,14].
The appearance of AD biomarkers is supposed to follow the amyloid cascade (figure 
2). Since abnormal beta amyloid processing is the primary event in AD, biomarkers for 
processing beta amyloid are abnormal at the start of the asymptomatic stage. Markers 
for secondary events such as cell loss as assessed on MRI scans will become abnormal 
in the late asymptomatic phase. However, the relation between biomarkers and disease 
stage is not well established for many biomarkers. Moreover, not all biomarkers will 
become abnormal in all patients. For example, inflammation as assessed by TGF-β1was 
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abnormal in 67% of the patients with AD-dementia[15]. In addition, biomarkers may 
change in a non-linear way over time[16]. For example, beta secretase activity showed 
a bell-shape curve and was higher in subjects with MCI compared to both healthy 
controls and subjects with AD-dementia[17]. Finally, also the sensitivity of biomarkers 
may determine the stage at which the underlying pathophysiology can be detected.
Therapeutic approaches
A wide range of therapeutic possibilities can potentially be used for the prevention of AD 
and these can be categorized in 4 types of approaches[18]. The first approach targets 
the primary event by reducing the presence of abnormally aggregated aß1-42 either 
by decreasing the production aß1-42, preventing aggregation, or stimulating removal 
of aggregated aß1-42. The second approach focuses on the secondary events such 
as abnormal tau phosphorylation, inflammation, oxidative stress or neurotransmitter 
disturbances. The third approach aims to influence modifiable risk factors and co-
morbid disorders [19]. The fourth approach does not directly target AD pathophysiology 
but focuses on general approaches for brain protection or compensation such as 
cognitive enhancers or specific nutrients. Prevention trials in non-demented subjects 
before 2010 typically used the third and fourth type of interventions. For example, 
prevention trials have investigated whether treatment of cardiovascular risk factors 
such as hypertension, diabetes, or hypercholesterolemia may prevent AD. Other studies 
investigated whether physical activity, cognitive stimulation, specific nutrients, Gingko 
biloba, or homocysteinemia lowering treatments could reduce dementia risk.
Design of previous and ongoing prevention trials
Trials without use of biomarkers
Before 2010 the majority of the AD prevention trials in non-demented participants have 
not used biomarkers for inclusion or as endpoint. Participants were selected based on 
risk factors for AD such as age [20,21], a family history for AD [22], the presence of the 
presence of cognitive complaints [23] or mild cognitive impairment [24]. Moreover, AD 
prevention was part of a number of prevention studies, which were primarily designed 
to prevent cardiovascular events [25–28] or as part of hormonal replacement studies. 
These studies should be considered as mixed primary, secondary, tertiary prevention 
trials because subjects with or without AD biomarkers and with cognition ranging from 
normal to MCI could have been included. Outcome measures in previous trials were 
either change on cognitive tests or progression to dementia or AD-dementia. The 
sample size of these trials was often large and the follow-up long because the rate of 
cognitive decline was expected to be slow.
3.1
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Prevention trials that used biomarkers for inclusion or as 
endpoint
To identify AD prevention trials in non-demented participants with biomarkers as 
inclusion criteria or endpoint, we searched in July 2019 on the following online resources: 
http://www.pubmed.com, www.clinicaltrials.gov, www.who.int, www.controlled-trials.
com and www.alzforum.org. Search terms used were ‘prevention Alzheimer’s disease’, 
‘ therapy preclinical AD’, ‘therapy prodromal AD’, ‘therapy MCI’, ‘ preclinical AD’, ‘MCI’, 
and ‘mild cognitive impairment’. We included trials that included individuals with normal 
cognition, with MCI or mild AD dementia. We excluded trials in healthy volunteers, 
studies that used a single dose intervention, that did not have a cognitive outcome, and 
trials that had not started in 2019. Sample size had to be over twenty subjects and the 
study duration over four weeks. In total 69 trials met our criteria. Fifteen trials included 
cognitively normal individuals, seven trials included cognitively normal individuals 
and individuals with MCI, 27 trials included individuals with MCI and seventeen trials 
included individuals with MCI and mild AD. Three studies included individuals with 
normal cognition, MCI, and mild AD (see supplementary data Table 1).
The number of individuals and average follow-up according to clinical population and 
trial phase is shown in table 1. Phase I/II and II studies included 100-255 individuals and 
less than 2 years of follow-up time. In phase II/III and III studies sample size and study 
duration depended on the clinical stage. Sample size was on average 1338 individuals 
and follow-up 4 years in cognitively normal individuals and in MCI sample size was on 
average 814 and follow-up 2.5 years.













Normal cognition 15 Phase I/II and phase II 4 108 1.2
Phase II/III and phase III 6 1338 4
Normal cognition and MCI 7 Phase I/II and phase II 3 118 1
Phase II/III and phase III 1 600 1.4
MCI 27 Phase I/II and phase II 13 132 1.8
Phase II/III and phase III 7 814 2.5
MCI and mild AD dementia 17 Phase I/II and phase II 8 255 1
Phase II/III and phase III 5 924 1.5
Normal cognition, MCI and 
mild AD dementia
3 Phase II/III and phase III 3 95 1.3
*Phase was not known for all trials. Phase I and Phase IV were not included
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Use of biomarkers in prevention trials
Trials in participants with normal cognition
Three trials used amyloid biomarkers for inclusion, one trial the presence of two 
apolipoprotein E4 (APOE-ε4) alleles, one trial the presence of a PSEN1 mutation, and 
the presence of a specific APOE and TOMM40 genotype. All trials used biomarkers as 
endpoint. In eight of these, change in CSF aß1-42, CSF tau, amyloid PET, FDG-PET, or fMRI 
activation pattern was the (co-)primary outcome. These eight trials tested the effect of a 
cholesterol inhibitor, acetylcholinesterase inhibitor, a cyclo-oxygenase type-2 inhibitor, or 
exercise. Sample size varied between 25-120 participants and trial duration between 3-18 
months. Seven trials used change in amyloid markers, tau markers, FDG-PET or atrophy on 
MRI as secondary outcome. Interventions were anti-amyloid therapy, antidiabetic drugs, 
dietary supplements or an anti-inflammatory drug. Sample size varied from 30-3500 and 
trial duration between 1-5 years.
Trials in participants with normal cognition and MCI
One of the 7 trials used CSF aß1-42 for inclusion.
Four trials used CSF aß1-42, aß1-40 or microRNA 170, MRI-ASL, amyloid PET or 
hippocampal volume on MRI as the (co-)primary outcome. The studies tested the effect 
of cholesterol inhibitors, curcumin or exercise and had a sample size of 70-150 with 
trial duration of 12 to 24 months. Two trials used biomarkers as FDG-PET and brain 
atrophy on MRI as secondary outcome. Interventions were diet, exercise and intellectual 
stimulation. Sample size was 120-1680 with trial duration of 9 months to 3 years. One 
study did not use any biomarker as end-point.
Trials in participants with MCI
Of the 27 intervention trials in participants with MCI, six used an amyloid marker or 
injury marker for inclusion. Eleven trials used amyloid PET, FDG-PET, ventricular or 
hippocampal volume, Magnetic Resonance Spectroscopy (MRS), functional-near-
infrared-spectroscopy (fNIRS), or functional MRI as (co-) primary outcome. Intervention 
consisted of active amyloid immunization, immunoglobulins, cholinesterase inhibitor, 
curcumin, noradrenalin re-uptake inhibitor, vitamins, lithium, anti-diabetic drug, or 
physical exercise. Sample size varied from 40 to 270 and duration from 1.5 to 24 months.
Thirteen trials used amyloid or neuronal injury markers as secondary outcome. 
Interventions were anti-amyloid therapy, fortasyn-connect, anti-diabetic therapy, 
cholinesterase inhibitors, phosphodiesterase type-3 inhibitor, lithium, dietary 
intervention, and physical exercise. Sample size of trials varied from 33 to 1500 subjects 
with a duration of six months to four years.
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Trials in participants with MCI or mild AD
Of the 17 trials in individuals with MCI or mild AD, twelve trials used amyloid markers 
with or without injury markers for inclusion. Two trials used change on amyloid markers 
as primary outcome. Both studies used a BACE inhibitor with 40 and 129 participants 
respectively, and trial duration of six and twelve months. One trial used plasma amyloid 
as co-primary outcome and tested intranasal insulin in 104 participants with trial 
duration of four months. Nine trials used amyloid or injury markers as a secondary 
outcome. These trials tested anti-amyloid therapy, intranasal insulin, GLP-1 agonist, 
cognitive or physical exercise or curcumin as intervention with a sample size between 
30 and 2202 and duration of 10 weeks to 24 months. Three trials used only cognition as 
outcome. Two trials were safety studies using cognition and biomarkers as secondary 
outcome. Biomarker outcome were amyloid markers with or without injury markers. 
One trial tested an inhibitor of glutaminyl cyclase and the other one human umbilical 
cord blood. Sample size was 42 to110 and duration three months.
Trials in participants with normal cognition, MCI and mild AD
None of the three trials used biomarkers for inclusion. One trial included individuals 
with a known autosomal dominant AD mutation or siblings of patient with a known 
mutation. Outcome measures were amyloid markers (primary outcome), or FDG-PET 
or atrophy (primary or secondary outcome). These trials tested an anti-amyloid therapy, 
Gingko biloba, and minocycline in 26-210 subjects, over duration of 6-24 months.
Results of prevention trials
Until now 40 trials were completed or terminated and published results (see table 
appendix 1). These results include trials conducted in individuals with normal cognition 
(n=10), individuals with normal cognition and MCI (n=4), MCI only (n=14), or MCI and AD 
(n=11) and one trial with patients with normal cognition, MCI and AD.
Pharmaceutical interventions
Of twelve anti-amyloid trials, in patients with MCI and mild AD, one trial showed an effect on 
cognition [29–31]. Six trials showed an effect on amyloid markers [29–35]. Ten anti-amyloid 
trials were terminated because of liver safety reasons (n=2, both BACE inhibitor), worse 
clinical outcome (n= 3) or futility (n=5) [29,30,32,34–40]. In patients with MCI, none of the 
five cholinesterase inhibitor trials showed an effect on cognition, but three of them reported 
reduced atrophy rates [41–46]. One trial using an anti-inflammatory drug showed an effect 
on both clinical and biomarker outcome, while another study did not show this effect 
[47,48]. Four cholesterol inhibitor trials did not show an effect on biomarkers or cognition 
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[49–52]. One trial testing lithium in patients with MCI showed less cognitive decline and an 
increased level of CSF aß1-42 in the treatment group[53]. Intranasal insulin in patients with 
MCI and mild AD showed some effects on cognitive scores and metabolism on FDG PET, 
but no change in CSF aß1-42. A follow-up trial with higher doses of intranasal insulin did not 
replicate this effect on cognition[54–56] . One trial testing a GLP-1 agonist was terminated 
due to withdrawn support from the pharmaceutical company [57].
Physical, cognitive and nutritional interventions
Two out of four exercise trials reported an effect on atrophy[58,59]. Cognitive training 
in patients with MCI or mild AD showed marginal improvement on cognition, but not on 
biomarkers[60]. One trial found that curcumin had an effect on memory and amyloid 
binding [61]. Another curcumin trial was stopped because of problems with enrollment 
[62]. One dietary intervention did not show an effect on outcome, while another trial 
found a slower decline on secondary cognitive outcomes and brain atrophy[63,64]. A 
vitamin trial showed some effect on atrophy measures, but not on cognition[65,66].
Time-line for the use of biomarkers for inclusion or outcome
In 2009 biomarkers for inclusion were first introduced in two MCI trials. Both trials used 
CSF aß1-42 for inclusion and tested efficacy of respectively, an anti-amyloid therapy or a 
nutritional drink. Outcome measures were CSF aß1-42 with or without total tau or p-tau 
and atrophy measures on MRI. Since then 18 trials used biomarkers for inclusion. Except 
for one, all trials using biomarkers for inclusion, used markers of amyloidosis. Since 2013, 
three trials included participants with normal cognition and an abnormal amyloid PET-scan.
The first trial to use biomarkers as outcome measure was performed in 1998 in 
cognitively normal individuals and patients with MCI, testing the efficacy of exercise 
on memory and hippocampal volume. Since then 29 trials used biomarkers as primary 
outcome. Outcome measures used as primary outcome were mostly amyloidosis in 
CSF or on PET and atrophy measures on MRI (see also figure 3,4 and 5).
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Figure 3. Biomarker Inclusion Criteria for Clinical Trials Ordered by Study Start Date and Biomarker
Figure 4. Biomarker Primary Endpoint for Clinical Trials Ordered by Study Start Date and Biomarker 
(a study can be included more than once) 
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Figure 5. Biomarker Secondary Endpoint for Clinical Trials Ordered by Study Start Date and 
Biomarker (substudies are not added, a study can be included more than once)
Discussion
We performed a review of trials that covered the period 1998-2019 in non-demented 
subjects that used a biomarker for selection of subjects or as endpoint. We found 
increasing use of biomarkers in trials for these purposes over time; mostly amyloid 
measures for selection purposes and neurodegeneration markers as outcomes to 
detect slowing of disease progression.
Biomarkers for inclusion
In 2007 research criteria were introduced and were further modified in 2010 and 2018 
[14,67–69]. With these criteria it is possible to include individuals with or without clinical 
symptoms in combination with abnormal AD biomarkers. This new framework allows for 
diagnosis of AD based on biomarkers alone and resulted in a shift from AD diagnosis 
from a clinical perspective to a pathophysiological diagnosis. The upcoming research 
criteria also reflected on the clinical trials. Since 2009 biomarkers have been used for 
inclusion of non-demented individuals in AD trials and these were typically amyloid 
markers. In addition, trials included individuals based on autosomal dominant AD 
mutation, APOE genotype, or a family history of AD. However, clinical inclusion criteria, 
such as a diagnosis of MCI or AD-type dementia continued to be used.
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Endpoints and efficacy
Biomarkers as endpoint have been used since 1998 and the most common outcome 
measures were neuronal injury markers (ie brain atrophy and glucose metabolism). 
Since 2009 amyloid biomarkers have also been used as endpoint. Of the 40 studies only 
two showed an effect on cognition while there was no effect on biomarkers[51,60] while 
five showed an effect on biomarkers but not on cognitive markers[29–32,34,35,70]. This 
supports the view that biomarker outcomes could be more sensitive than cognitive 
markers for detecting treatment effects in predementia AD in a short time frame. 
Amyloid measures used included CSF and PET measures. As these measures reflect 
different aspects of amyloid pathology it remains to be investigated whether their 
response to AD treatment varies.
The majority of the studies were negative on cognitive outcomes. More than 50% of 
the trials included less than 140 individuals and 40% of the trials had a duration of 12 
months or shorter, which both may have limited statistical power for cognition in those 
samples. One previous longitudinal study showed that the sample size needed to show 
a treatment effect, depended on the use of (a combination of) biomarkers used for 
inclusion. For instance, a minimum of 636 participants with MCI were needed to show 
a treatment effect on CDR sum of boxes when no biomarkers were used for inclusion, 
while 355 were needed when they were included based on abnormal beta amyloid and 
CSF tau[7]. Still, the lack of clinical benefit may also have been due to the intervention 
itself or limitations of the cognitive measures with respect to sensitivity to change[71].
Biomarkers for inclusion and as endpoint are increasingly used in prevention studies. 
Most trials had a small sample size that may have limited statistical power. Longitudinal 
modeling studies are needed across different clinical stages of AD to determine how 
biomarkers for inclusion and as endpoint impact sample size[72,73]. Pathophysiological 
studies may also benefit from results of former (failed) clinical trials as they give us 
inside in how a certain treatment in a certain population changes AD biomarkers. This 
information may help future trials in developing more specific interventions.
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Intervention Duration Cognitive 
endpoint







CAD106 and CNP520 Versus 
Placebo in Participants at 
Risk for the Onset of Clinical 
Symptoms of Alzheimer’s 
Disease (Generation)
(alzforum.org)





Age 60-75, cognitively 
normal




CAD106 im ~every 3 
months vs placebo;
CNP520 (BACE inhibitor) 
capsule daily vs placebo
5 years Time to MCI or 
dementia due to AD. 
Change in APCC (P)
CDR-SOB, RBANS, 
ECog (S)
Change in Amyloid en 
Tau PET, volumetric 
MRI, CSF Abeta, t-Tau 
and p-Tau (S)
(2 years and 5 years)
CNP520 terminated due to 
early worsening of some 








Efficacy and Safety of JNJ-
54861911 in Participants 
Who Are Asymptomatic 




II/III NCT02569398 Terminated Age 60-85, CDR=0 Amyloid PET scan 
positive OR CSF 
Abeta 1-42 level 
decreased
1650 JNJ-54861911 (BACE 
inhibitor); 5 mg vs 25 mg 
vs placebo
4.5 years Change ADCS-PACC 
(P)
Change in CDR-SOB, 
RBANS, CFI, ADCS-
ADL, NABDLTs (S)
Change in Amyloid 
PET, change in MRI 
imaging biomarkers, 
serum Tau (S)
terminated because of 
liver safety reasons. In 
interim analyses worsening 
of cognition in treatment 






Anti-amyloid treatment in 
asymptomatic AD (A4)
II/III NCT02008357 Ongoing Age 65-85, cognitively 
normal, CDR= 0.
Amyloid PET scan 
positive
1150 Solanezumab 400mg 
iv (monoclonal abeta 
antibody); every 4 
weeks vs placebo
3 years Change ADCS-PACC 
(P)
CFI, ADCS-ADL (S)
Change in Amyloid 
PET SUVr, volumetric 





Crenezumab Versus Placebo 
in Preclinical PSEN1 E280A 
Mutation Carriers to Evaluate 
Efficacy and Safety of AD-AD





300 Carriers: Crenezumab 
sc (passive 
immunotherapy) every 
2 weeks vs placebo.
5 years Change APCC (P)
Change and CDR-
SOB, FCSRT, RBANS, 
time to CDR>0, MCI 
or AD due to AD (S)
Change Amyloid PET, 
FDG-PET, volumetric 
MRI and CSF tau (S)
5 Sept-
2000
Brain imaging and 
mental disorders of aging 
intervention (Silverman 
2008)




None 25 Donepezil (acetylcho-
linesterase inhibitor) 
placebo
1.5 years NTB (P) FDG-PET, fMRI (P) Effect on metabolism dorsal 
prefrontal and left parieto-






for Risk of Mild Cognitive 
Impairment (MCI) Due to 
Alzheimer’s Disease (AD) and 
Safety and Efficacy Evaluation 
of Pioglitazone in Delaying 
Its Onset (TOMMORROW, 
alzforum.org)
III NCT01931566 Terminated Age 65-83, CDR=0, 




genetic risk profile 
APOE and TOMM 
genotype






Volumetric MRI (S in 
substudy 300)




Pilot Study: Lipoic Acid and 
Omega-3 Fatty Acids for 
Alzheimer’s Prevention




None 30 Lipoic Acid and Omega-
3 Fatty Acids
1 year TMT-B (P) MRI-WMH (S) -
8 Jun-
2010
Effects of Simvastatin on 
Biomarkers (SimBio)
(Li 2017)
NCT01142336 Completed Age 45-64, cognitively 
normal, CDR= 0. 
MMSE > 26, BMI 18-34
None 120 Simvastatine 40mg vs 
placebo
1 year Informant base 
questionnaires of 
functioning
CSF Abeta 1-42, t-Tau 
and p-Tau (P)
No effect on cognitive 
outcome. No effect on CSF 
Abeta 1-42 an t-Tau or p-Tau
-/-/-
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dementia due to AD. 
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ECog (S)
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and p-Tau (S)
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CNP520 terminated due to 
early worsening of some 








Efficacy and Safety of JNJ-
54861911 in Participants 
Who Are Asymptomatic 




II/III NCT02569398 Terminated Age 60-85, CDR=0 Amyloid PET scan 
positive OR CSF 
Abeta 1-42 level 
decreased
1650 JNJ-54861911 (BACE 
inhibitor); 5 mg vs 25 mg 
vs placebo
4.5 years Change ADCS-PACC 
(P)
Change in CDR-SOB, 
RBANS, CFI, ADCS-
ADL, NABDLTs (S)
Change in Amyloid 
PET, change in MRI 
imaging biomarkers, 
serum Tau (S)
terminated because of 
liver safety reasons. In 
interim analyses worsening 
of cognition in treatment 






Anti-amyloid treatment in 
asymptomatic AD (A4)
II/III NCT02008357 Ongoing Age 65-85, cognitively 
normal, CDR= 0.
Amyloid PET scan 
positive
1150 Solanezumab 400mg 
iv (monoclonal abeta 
antibody); every 4 
weeks vs placebo
3 years Change ADCS-PACC 
(P)
CFI, ADCS-ADL (S)
Change in Amyloid 
PET SUVr, volumetric 





Crenezumab Versus Placebo 
in Preclinical PSEN1 E280A 
Mutation Carriers to Evaluate 
Efficacy and Safety of AD-AD





300 Carriers: Crenezumab 
sc (passive 
immunotherapy) every 
2 weeks vs placebo.
5 years Change APCC (P)
Change and CDR-
SOB, FCSRT, RBANS, 
time to CDR>0, MCI 
or AD due to AD (S)
Change Amyloid PET, 
FDG-PET, volumetric 
MRI and CSF tau (S)
5 Sept-
2000
Brain imaging and 
mental disorders of aging 
intervention (Silverman 
2008)




None 25 Donepezil (acetylcho-
linesterase inhibitor) 
placebo
1.5 years NTB (P) FDG-PET, fMRI (P) Effect on metabolism dorsal 
prefrontal and left parieto-






for Risk of Mild Cognitive 
Impairment (MCI) Due to 
Alzheimer’s Disease (AD) and 
Safety and Efficacy Evaluation 
of Pioglitazone in Delaying 
Its Onset (TOMMORROW, 
alzforum.org)
III NCT01931566 Terminated Age 65-83, CDR=0, 




genetic risk profile 
APOE and TOMM 
genotype






Volumetric MRI (S in 
substudy 300)




Pilot Study: Lipoic Acid and 
Omega-3 Fatty Acids for 
Alzheimer’s Prevention




None 30 Lipoic Acid and Omega-
3 Fatty Acids
1 year TMT-B (P) MRI-WMH (S) -
8 Jun-
2010
Effects of Simvastatin on 
Biomarkers (SimBio)
(Li 2017)
NCT01142336 Completed Age 45-64, cognitively 
normal, CDR= 0. 
MMSE > 26, BMI 18-34
None 120 Simvastatine 40mg vs 
placebo
1 year Informant base 
questionnaires of 
functioning
CSF Abeta 1-42, t-Tau 
and p-Tau (P)
No effect on cognitive 
outcome. No effect on CSF 
Abeta 1-42 an t-Tau or p-Tau
-/-/-
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Intervention Duration Cognitive 
endpoint






Statin Effects on Beta-
Amyloid and Cerebral 
Perfusion in Adults at Risk for 
Alzheimer’s Disease (SHARP)
NCT00939822 Completed Age 42-72. 
Asymptomatic. Parent 
with AD dementia.
None 88 Simvastatin 40mg vs 
placebo
1.5 years Memory testing (S) CSF Abeta 1-42 and 
t-Tau (P) MRI (S in 
substudy)
(t: 9 + 18 months)






Potential Role in Therapy, 
ESPRIT (Carlsson et al, 2010)
II NCT00486044 Completed Age 35-69. 
Asymptomatic. Parent 
with AD dementia
None 100 Simvastatin 40mg one 
month, then 80mg 8 
months vs placebo
9 months NTB (S) CSF Abeta (P) MRI 
regional blood flow (S 
in substudy), plasma 
CRP
No effect on CSF Abeta, 
bloodflow or cognition
-/-/-
11 - Effects of simvastatin on 
cerebral fluid biomarkers 
in patients at risk for AD 
(Carlsson et al, 2008)
NA Completed Middle aged adult, 
asymptomatic, parent 
with AD dementia
None 57 Simvastatin 40mg vs 
placebo
4 months NTB (P)
(time: 1month, 4 
months)
CSF Abeta 1-42 and 
t-Tau (P)
No effect on CSF Abeta 
1-42 and t-Tau. Significant 
improvement in verbal 
fluency and working 





Randomized Trial of Low-
dose Naproxen in Cognitively 
Intact Persons at Risk of 
Alzheimer’s Dementia
(Meyer et al 2019)
II NCT02702817 Completed Age>=55, parent or 
two siblings with AD 
dementia








(time: 2 years, 4 
years) (P)
APS (time: 3 months, 
2 years, 4 years) (P)
CSF Abeta, t-Tau, 
p-Tau; CSF and serum 
cytokines. (time: 3 
months, 2 years, 4 
years) (S)
No effect on cognition or 
biomarkers. In treatment 





Anti-Inflammation in AD: PET 








None 88 Celecoxib (COX2- 
inhibitor) 400mg/day
1.5 years NTB (P) FDG-PET (P)
volumetric MRI: whole 
brain (S)
6% bilateral metabolic 
increase in prefrontal 
cortex and significant 
better performance in 
2 cognitive domains in 
treatment group. Cognitive 
improvement was in 





Effects of exercise and 
cognitive training on 
cognitive function in older 
adults
NCT01038726 Completed Age 60-85, Family 
history positive 
for AD.
None 96 Exercise training vs 
cognitive training vs 
flexibility training vs 
educational session





Effect of Aerobic Exercise 
on Pathophysiology of Pre-
clinical Alzheimer’s Disease
II NCT02000583 Ongoing Age>=65, CDR 




Amyloid PET scan 
positive
100 Aerobic exercise vs 
standard of care
1 year Change cognitive 
function (S)
Change Amyloid PET, 
measured by ratio 6 
ROI (P)
On MRI reduction of 
atrophy (S)
-
Normal cognition and MCI
1 Sept-
2015
Safety and Efficacy Study of 
ALZT-OP1 in Subjects With 
Evidence of Early Alzheimer’s 
Disease (COGNITE)





600 8 arms of ALZT-OP1a/
ALZT-OP1b (mast cell 
stabilizer+NSAID) and 
placebo for each.
~1.4 years CDR-SOB - -
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Statin Effects on Beta-
Amyloid and Cerebral 
Perfusion in Adults at Risk for 
Alzheimer’s Disease (SHARP)
NCT00939822 Completed Age 42-72. 
Asymptomatic. Parent 
with AD dementia.
None 88 Simvastatin 40mg vs 
placebo
1.5 years Memory testing (S) CSF Abeta 1-42 and 
t-Tau (P) MRI (S in 
substudy)
(t: 9 + 18 months)






Potential Role in Therapy, 
ESPRIT (Carlsson et al, 2010)
II NCT00486044 Completed Age 35-69. 
Asymptomatic. Parent 
with AD dementia
None 100 Simvastatin 40mg one 
month, then 80mg 8 
months vs placebo
9 months NTB (S) CSF Abeta (P) MRI 
regional blood flow (S 
in substudy), plasma 
CRP
No effect on CSF Abeta, 
bloodflow or cognition
-/-/-
11 - Effects of simvastatin on 
cerebral fluid biomarkers 
in patients at risk for AD 
(Carlsson et al, 2008)
NA Completed Middle aged adult, 
asymptomatic, parent 
with AD dementia
None 57 Simvastatin 40mg vs 
placebo
4 months NTB (P)
(time: 1month, 4 
months)
CSF Abeta 1-42 and 
t-Tau (P)
No effect on CSF Abeta 
1-42 and t-Tau. Significant 
improvement in verbal 
fluency and working 





Randomized Trial of Low-
dose Naproxen in Cognitively 
Intact Persons at Risk of 
Alzheimer’s Dementia
(Meyer et al 2019)
II NCT02702817 Completed Age>=55, parent or 
two siblings with AD 
dementia








(time: 2 years, 4 
years) (P)
APS (time: 3 months, 
2 years, 4 years) (P)
CSF Abeta, t-Tau, 
p-Tau; CSF and serum 
cytokines. (time: 3 
months, 2 years, 4 
years) (S)
No effect on cognition or 
biomarkers. In treatment 





Anti-Inflammation in AD: PET 








None 88 Celecoxib (COX2- 
inhibitor) 400mg/day
1.5 years NTB (P) FDG-PET (P)
volumetric MRI: whole 
brain (S)
6% bilateral metabolic 
increase in prefrontal 
cortex and significant 
better performance in 
2 cognitive domains in 
treatment group. Cognitive 
improvement was in 





Effects of exercise and 
cognitive training on 
cognitive function in older 
adults
NCT01038726 Completed Age 60-85, Family 
history positive 
for AD.
None 96 Exercise training vs 
cognitive training vs 
flexibility training vs 
educational session





Effect of Aerobic Exercise 
on Pathophysiology of Pre-
clinical Alzheimer’s Disease
II NCT02000583 Ongoing Age>=65, CDR 




Amyloid PET scan 
positive
100 Aerobic exercise vs 
standard of care
1 year Change cognitive 
function (S)
Change Amyloid PET, 
measured by ratio 6 
ROI (P)
On MRI reduction of 
atrophy (S)
-
Normal cognition and MCI
1 Sept-
2015
Safety and Efficacy Study of 
ALZT-OP1 in Subjects With 
Evidence of Early Alzheimer’s 
Disease (COGNITE)





600 8 arms of ALZT-OP1a/
ALZT-OP1b (mast cell 
stabilizer+NSAID) and 
placebo for each.
~1.4 years CDR-SOB - -
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endpoint







(Small et al. 2018)
II NCT01383161  Completed Age 50-90, MCI or 
AAMI
None 132 Curcumin 30mg vs 
placebo
1.5 years Cognitive tests (P)




Effect on memory tests in 
treatment group. Decreased 
FDDNP uptake on PET in 
amygdala in treatment 
group. Stable uptake in 
hypothalamus in treatment 





Omega-3 Fatty Acids and/or 
Multi-domain Intervention in 
the Prevention of Age-related 
Cognitive Decline (MAPT)
(Andrieu et al 2017)
NCT00672685 Completed Age>70, frail, MMSE 
≥ 24
None 1680 1. omega-3;







Placebo + multi domain 
intervention;
4. placebo
3 years Changes composite 
score, FCSRT (P)
Changes in other 
cognitive functions 
(S)
(time: every 6 
months)
FDG-PET, volumetric 
MRI whole brain (S in 
substudy)
(time: 6 months (only 
PET), 12 months)





Impact of Icosapent Ethyl 
on Alzheimers Disease 
Biomarkers in Preclinical 
Adults
II NCT02719327 Recruiting Cognitively normal, 
50-70, family history 
AD.
None 150 Icosapent ethyl (IPE) 
4g (OMEGA-3 acid) vs 
placebo
18 months PACC (S) MRI-ASL (P)





Modulation of Micro-RNA 
Pathways by Gemfibrozil in 
Pre-dementia AD
II NCT02045056 Completed Age 65-90, non-
diabetic or controlled.
None 72 Gemfibrozil vs placebo ~1 year FCSRT en Paired 
associates learning, 
PAL (S)
CSF Abeta 1-40 and 
1-42, CSF and serum 
microRNA 107 (P)
-
6 1998 Exercise training increases 
size of hippocampus and 
improves memory (Erickson 
et al, 2010)
NA Completed Age 55-80, >/51 on 
modified MMSE, not 
demented
None 120 Aerobic exercise vs 
stretching
2 years Spatial memory (P)




(time: 6 months, 24 
months)
Increased volume of 
anterior hippocampus 
after treatment. Greater 
improvements in aerobic 
fitness levels were 
associated with greater 
increases in hippocampal 
volume. No difference in 




RCT of exercise and social 
interaction in a Community-
Based Sample of Non-
Demented Chinese Elders 
(Mortimer et al,2012)
NCT01696019 Completed Age 60-79, no 
dementia. Chinese 
MMSE>26
None 120 Fast walking vs tai chi vs 
intellectual stimulation 
vs controls.
~9 months NTB (P)
(time: 4 months, 9 
months)
Volumetric MRI whole 
brain (S)
Tai chi and intellectual 
stimulation showed a 
positive effect on NTB and 
whole brain volume. Aerobic 






Verubecestat (MK-8931) in 
Participants With Prodromal 
Alzheimer’s Disease (MK-
8931-019) (APECS)
(Egan et al. 2019)
III NCT01953601 Terminated Age 50-85, MCI, 
including, memory 
impairment.
Amyloid PET scan 
positive OR CSF 
Tau/Abeta ratio 
increased
1500 Verubecestat 12mg vs 








CDR-SOB (t: 2 years+ 
extension) (P)
Time to dementia, 
change CCS-3D, 
ADCS-ADL-MCI (S)
Change Amyloid PET, 
CSF t-Tau, volumetric 
MRI hippocampus (S)
Worse stable clinical 
outcome in treatment 
group. Decline in amyloid 
load on PET in treatment 
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(Small et al. 2018)
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None 132 Curcumin 30mg vs 
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1.5 years Cognitive tests (P)




Effect on memory tests in 
treatment group. Decreased 
FDDNP uptake on PET in 
amygdala in treatment 
group. Stable uptake in 
hypothalamus in treatment 





Omega-3 Fatty Acids and/or 
Multi-domain Intervention in 
the Prevention of Age-related 
Cognitive Decline (MAPT)
(Andrieu et al 2017)
NCT00672685 Completed Age>70, frail, MMSE 
≥ 24
None 1680 1. omega-3;







Placebo + multi domain 
intervention;
4. placebo
3 years Changes composite 
score, FCSRT (P)
Changes in other 
cognitive functions 
(S)
(time: every 6 
months)
FDG-PET, volumetric 
MRI whole brain (S in 
substudy)
(time: 6 months (only 
PET), 12 months)





Impact of Icosapent Ethyl 
on Alzheimers Disease 
Biomarkers in Preclinical 
Adults
II NCT02719327 Recruiting Cognitively normal, 
50-70, family history 
AD.
None 150 Icosapent ethyl (IPE) 
4g (OMEGA-3 acid) vs 
placebo
18 months PACC (S) MRI-ASL (P)





Modulation of Micro-RNA 
Pathways by Gemfibrozil in 
Pre-dementia AD
II NCT02045056 Completed Age 65-90, non-
diabetic or controlled.
None 72 Gemfibrozil vs placebo ~1 year FCSRT en Paired 
associates learning, 
PAL (S)
CSF Abeta 1-40 and 
1-42, CSF and serum 
microRNA 107 (P)
-
6 1998 Exercise training increases 
size of hippocampus and 
improves memory (Erickson 
et al, 2010)
NA Completed Age 55-80, >/51 on 
modified MMSE, not 
demented
None 120 Aerobic exercise vs 
stretching
2 years Spatial memory (P)




(time: 6 months, 24 
months)
Increased volume of 
anterior hippocampus 
after treatment. Greater 
improvements in aerobic 
fitness levels were 
associated with greater 
increases in hippocampal 
volume. No difference in 




RCT of exercise and social 
interaction in a Community-
Based Sample of Non-
Demented Chinese Elders 
(Mortimer et al,2012)
NCT01696019 Completed Age 60-79, no 
dementia. Chinese 
MMSE>26
None 120 Fast walking vs tai chi vs 
intellectual stimulation 
vs controls.
~9 months NTB (P)
(time: 4 months, 9 
months)
Volumetric MRI whole 
brain (S)
Tai chi and intellectual 
stimulation showed a 
positive effect on NTB and 
whole brain volume. Aerobic 






Verubecestat (MK-8931) in 
Participants With Prodromal 
Alzheimer’s Disease (MK-
8931-019) (APECS)
(Egan et al. 2019)
III NCT01953601 Terminated Age 50-85, MCI, 
including, memory 
impairment.
Amyloid PET scan 
positive OR CSF 
Tau/Abeta ratio 
increased
1500 Verubecestat 12mg vs 








CDR-SOB (t: 2 years+ 
extension) (P)
Time to dementia, 
change CCS-3D, 
ADCS-ADL-MCI (S)
Change Amyloid PET, 
CSF t-Tau, volumetric 
MRI hippocampus (S)
Worse stable clinical 
outcome in treatment 
group. Decline in amyloid 
load on PET in treatment 





Daniela_VolledigBinnenwerk_final.indd   97 15-3-2021   10:08:41
98 Chapter 3.1













Intervention Duration Cognitive 
endpoint






Amyloid imaging and safety 
study of ACC-001 in subjects 
with early Alzheimer’s 
disease
(van Dyck 2016)
II NCT01227564 Completed Age 50-80, CDR=0.5, 
MMSE >= 25, concern 
about cognition by 
patient or relative
Amyloid PET scan 
positive
63 ACC-001 (active abeta 
immunization) 3mcg/
QS-21 50mcg vs 
ACC-001 10mcg/QS-21 
50mcg




CSF and plasma and 
Abeta 1-40 and 1-42. 
CSF t-Tau and p-Tau, 
volumetric MRI whole 
brain, hippocampus 
(S)
No change amyloid PET in 
treatment group compared 
to placebo. A β x–40 was 
significantly higher in all ACC-
001 + QS-21 groups versus 
placebo, no dose response. 
Volumetric brain MRI, and 
other CSF biomarkers did 
not show differences or 





A study of Gantenerumab 
in patients with prodromal 
Alzheimer’s disease








225mg/4 weeks, vs 
105mg/4weeks vs 
placebo
2 years CDR-SOB (P), ADAS-
Cog (S)
Change Amyloid PET 
(P in substudy)
CSF and plasma and 
Abeta 1-40 and 1 -42. 
CSF Tau and pTau. 
Volumetric MRI whole 
brain, hippocampus, 
ventricles (S)
Preliminary: no efficacy 
on primary or secondary 
endpoints in this trial, but 
a trend toward a benefit 
in the fastest progressors, 
restarted with higher doses
4 May-
2009
Safety and tolerability of 
BMS-708163 in patients 
with prodromal Alzheimer’s 
disease
(Coric et al. 2015)
II NCT00890890 Terminated, 









Age 45-90, prodromal 






270 BMS-708163 50mg 
(gamma secretase 
inhibitor) vs placebo
2-4 years Dementia (S)
(time: at all 
scheduled visits)
CSF Abeta 1-40, 
Abeta 1-42, t-Tau and 
p-Tau (S)
(time:week 2 optional, 
week 24, week 52)
At weeks 24 and 104, 
lowering of CSF Aβ40 
by 10% to 15% and non-
significant reduction of CSF 
Aβ42. Higher atrophy rates 
and conversion to dementia 
in the avagacestat arm for 









I.v. immunoglobulin in MCI II NCT01300728 Ongoing Age 50-84, aMCI, 
CDR=0,5, MMSE >24, 
mHachinski, ischemic 
score <= 4
None 50 NewGam 10% IVIG vs 
placebo, every 2 weeks, 
for 2 months. Total 5 
infusions.
2 years Conversion to AD, 
CDR, CDR-SOB, 
ADAS-Cog, MMSE (S)





ventricles in patients 
with in CSF decreased 
Abeta1-42 and 
increased p-Tau (S)
Unadjusted analysis of 
APCV between the groups 
at 12 months indicated a 
28% reduction in rate of 
atrophy in the IVIG group, 






A 3 Year Study Low Dose 
Ladostigil in Patients With 
(MCI)
(Schneider 2019)
II/III NCT01429623 Completed Age 55-85, CDR=0.5 
(memory can be 









3 years Conversion to AD-
dementia, defined 
by CDR. (P)




- No effect of treatment -/-/NA
7 Jun-
2004
A RCT to examine the efficacy 
of oral Donepezil in subjects 
with MCI
NCT00483028 Completed Age 55-90, MCI, 
MMSE 24-30, BMI 
18-34.
None 38 Donepezil 5mg vs 
placebo
6 weeks NTB (P) MRS (P) Not yet reported
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endpoint






Amyloid imaging and safety 
study of ACC-001 in subjects 
with early Alzheimer’s 
disease
(van Dyck 2016)
II NCT01227564 Completed Age 50-80, CDR=0.5, 
MMSE >= 25, concern 
about cognition by 
patient or relative
Amyloid PET scan 
positive
63 ACC-001 (active abeta 
immunization) 3mcg/
QS-21 50mcg vs 
ACC-001 10mcg/QS-21 
50mcg




CSF and plasma and 
Abeta 1-40 and 1-42. 
CSF t-Tau and p-Tau, 
volumetric MRI whole 
brain, hippocampus 
(S)
No change amyloid PET in 
treatment group compared 
to placebo. A β x–40 was 
significantly higher in all ACC-
001 + QS-21 groups versus 
placebo, no dose response. 
Volumetric brain MRI, and 
other CSF biomarkers did 
not show differences or 





A study of Gantenerumab 
in patients with prodromal 
Alzheimer’s disease








225mg/4 weeks, vs 
105mg/4weeks vs 
placebo
2 years CDR-SOB (P), ADAS-
Cog (S)
Change Amyloid PET 
(P in substudy)
CSF and plasma and 
Abeta 1-40 and 1 -42. 
CSF Tau and pTau. 
Volumetric MRI whole 
brain, hippocampus, 
ventricles (S)
Preliminary: no efficacy 
on primary or secondary 
endpoints in this trial, but 
a trend toward a benefit 
in the fastest progressors, 
restarted with higher doses
4 May-
2009
Safety and tolerability of 
BMS-708163 in patients 
with prodromal Alzheimer’s 
disease
(Coric et al. 2015)
II NCT00890890 Terminated, 









Age 45-90, prodromal 






270 BMS-708163 50mg 
(gamma secretase 
inhibitor) vs placebo
2-4 years Dementia (S)
(time: at all 
scheduled visits)
CSF Abeta 1-40, 
Abeta 1-42, t-Tau and 
p-Tau (S)
(time:week 2 optional, 
week 24, week 52)
At weeks 24 and 104, 
lowering of CSF Aβ40 
by 10% to 15% and non-
significant reduction of CSF 
Aβ42. Higher atrophy rates 
and conversion to dementia 
in the avagacestat arm for 









I.v. immunoglobulin in MCI II NCT01300728 Ongoing Age 50-84, aMCI, 
CDR=0,5, MMSE >24, 
mHachinski, ischemic 
score <= 4
None 50 NewGam 10% IVIG vs 
placebo, every 2 weeks, 
for 2 months. Total 5 
infusions.
2 years Conversion to AD, 
CDR, CDR-SOB, 
ADAS-Cog, MMSE (S)





ventricles in patients 
with in CSF decreased 
Abeta1-42 and 
increased p-Tau (S)
Unadjusted analysis of 
APCV between the groups 
at 12 months indicated a 
28% reduction in rate of 
atrophy in the IVIG group, 






A 3 Year Study Low Dose 
Ladostigil in Patients With 
(MCI)
(Schneider 2019)
II/III NCT01429623 Completed Age 55-85, CDR=0.5 
(memory can be 









3 years Conversion to AD-
dementia, defined 
by CDR. (P)




- No effect of treatment -/-/NA
7 Jun-
2004
A RCT to examine the efficacy 
of oral Donepezil in subjects 
with MCI
NCT00483028 Completed Age 55-90, MCI, 
MMSE 24-30, BMI 
18-34.
None 38 Donepezil 5mg vs 
placebo
6 weeks NTB (P) MRS (P) Not yet reported
3.1
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Intervention Duration Cognitive 
endpoint







comparative effect of 
Donepezil 10mg/d on clinical 
and radiological markers 
(Dubois 2015, Teipel 2016)
IV NCT00403520 Completed Age>50, aMCI, 
CDR=0.5, FCSRT<=17
None 240 Donepezil 
hydrochloride 10mg vs 
placebo





Effect on hippocampal 
volume (45% less decline 





Evaluation of efficacy and 
safety of Donepezil in MCI
(Schuff et al. 2011)
IV NCT00293176 Completed Age 45-90, aMCI, 
MMSE 24-28
None 821 Donepezil 5mg in week 
1-9. After week 9 10mg 
daily
1 year CDR-SOB, modified 
ADAS-Cog (P).
(time: weeks 6, 12, 
24, 36 and 48)
Volumetric MRI: 
hippocampus and 
whole brain substudy 
(S)
Effect on whole brain 
volume. No effect on 
cognition. Cognitive function 





ADCS-MCI trial (Jack et al, 
2008)
III NCT00000173 Completed Age 55-90, aMCI, 
CDR=0.5, MMSE >24
None 720 Donepezil 10mgl 
(n=240) vs Vitamin E 
2000 I
3 years CDR, MMSE, 






whole brain, and 
ventricle (S in 
substudy)
(t: 36 months, at 
conversion to AD 
or withdrawal from 
study)
No effect of on atrophy 
rates or conversion to AD. 
There was a trend toward 
lower rates of hippocampal 
atrophy in APOE4 carriers 







III NCT00236574 Completed Age >50, MCI None 890 (437 
vs 453)
Galantamine 8mg for 
4 weeks, followed by 
16mg for 4 weeks. 
Followed by 24mg/day 
for 24 months





Effect on whole brain 
volume. No effect on 





InDDex study (Feldman et 
al, 2007)
III NCT00000174 Completed Age 55-85, MCI None 1018 Rivastigmine 3-12 mg/
day vs placebo
4 years NTB (P) Volumetric MRI 
hippocampus, whole 
brain and ventricles (S)
Increase of ventricular 
volume at 12 and 24 months 
in the placebo group. This 
effect was lost at 4 years. 
No effect of treatment on 
hippocampal or whole 





Cilostazol in Patients With 
Mild Cognitive Impairment 
(COMCID)
II NCT02491268 Ongoing Age 55-84, CDR=0.5
MMSE 22-28
None 200 Cilostazol 50mg (phos-
phodiesterase type 3 
inhibitor) vs placebo




Cog, memory test, 
ADCS-MCI-ADL. (S)
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endpoint







comparative effect of 
Donepezil 10mg/d on clinical 
and radiological markers 
(Dubois 2015, Teipel 2016)
IV NCT00403520 Completed Age>50, aMCI, 
CDR=0.5, FCSRT<=17
None 240 Donepezil 
hydrochloride 10mg vs 
placebo





Effect on hippocampal 
volume (45% less decline 





Evaluation of efficacy and 
safety of Donepezil in MCI
(Schuff et al. 2011)
IV NCT00293176 Completed Age 45-90, aMCI, 
MMSE 24-28
None 821 Donepezil 5mg in week 
1-9. After week 9 10mg 
daily
1 year CDR-SOB, modified 
ADAS-Cog (P).
(time: weeks 6, 12, 
24, 36 and 48)
Volumetric MRI: 
hippocampus and 
whole brain substudy 
(S)
Effect on whole brain 
volume. No effect on 
cognition. Cognitive function 





ADCS-MCI trial (Jack et al, 
2008)
III NCT00000173 Completed Age 55-90, aMCI, 
CDR=0.5, MMSE >24
None 720 Donepezil 10mgl 
(n=240) vs Vitamin E 
2000 I
3 years CDR, MMSE, 






whole brain, and 
ventricle (S in 
substudy)
(t: 36 months, at 
conversion to AD 
or withdrawal from 
study)
No effect of on atrophy 
rates or conversion to AD. 
There was a trend toward 
lower rates of hippocampal 
atrophy in APOE4 carriers 







III NCT00236574 Completed Age >50, MCI None 890 (437 
vs 453)
Galantamine 8mg for 
4 weeks, followed by 
16mg for 4 weeks. 
Followed by 24mg/day 
for 24 months





Effect on whole brain 
volume. No effect on 





InDDex study (Feldman et 
al, 2007)
III NCT00000174 Completed Age 55-85, MCI None 1018 Rivastigmine 3-12 mg/
day vs placebo
4 years NTB (P) Volumetric MRI 
hippocampus, whole 
brain and ventricles (S)
Increase of ventricular 
volume at 12 and 24 months 
in the placebo group. This 
effect was lost at 4 years. 
No effect of treatment on 
hippocampal or whole 





Cilostazol in Patients With 
Mild Cognitive Impairment 
(COMCID)
II NCT02491268 Ongoing Age 55-84, CDR=0.5
MMSE 22-28
None 200 Cilostazol 50mg (phos-
phodiesterase type 3 
inhibitor) vs placebo




Cog, memory test, 
ADCS-MCI-ADL. (S)
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Intervention Duration Cognitive 
endpoint






Curcumin and yoga therapy 
for those at risk for AD
II NCT01811381 Recruiting Age 60-90, MCI, 
sedentary (exercise 
<30mn, 3 times a 
week)
None 80 Experimental (curcumin 
800mg and aerobic 
exercise) vs placebo vs 
placebo and aerobic 
yoga vs curcumin and 
non-aerobic yoga
1 year CDR-SOB, NPI-Q, 
functional activities 
questionnaire (S)
(time: 6 and 12 
months)
FDG-PET (P)
Plasma: clusterin, CRP, 
Abeta, TNF alpha (P)





Effects of Atomoxetine in MCI 
(ATX-001)
(clinicaltrials.gov)









uptake inhibitor) dose 
escalating to max 
100mg. Crossover after 
6months.
1 year Cognitive tests, not 
specified (S)
CSF biomarkers of 
inflammation (P), 










II-b NTR1705 Completed Age 55-85, aMCI, 
MMSE>=24
CSF Abeta 1-42/1-
40 ratio <1 OR 
t-Tau> 350pg/
ml or pTau> 
60pg/ml OR MTA 




300 Souvenaid (fortasyn) 
125ml vs placebo
2 years NTB (P), MMSE, 
ADAS-Cog, CDR-
SOB (S)
(time: every 6 
months)
CSF and plasma 
Abeta. Volumetric 
MRI whole brain and 
hippocampus (S)
(time:12 months, 24 
months)
No effect on primary 
outcome. Significant 
differences between active 
and control study groups 
for CDR-SOB, hippocampal 
atrophy, less atrophy in 
treatment group. Analyses 
are ongoing for progression 






(Luchsinger et al 2016)
II NCT00620191 Completed Age 55-90 aMCI 
BMI>/ 25
None 80 Metformin vs placebo 1 year ADAS-Cog, FCSRT 
total recall (P)
Plasma Abeta-42 (S). 
FDG-PET and MRI (S, 
substudy)






properties of Lithium in AD
(Forlenza 2019)
II NCT01055392 Unknown Age 60-80, aMCI None 80 Lithium serum titration 
serum levels 0.25-0.5 
mmol/L vs placebo
2 years Progression to AD. 
CDR, CDR-SOB, 
ADAS-Cog, CERAD 
delayed recall test, 
Sequence of letters 
and numbers (SLN), 
TMT (P).
CSF Abeta 1-42, t-Tau 
and p-Tau (S)
Effect on cognition and CSF 
abeta 1-42 in treatment 
group after two years. 





Lithium As a Treatment 
to Prevent Impairment of 
Cognition in Elders (LATTICE)
IV NCT03185208 Recruiting Age>60, MCI None 80 Lithium 150mg vs 
placebo
2 years Preclinical Alzheimer 
Cognitive Composite 
composed of 
Memory and other 
cognitive tests (P)
GSK-3β activity, BDNF, 
volumetric MRI (P)
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Curcumin and yoga therapy 
for those at risk for AD
II NCT01811381 Recruiting Age 60-90, MCI, 
sedentary (exercise 
<30mn, 3 times a 
week)
None 80 Experimental (curcumin 
800mg and aerobic 
exercise) vs placebo vs 
placebo and aerobic 
yoga vs curcumin and 
non-aerobic yoga
1 year CDR-SOB, NPI-Q, 
functional activities 
questionnaire (S)
(time: 6 and 12 
months)
FDG-PET (P)
Plasma: clusterin, CRP, 
Abeta, TNF alpha (P)





Effects of Atomoxetine in MCI 
(ATX-001)
(clinicaltrials.gov)









uptake inhibitor) dose 
escalating to max 
100mg. Crossover after 
6months.
1 year Cognitive tests, not 
specified (S)
CSF biomarkers of 
inflammation (P), 










II-b NTR1705 Completed Age 55-85, aMCI, 
MMSE>=24
CSF Abeta 1-42/1-
40 ratio <1 OR 
t-Tau> 350pg/
ml or pTau> 
60pg/ml OR MTA 




300 Souvenaid (fortasyn) 
125ml vs placebo
2 years NTB (P), MMSE, 
ADAS-Cog, CDR-
SOB (S)
(time: every 6 
months)
CSF and plasma 
Abeta. Volumetric 
MRI whole brain and 
hippocampus (S)
(time:12 months, 24 
months)
No effect on primary 
outcome. Significant 
differences between active 
and control study groups 
for CDR-SOB, hippocampal 
atrophy, less atrophy in 
treatment group. Analyses 
are ongoing for progression 






(Luchsinger et al 2016)
II NCT00620191 Completed Age 55-90 aMCI 
BMI>/ 25
None 80 Metformin vs placebo 1 year ADAS-Cog, FCSRT 
total recall (P)
Plasma Abeta-42 (S). 
FDG-PET and MRI (S, 
substudy)






properties of Lithium in AD
(Forlenza 2019)
II NCT01055392 Unknown Age 60-80, aMCI None 80 Lithium serum titration 
serum levels 0.25-0.5 
mmol/L vs placebo
2 years Progression to AD. 
CDR, CDR-SOB, 
ADAS-Cog, CERAD 
delayed recall test, 
Sequence of letters 
and numbers (SLN), 
TMT (P).
CSF Abeta 1-42, t-Tau 
and p-Tau (S)
Effect on cognition and CSF 
abeta 1-42 in treatment 
group after two years. 





Lithium As a Treatment 
to Prevent Impairment of 
Cognition in Elders (LATTICE)
IV NCT03185208 Recruiting Age>60, MCI None 80 Lithium 150mg vs 
placebo
2 years Preclinical Alzheimer 
Cognitive Composite 
composed of 
Memory and other 
cognitive tests (P)
GSK-3β activity, BDNF, 
volumetric MRI (P)
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Intervention Duration Cognitive 
endpoint






RECALL study II NCT00242593 Unknown Age >54, MCI 
(Petersen criteria)
None 120 Rosiglitazone 
(antidiabetic drug) 4mg 
2dd vs placebo
1.5 years Delayed list recall, 
Stroop interference 
test (P)
(time: every 6 




whole brain atrophy 
rate (P)
Plasma: Abeta 1-42 
and 1-40 (P)




Homocysteine and B 
vitamins in cognitive 
impairment (Vitacog study. 
Smith et al, 2010. De Jager 
et al 2012)
ISRCTN94410159 Completed Age >70, MCI, 
MMSE>24
None 271 (138 
vs 133)
TrioBePlusH (0.8 mg 
folic acid, 0.5 mg, 
cyanocobalamin and 20 
mg pyridoxine)
2 years MMSE, TICS, TICS-M 
(S)
Volumetric MRI whole 
brain (P)
30% reduction of atrophy 
rate in treatment group. 
Effect on executive tests in 
the treatment group with 
high homocysteine levels. 





Candesartan’s Effects on 
Alzheimer’s Disease And 
Related Biomarkers
II NCT02646982 Recruiting Age>50, MCI Amyloid PET or 
CSF amyloid
72 Maximum tolerated 
dose up to 32mg 
candesartan vs placebo
1 year CDR, ADAS-cog, 
Examiner, statial 
1-back test (S)
CSF Abeta, t-Tau, p-Tau, 
cytokine;
Arterial stiffness, 
aortic stiffness, MRI 
cerebral vasoreactivity, 









Effects of Dietary 
Interventions on the Brain 
in MCI
IV NCT01219244  Completed Age 50-80, MCI, BMI 
25-35
None 330 6 arms: 1 Caloric 
restriction; 2 Omega 
3 supp; 3 Resveratrol; 
4 Placebo; 5 Physical/
cognitive training in 
most effective dietary 
intervention; 6 Placebo 
comparator
6 months ADAS-Cog (P) Plasma biomarkers 
and functional/ 
structural brain 





AETMCI NCT01146717 Completed Age 55-80, MCI None 204 Exercise vs balance 
training
1 year NTB (memory, 
executive function) 
(P)
MRI: brain volume and 
white matter integrity. 
Transcranial Doppler 






RCT for preventing decline 
of cognitive functions in the 
community living elderly 
with MCI
(Suzuki et al 2013)
JPRN-UMIN000003662 Completed Age >65, MCI, CDR 0.5 None 150 Supervised aerobic 
exercise for 1 year vs 
lecture about disease 
and health 3 times 
per year
1 year ADAS-Cog (P) FDG PET, volumetric 
MRI, fNIRS (functional 
Near-Infrared 
Spectroscopy). (P)
FDG not reported, MRI less 
progression of atrophy 
in aMCI subgroup and 
ADAS-Cog; improvement 
in aMCI subgroup, control 
group cognitive stable over 
6 months
+/+/NA
Daniela_VolledigBinnenwerk_final.indd   104 15-3-2021   10:08:43
105Use of biomarkers in the design of prevention studies in Alzheimer’s disease













Intervention Duration Cognitive 
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RECALL study II NCT00242593 Unknown Age >54, MCI 
(Petersen criteria)
None 120 Rosiglitazone 
(antidiabetic drug) 4mg 
2dd vs placebo
1.5 years Delayed list recall, 
Stroop interference 
test (P)
(time: every 6 




whole brain atrophy 
rate (P)
Plasma: Abeta 1-42 
and 1-40 (P)




Homocysteine and B 
vitamins in cognitive 
impairment (Vitacog study. 
Smith et al, 2010. De Jager 
et al 2012)
ISRCTN94410159 Completed Age >70, MCI, 
MMSE>24
None 271 (138 
vs 133)
TrioBePlusH (0.8 mg 
folic acid, 0.5 mg, 
cyanocobalamin and 20 
mg pyridoxine)
2 years MMSE, TICS, TICS-M 
(S)
Volumetric MRI whole 
brain (P)
30% reduction of atrophy 
rate in treatment group. 
Effect on executive tests in 
the treatment group with 
high homocysteine levels. 





Candesartan’s Effects on 
Alzheimer’s Disease And 
Related Biomarkers
II NCT02646982 Recruiting Age>50, MCI Amyloid PET or 
CSF amyloid
72 Maximum tolerated 
dose up to 32mg 
candesartan vs placebo
1 year CDR, ADAS-cog, 
Examiner, statial 
1-back test (S)
CSF Abeta, t-Tau, p-Tau, 
cytokine;
Arterial stiffness, 
aortic stiffness, MRI 
cerebral vasoreactivity, 









Effects of Dietary 
Interventions on the Brain 
in MCI
IV NCT01219244  Completed Age 50-80, MCI, BMI 
25-35
None 330 6 arms: 1 Caloric 
restriction; 2 Omega 
3 supp; 3 Resveratrol; 
4 Placebo; 5 Physical/
cognitive training in 
most effective dietary 
intervention; 6 Placebo 
comparator
6 months ADAS-Cog (P) Plasma biomarkers 
and functional/ 
structural brain 





AETMCI NCT01146717 Completed Age 55-80, MCI None 204 Exercise vs balance 
training
1 year NTB (memory, 
executive function) 
(P)
MRI: brain volume and 
white matter integrity. 
Transcranial Doppler 






RCT for preventing decline 
of cognitive functions in the 
community living elderly 
with MCI
(Suzuki et al 2013)
JPRN-UMIN000003662 Completed Age >65, MCI, CDR 0.5 None 150 Supervised aerobic 
exercise for 1 year vs 
lecture about disease 
and health 3 times 
per year
1 year ADAS-Cog (P) FDG PET, volumetric 
MRI, fNIRS (functional 
Near-Infrared 
Spectroscopy). (P)
FDG not reported, MRI less 
progression of atrophy 
in aMCI subgroup and 
ADAS-Cog; improvement 
in aMCI subgroup, control 
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endpoint






Lifestyle Effects on the Aging 
Brain (LEARN)
II NCT02726906 Recruiting Age 60-80, CDR 0 or 
0.5. no dementia, at 
least one SD below 
normative values on 
cogn tests. MMSE 26, 
sedentary beharior
None 100 Aerobic exercise 
program






Cognitive effects of aerobic 
exercise for MCI adults 
(Baker et al, 2010)
II NCT00220467 Completed Age 55-90, aMCI None 33 Aerobic vs stretching 6 months NTB (memory, 
executive function) 
(P).
(time:3 months, 6 
months)
Plasma Abeta 1-42 
and 1-40 (S)
No significant effect 
on plasma Abeta 1-42. 
For women: significant 






CREAD Study” A Study of 
Crenezumab Versus Placebo 
to Evaluate the Efficacy 
and Safety in Participants 
With Prodromal to Mild 
Alzheimer’s Disease (AD)
(Alzforum.org)
III NCT02670083 Terminated Age 55-85, prodromal 
or probable AD.
MMSE >21, CDR=0.5 
or 1.0, abnormal 
memory function.
Amyloid PET scan 
positive OR CSF 
Abeta decreased
750 Crenezumab (passive 
immunotherapy) vs 
placebo




Plasma amyloid beta, 
amyloid PET, tau 
PET, CSF markers of 
disease (s)





221AD302 Phase 3 Study of 
Aducanumab (BIIB037) in 
Early Alzheimer’s Disease 
(EMERGE)
(Cohen 2019, Schneider 
2020, alzforum.org)
III NCT02484547 Terminated Age 50-85, MCI or 
mild AD. MMSE>24, 
CDR 0.5,






Low dose or high dose 
Aducanumab (BIIB037) 
vs placebo, monthly iv 
infusion.




PET, CSF markers, and 
atrophy
Terminated due to futiliy 
analysis. In further analysis 
23% decline reduction 





Study of Aducanumab 
(BIIB037) in Early Alzheimer’ 
Disease (ENGAGE)
Cohen 2019, Schneider 2020, 
alzforum.org)
III NCT02477800 Terminated Age 55-85, MCI or 
mild AD, CDR=0.5, 
MMSE 24-30.






Low dose or high dose 
Aducanumab (BIIB037) 
vs placebo, monthly iv 
infusion.




PET, CSF markers, and 
atrophy
Terminated because 
primary outcome was not 
met in futility analysis.
Exploratory analysis in 
suggests that the subgroup 
who had received>10mg/kg 
doses declined more slowly.
Also dose dependent 











Study to evaluate safety, 
tolerability, and efficacy of 
BAN2401 in subjects with 
early AD
(alzforum.org)
II NCT01767311 Ongoing Age 50-90, MCI or 
mild AD, CDR 0.5-1.0, 
MMSE >=22
Amyloid PET scan 
positive
800 BAN2401 (monoclonal 
abeta antibody) 2.5mg/
kg vs 5mg/kg, 10mg/kg 
vs placebo iv
once every 2 weeks vs 
once every 4 weeks





On interim analysis 93% drop 
in amyloid load in the highest 
dose group. 81% conversion 
of amyloid positive to amyloid 
negative patients.
In highest biweekly treatment 
group 47 % reduction in 
cognitive decline on ADAS-
COG and 30% reduction in 
decline on ADCOMS.
In the highest monthly group 
no significant reduction on 
cognitive decline.
?/+/+
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Lifestyle Effects on the Aging 
Brain (LEARN)
II NCT02726906 Recruiting Age 60-80, CDR 0 or 
0.5. no dementia, at 
least one SD below 
normative values on 
cogn tests. MMSE 26, 
sedentary beharior
None 100 Aerobic exercise 
program






Cognitive effects of aerobic 
exercise for MCI adults 
(Baker et al, 2010)
II NCT00220467 Completed Age 55-90, aMCI None 33 Aerobic vs stretching 6 months NTB (memory, 
executive function) 
(P).
(time:3 months, 6 
months)
Plasma Abeta 1-42 
and 1-40 (S)
No significant effect 
on plasma Abeta 1-42. 
For women: significant 






CREAD Study” A Study of 
Crenezumab Versus Placebo 
to Evaluate the Efficacy 
and Safety in Participants 
With Prodromal to Mild 
Alzheimer’s Disease (AD)
(Alzforum.org)
III NCT02670083 Terminated Age 55-85, prodromal 
or probable AD.
MMSE >21, CDR=0.5 
or 1.0, abnormal 
memory function.
Amyloid PET scan 
positive OR CSF 
Abeta decreased
750 Crenezumab (passive 
immunotherapy) vs 
placebo




Plasma amyloid beta, 
amyloid PET, tau 
PET, CSF markers of 
disease (s)





221AD302 Phase 3 Study of 
Aducanumab (BIIB037) in 
Early Alzheimer’s Disease 
(EMERGE)
(Cohen 2019, Schneider 
2020, alzforum.org)
III NCT02484547 Terminated Age 50-85, MCI or 
mild AD. MMSE>24, 
CDR 0.5,






Low dose or high dose 
Aducanumab (BIIB037) 
vs placebo, monthly iv 
infusion.




PET, CSF markers, and 
atrophy
Terminated due to futiliy 
analysis. In further analysis 
23% decline reduction 





Study of Aducanumab 
(BIIB037) in Early Alzheimer’ 
Disease (ENGAGE)
Cohen 2019, Schneider 2020, 
alzforum.org)
III NCT02477800 Terminated Age 55-85, MCI or 
mild AD, CDR=0.5, 
MMSE 24-30.






Low dose or high dose 
Aducanumab (BIIB037) 
vs placebo, monthly iv 
infusion.




PET, CSF markers, and 
atrophy
Terminated because 
primary outcome was not 
met in futility analysis.
Exploratory analysis in 
suggests that the subgroup 
who had received>10mg/kg 
doses declined more slowly.
Also dose dependent 











Study to evaluate safety, 
tolerability, and efficacy of 
BAN2401 in subjects with 
early AD
(alzforum.org)
II NCT01767311 Ongoing Age 50-90, MCI or 
mild AD, CDR 0.5-1.0, 
MMSE >=22
Amyloid PET scan 
positive
800 BAN2401 (monoclonal 
abeta antibody) 2.5mg/
kg vs 5mg/kg, 10mg/kg 
vs placebo iv
once every 2 weeks vs 
once every 4 weeks





On interim analysis 93% drop 
in amyloid load in the highest 
dose group. 81% conversion 
of amyloid positive to amyloid 
negative patients.
In highest biweekly treatment 
group 47 % reduction in 
cognitive decline on ADAS-
COG and 30% reduction in 
decline on ADCOMS.
In the highest monthly group 
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Intervention Duration Cognitive 
endpoint






Study of E2609 in Subjects 
With Mild Cognitive 
Impairment Due to 
Alzheimer’s Disease and Mild 
to Moderate Dementia Due 
to Alzheimer’s Disease
II NCT02322021 Ongoing Age 50-85, MCI due 
to AD or mild to 
moderate dementia
Amyloid PET scan 
positive
700 E2609 (BACE inhibitor) 
low,middle, high dose vs 
placebo.











PBT2 and its effect on 
amyloid levels in the brains of 
patients with prodromal or 
mild Alzheimer’s disease.
(Villemagne et al. 2017)
II ACTRN12613000777796 Terminated >55, prodromal or 
mild AD.
Amyloid PET scan 
positive OR CSF 
ratio Tau/abeta 
increased
40 Open label extension 
verubecestat. (BACE 
inhibitor)
1 year NTB, ADCS-ADL, 
MMSE, (S)
Change Amyloid PET 




Significant decline in 
amyloid load in treatment 
group. In the open label 
12-month extension study, 
IB-SUVR stabilized. No 
difference in FDG PET, MRI, 
blood abeta markers of 





Study of LY3314814 in 
Early Alzheimer’s Disease 
(AMARANTH)
(Wessels 2020)
II/III NCT02245737 Terminated Age 55-85, MCI or AD 
based on FCSRT>=16 
free recall or>=40 
total recall. CDR 0.5-1, 
memory box=<0.5, 
MMSE 20-30
Amyloid PET scan 
positive OR CSF 
Abeta decreased
2202 LY3314814 (BACE 
inhibitor) capsule 20 mg 
vs 50 mg vs placebo
2 years Change in CDR-
SOB (P)
Change in CDR, 
ADAS-Cog13, ADCS-
ADL, FAQ, NPI. (S)
Amyloid PET, tau 
PET, FDG-PET; CSF 
Abeta, p-Tau, t-Tau; 
volumetric MRI whole 
brain. (S)
Trial not likely to meet the 
primary endpoints on 
interim analysis. Higher 
atrophy ratesi n treatment 
group. Dose related 
reduction in CSF abeta 1-40 





Study of LY2886721 in MCI 
due to AD or mild AD
(clinicaltrials.gov)
I/II NCT01561430 Terminated Age >55, MCI or 
mild AD, CDR 0.5-1, 
memorybox=<0.5, 
MMSE 20-30
Amyloid PET scan 
positive
129 LY2886721 (BACE 
inhibitor) capsule 15 mg 
vs placebo
6 months NTB, ADAS-Cog, 
CDR-SOB, MMSE (S)
CSF abeta 40 and 42 
(P). plasma abeta 40 
and 42.
(time:12 weeks, 24 
weeks).
Terminated due to 
abnormal liver biochemical 




Safety and Tolerability of 
PQ912 in Subjects With Early 
Alzheimer’s Disease (SAPHIR)
(Scheltens et al 2018)
II NCT02389413 Completed Age 55-90, MCI or 
mild AD, MMSE 21-30.
Amyloid PET scan 
positive OR CSF 
Abeta decreased 
AND EITHER 
t-Tau OR p-Tau 
increased
110 PQ912 (inhibitor of 
glutaminyl cyclase) vs 
placebo




rsfMRI, EEG, CSF t-Tau, 





change in CSF t-Tau, p-Tau or 
Abeta. No effect on MRI
Effect on EEG theta 
frequency and One Back test 
in treatment group. No effect 
on other cognitive tests.
More subjects in the 
PQ912 treatment group 





Safety and Exploratory 
Efficacy Study of 
NEUROSTEM® Versus 
Placebo in Patients With 
Alzheimer’s Disease
I/II NCT02054208 Recruiting Age 50-85, MCI or AD. 
MMSE 18-26.
Amyloid PET scan 
positive, MRI mild 
atrophy.
42 Human umbilical 
cord blood derived 
mesenchymal stem 
cells, low dose/high 
dose, vs placebo.
3 months CDR-SOB, ADAS-
Cog, S-IADL, CIBIC. 
(S)
Amyloid PET, CSF 





Benfotiamine in Alzheimer’s 
Disease
III NCT02292238 Ongoing Age>65, aMCI 
or probably AD, 
MMSE>21, CDR>0.5
Amyloid PET scan 
positive
76 Benfotiamine 600mg/
day (vitamine B1 like) vs 
placebo
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Intervention Duration Cognitive 
endpoint






Study of E2609 in Subjects 
With Mild Cognitive 
Impairment Due to 
Alzheimer’s Disease and Mild 
to Moderate Dementia Due 
to Alzheimer’s Disease
II NCT02322021 Ongoing Age 50-85, MCI due 
to AD or mild to 
moderate dementia
Amyloid PET scan 
positive
700 E2609 (BACE inhibitor) 
low,middle, high dose vs 
placebo.











PBT2 and its effect on 
amyloid levels in the brains of 
patients with prodromal or 
mild Alzheimer’s disease.
(Villemagne et al. 2017)
II ACTRN12613000777796 Terminated >55, prodromal or 
mild AD.
Amyloid PET scan 
positive OR CSF 
ratio Tau/abeta 
increased
40 Open label extension 
verubecestat. (BACE 
inhibitor)
1 year NTB, ADCS-ADL, 
MMSE, (S)
Change Amyloid PET 




Significant decline in 
amyloid load in treatment 
group. In the open label 
12-month extension study, 
IB-SUVR stabilized. No 
difference in FDG PET, MRI, 
blood abeta markers of 





Study of LY3314814 in 
Early Alzheimer’s Disease 
(AMARANTH)
(Wessels 2020)
II/III NCT02245737 Terminated Age 55-85, MCI or AD 
based on FCSRT>=16 
free recall or>=40 
total recall. CDR 0.5-1, 
memory box=<0.5, 
MMSE 20-30
Amyloid PET scan 
positive OR CSF 
Abeta decreased
2202 LY3314814 (BACE 
inhibitor) capsule 20 mg 
vs 50 mg vs placebo
2 years Change in CDR-
SOB (P)
Change in CDR, 
ADAS-Cog13, ADCS-
ADL, FAQ, NPI. (S)
Amyloid PET, tau 
PET, FDG-PET; CSF 
Abeta, p-Tau, t-Tau; 
volumetric MRI whole 
brain. (S)
Trial not likely to meet the 
primary endpoints on 
interim analysis. Higher 
atrophy ratesi n treatment 
group. Dose related 
reduction in CSF abeta 1-40 





Study of LY2886721 in MCI 
due to AD or mild AD
(clinicaltrials.gov)
I/II NCT01561430 Terminated Age >55, MCI or 
mild AD, CDR 0.5-1, 
memorybox=<0.5, 
MMSE 20-30
Amyloid PET scan 
positive
129 LY2886721 (BACE 
inhibitor) capsule 15 mg 
vs placebo
6 months NTB, ADAS-Cog, 
CDR-SOB, MMSE (S)
CSF abeta 40 and 42 
(P). plasma abeta 40 
and 42.
(time:12 weeks, 24 
weeks).
Terminated due to 
abnormal liver biochemical 




Safety and Tolerability of 
PQ912 in Subjects With Early 
Alzheimer’s Disease (SAPHIR)
(Scheltens et al 2018)
II NCT02389413 Completed Age 55-90, MCI or 
mild AD, MMSE 21-30.
Amyloid PET scan 
positive OR CSF 
Abeta decreased 
AND EITHER 
t-Tau OR p-Tau 
increased
110 PQ912 (inhibitor of 
glutaminyl cyclase) vs 
placebo




rsfMRI, EEG, CSF t-Tau, 





change in CSF t-Tau, p-Tau or 
Abeta. No effect on MRI
Effect on EEG theta 
frequency and One Back test 
in treatment group. No effect 
on other cognitive tests.
More subjects in the 
PQ912 treatment group 





Safety and Exploratory 
Efficacy Study of 
NEUROSTEM® Versus 
Placebo in Patients With 
Alzheimer’s Disease
I/II NCT02054208 Recruiting Age 50-85, MCI or AD. 
MMSE 18-26.
Amyloid PET scan 
positive, MRI mild 
atrophy.
42 Human umbilical 
cord blood derived 
mesenchymal stem 
cells, low dose/high 
dose, vs placebo.
3 months CDR-SOB, ADAS-
Cog, S-IADL, CIBIC. 
(S)
Amyloid PET, CSF 





Benfotiamine in Alzheimer’s 
Disease
III NCT02292238 Ongoing Age>65, aMCI 
or probably AD, 
MMSE>21, CDR>0.5
Amyloid PET scan 
positive
76 Benfotiamine 600mg/
day (vitamine B1 like) vs 
placebo





Daniela_VolledigBinnenwerk_final.indd   109 15-3-2021   10:08:44
110 Chapter 3.1













Intervention Duration Cognitive 
endpoint








II NCT00438568 Completed Age >55, aMCI (n=64) 
or AD (n=40)
None 104 Intranasal insulin 10 IU 
(n=36) or 20 IU (n=38) IU 
vs placebo (n=30)
4 months Delayed story recall 
score (DSRS) (P). 
ADAS-Cog, ADCS-
ADL (S)
Plasma Abeta (P). CSF 
Abeta and FDG-PET (S, 
in substudy).




precuneus and cuneus in 
placebo group on FDG-PET. 
In 20 IU group improved 
delayed memory. No 
change in DSRS. In insulin 





The Study of Nasal Insulin 
in the Fight Against 
Forgetfulness (SNIFF)
(alzforum.org)
II/III NCT01767909 Completed Age 55-85, aMCI or 
AD MMSE>19, CDR 
0.5-1.0; abnormal 
memory
None 240 Intranasal insulin 20 IU 
twice a day vs placebo








Abeta/t-Tau ratio, MRI 
hippocampal atrophy 
rate (S)
No effect on cognition or 





Exendin-4 for treatment 
of AD
(clinicaltrials.gov)
II NCT01255163 Terminated Age>65, MCI or early 
stage AD, CDR 0.5 or 
1, MMSE >20
CSF Abeta <190 
(+10%) pg/ml
115 Exendin 4 (GLP-1 
agonist)
36 months CDR-SOB, ADAS-
Cog (P)
MRI, fMRI, MRS: 
changes after treatment 
CSF: AD markers (not 
specified) (S)
Terminated due to 
withdrawn support by 
AstraZeneca. Too small 
sample size to analyze.
15 Aug-
2009
Sensory cognitive and 
physical fitness training in MCI
(Kuster et al, 2016)
NCT01061489 Completed Age >55years, MCI, 
Mild AD (MMSE >21)
None 100 Sensory cognitive 
training vs physical 
fitness vs waiting list
10 weeks ADAS-Cog (P) EEG, MRI, CSF (not 
specified) (S)
No effect on cognition. 





Effects of cognitive 
intervention on brain 
metabolism in patients with 
aMCI and mild Alzheimer’s 
disease (Forster et al 2011).
NA Completed aMCI or mild AD None 24 MCI, 
15 AD
Group based cognitive 
intervention vs control 
self study group
6 months ADAS-Cog, MMSE, 
MADRS (P)
FDG PET (S) Marginally improvement 
in cognitive status in aMCI. 
Increased metabolism 
on FDG PET in aMCI (left 
anterior temporal pole and 
anterior cingulated). No 
association between change 




Early intervention MCI with 
Curcumin and bioperine
(clinicaltrials.gov)
NCT00595582 Terminated Age 55-85, MCI, Mild 
AD with, MMSE >20
None 34 no 
control
Curcumin and bioperine 
900mg 3dd2
24 months Cognitive tests (P) FDG-PET (S) 10 started, pilot study. 
Terminated.




DIAN-TU II/III NCT01760005 Recruiting Age 18-80. Cognitively 





or sibling with 
known ADAD 
mutation. Within 
-15 and +10 years 




vs Solanezumab 400mg 
vs placebo
24 months CDR, NTB, MMSE, 
FAQ, NPI-Q, GDS (S)
Gantenerumab: 
Amyloid PET (P), 
CSF Abeta (S); 
Solanezumab: CSF 
Abeta (P). Amyloid PET 
(S) Both: CSF t-Tau, 
p-Tau, MRI cortical 
thickness, FDG-PET (S)
-
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Intervention Duration Cognitive 
endpoint








II NCT00438568 Completed Age >55, aMCI (n=64) 
or AD (n=40)
None 104 Intranasal insulin 10 IU 
(n=36) or 20 IU (n=38) IU 
vs placebo (n=30)
4 months Delayed story recall 
score (DSRS) (P). 
ADAS-Cog, ADCS-
ADL (S)
Plasma Abeta (P). CSF 
Abeta and FDG-PET (S, 
in substudy).




precuneus and cuneus in 
placebo group on FDG-PET. 
In 20 IU group improved 
delayed memory. No 
change in DSRS. In insulin 





The Study of Nasal Insulin 
in the Fight Against 
Forgetfulness (SNIFF)
(alzforum.org)
II/III NCT01767909 Completed Age 55-85, aMCI or 
AD MMSE>19, CDR 
0.5-1.0; abnormal 
memory
None 240 Intranasal insulin 20 IU 
twice a day vs placebo








Abeta/t-Tau ratio, MRI 
hippocampal atrophy 
rate (S)
No effect on cognition or 





Exendin-4 for treatment 
of AD
(clinicaltrials.gov)
II NCT01255163 Terminated Age>65, MCI or early 
stage AD, CDR 0.5 or 
1, MMSE >20
CSF Abeta <190 
(+10%) pg/ml
115 Exendin 4 (GLP-1 
agonist)
36 months CDR-SOB, ADAS-
Cog (P)
MRI, fMRI, MRS: 
changes after treatment 
CSF: AD markers (not 
specified) (S)
Terminated due to 
withdrawn support by 
AstraZeneca. Too small 
sample size to analyze.
15 Aug-
2009
Sensory cognitive and 
physical fitness training in MCI
(Kuster et al, 2016)
NCT01061489 Completed Age >55years, MCI, 
Mild AD (MMSE >21)
None 100 Sensory cognitive 
training vs physical 
fitness vs waiting list
10 weeks ADAS-Cog (P) EEG, MRI, CSF (not 
specified) (S)
No effect on cognition. 





Effects of cognitive 
intervention on brain 
metabolism in patients with 
aMCI and mild Alzheimer’s 
disease (Forster et al 2011).
NA Completed aMCI or mild AD None 24 MCI, 
15 AD
Group based cognitive 
intervention vs control 
self study group
6 months ADAS-Cog, MMSE, 
MADRS (P)
FDG PET (S) Marginally improvement 
in cognitive status in aMCI. 
Increased metabolism 
on FDG PET in aMCI (left 
anterior temporal pole and 
anterior cingulated). No 
association between change 




Early intervention MCI with 
Curcumin and bioperine
(clinicaltrials.gov)
NCT00595582 Terminated Age 55-85, MCI, Mild 
AD with, MMSE >20
None 34 no 
control
Curcumin and bioperine 
900mg 3dd2
24 months Cognitive tests (P) FDG-PET (S) 10 started, pilot study. 
Terminated.




DIAN-TU II/III NCT01760005 Recruiting Age 18-80. Cognitively 





or sibling with 
known ADAD 
mutation. Within 
-15 and +10 years 




vs Solanezumab 400mg 
vs placebo
24 months CDR, NTB, MMSE, 
FAQ, NPI-Q, GDS (S)
Gantenerumab: 
Amyloid PET (P), 
CSF Abeta (S); 
Solanezumab: CSF 
Abeta (P). Amyloid PET 
(S) Both: CSF t-Tau, 
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endpoint






Minocycline in patients with 
Alzheimer’s disease.
(clinicaltrials.gov)
II NCT01463384 Completed Age 55-90, cognitively 
normal, MCI or AD
None 26 Minocycline 50mg 
(tetracycline) 2dd











EGb761 on brain glucose in 
normal, MCI and AD
(Andrieu 2008)
II NCT00814346 Completed Age > 64, Normal 
MMSE >27, MCI 
MMSE>24, AD MMSE 
20-28






Cognitive test (S) FDG-PET (P),MRI brain 
atrophy (S)
No significant effects on 
FDG-PET.
?/+/NA
ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive subscale; ADCS-ADL = Alzheimer’s Disease 
Cooperative Study Activities of Daily Living - Prevention Instrument; ADCS-MCI-ADL = Alzheimer’s disease 
Cooperative Study scale for activities of daily living in MCI; ADCS-PACC =ADCS preclinical Alzheimer cognitive 
composite; APCC = Alzheimer’s Prevention Initiative Composite Cognitive, consist of specific tests from the 
Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE), 
Raven’s Progressive Matrices. APS = Composite Alzheimer Progression Score, derived from multiple cognitive 
and biomarker measures of pre-clinical Alzheimer’s disease; CCS-3D = 3-domain Composite Cognition Score; 
CDRSB = Clinical Dementia Rating Sum of Boxes; CFI = Cognitive Function Index; ECog = Everyday Cognition 
scale; NABDLTs = Neuropsychological Assessment Battery Daily Living Tests; NPI-Q = Neuropsychiatric Inventory 
Questionnaire; NTB= neuropsychological test battery; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status
*+= statistically significant effect; - =no statistically significant effect; ?=not reported; na= not tested
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endpoint






Minocycline in patients with 
Alzheimer’s disease.
(clinicaltrials.gov)
II NCT01463384 Completed Age 55-90, cognitively 
normal, MCI or AD
None 26 Minocycline 50mg 
(tetracycline) 2dd











EGb761 on brain glucose in 
normal, MCI and AD
(Andrieu 2008)
II NCT00814346 Completed Age > 64, Normal 
MMSE >27, MCI 
MMSE>24, AD MMSE 
20-28






Cognitive test (S) FDG-PET (P),MRI brain 
atrophy (S)
No significant effects on 
FDG-PET.
?/+/NA
ADAS-Cog = Alzheimer’s Disease Assessment Scale-Cognitive subscale; ADCS-ADL = Alzheimer’s Disease 
Cooperative Study Activities of Daily Living - Prevention Instrument; ADCS-MCI-ADL = Alzheimer’s disease 
Cooperative Study scale for activities of daily living in MCI; ADCS-PACC =ADCS preclinical Alzheimer cognitive 
composite; APCC = Alzheimer’s Prevention Initiative Composite Cognitive, consist of specific tests from the 
Repeatable Battery for the Assessment of Neurological Status (RBANS), Mini-Mental State Examination (MMSE), 
Raven’s Progressive Matrices. APS = Composite Alzheimer Progression Score, derived from multiple cognitive 
and biomarker measures of pre-clinical Alzheimer’s disease; CCS-3D = 3-domain Composite Cognition Score; 
CDRSB = Clinical Dementia Rating Sum of Boxes; CFI = Cognitive Function Index; ECog = Everyday Cognition 
scale; NABDLTs = Neuropsychological Assessment Battery Daily Living Tests; NPI-Q = Neuropsychiatric Inventory 
Questionnaire; NTB= neuropsychological test battery; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status
*+= statistically significant effect; - =no statistically significant effect; ?=not reported; na= not tested 3.1
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CHAPTER 3.2
THE EFFECT OF DIAGNOSTIC 
CRITERIA ON OUTCOME MEASURES 
IN PRECLINICAL AND PRODROMAL 
ALZHEIMER’S DISEASE: 
IMPLICATIONS FOR TRIAL DESIGN.
Daniela Bertens, Betty M Tijms, Lisa Vermunt , Niels D Prins, Philip Scheltens, 
Pieter Jelle Visser for the Alzheimer’s Disease Neuroimaging Initiative.
Alzheimer’s and Dementia: Translational Research and Clinical intervention 2017 
Sep 21;3(4):513-52
Abstract
Introduction: We investigated the influence of different inclusion criteria for 
preclinical and prodromal Alzheimer’s disease (AD) on changes in biomarkers 
and cognitive markers and on trial sample size estimates.
Methods: We selected 522 cognitively normal subjects and 872 subjects 
with mild cognitive impairment from the Alzheimer’s Disease Neuroimaging 
Initiative study. Compared inclusion criteria were: preclinical or prodromal 
AD (amyloid marker abnormal); preclinical or prodromal AD stage-1 (amyloid 
marker abnormal, injury marker normal); preclinical or prodromal AD stage-
2 (amyloid and injury markers abnormal). Outcome measures were: amyloid, 
neuronal injury and cognitive markers.
Results: In both subjects with preclinical and prodromal AD stage-2 inclusion 
criteria resulted in the largest observed decline in brain volumetric measures 
on MRI and cognitive markers.
Discussion: Inclusion criteria influence the observed rate of worsening in 
outcome measures. This has implications for trial design.
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Introduction
Alzheimer’s disease (AD)–modifying therapy, targeting amyloid, is probably most 
effective when administered early, that is, before the stage of dementia. A number 
of research criteria have been proposed to identify nondemented subjects with AD 
based on the presence of AD biomarkers [1–3]. They can be applied in subjects without 
cognitive impairment (asymptomatic at risk for AD or preclinical AD) and subjects with 
mild cognitive impairment (MCI) (MCI due to AD or prodromal AD). However, these 
criteria allow for different combinations of AD pathology biomarkers, and it is unknown 
whether this impacts on observed changes in outcome measures. For trial design, it 
is critical to understand how selection criteria for subjects at such early stages of the 
disease influence change in outcome measures. Previous studies on outcome measures 
typically had a short follow-up, did not compare the effect of different inclusion criteria, 
or restricted their analyses to a limited set of outcome measures [4–12].
The aim of our study was to investigate whether changes in outcome measures are 
dependent on the inclusion criteria for preclinical and prodromal AD used. We studied 
three definitions for preclinical and prodromal AD: (1) having abnormal amyloid markers; 
(2) having abnormal amyloid markers and normal neuronal injury markers; and (3) 
having both abnormal amyloid and neuronal injury markers. As outcome measures, we 
used biomarkers for amyloid ß (Aß) in cerebrospinal fluid (CSF) or on positron emission 
tomography (PET), CSF tau, fludeoxyglucose PET (FDG-PET), brain atrophy measured 
with magnetic resonance imaging (MRI), and measures of cognitive functioning. To 
study the potential effects of different combinations of inclusion criteria and outcome 
measures on trial design, we calculated sample sizes for a hypothetical 3-year placebo-
controlled trial in subjects at predementia AD stages. To study the additive value of 
biomarkers to define predementia AD, we also calculated slopes and sample sizes for 
subjects with normal cognition and MCI, regardless of their biomarker status.
Methods
Alzheimer’s Disease Neuroimaging Initiative study
We studied data from subjects that participated in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) study (adni. loni.usc.edu). The ADNI was launched in 
2003 as a public- private partnership, led by Principal Investigator Michael W. Weiner, 
MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological 
markers, and clinical and neuropsychological assessment can be combined to measure 
the progression of MCI and early AD.
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Participants
We selected all participants with normal cognition (N=522) or MCI (N=872) from ADNI-1, 
ADNI-2 and ADNI-GO who had baseline and follow-up data available for at least one 
visit within a three year period for several biomarkers and cognitive tests (explained in 
more detail below). The ADNI inclusion criteria for participants with normal cognition 
were absence of memory complaints, a Mini Mental State Examination (MMSE)[13] 
score of 24-30, a Clinical Dementia Rating (CDR) [14] score of 0, and no MCI or dementia 
diagnosis. The inclusion criteria for subjects with MCI were memory complaints, 
objective memory loss, a MMSE score between 24 and 30, and a CDR score of 0.5. 
Exclusion criteria were the absence of an informant, a score of >4 on the modified 
Hachinski scale [15] and score of >5 on the Geriatric Depression Scale (GDS) [16], 
additional diseases expected to interfere with the study, use of investigational agents, 
multiple trial participation, and findings showing other reasons for cognitive problems. 
Permitted medication had to be stable for at least four weeks prior to screening. We 
downloaded ADNI data at 31st March 2014.
Subject classification based on AD biomarkers
Subjects were classified as preclinical or prodromal AD with the use of AD biomarkers 
for amyloidosis and/or neuronal injury (see below), as proposed by International Work 
Group-2 (IWG-2) or National Institute on Aging and Alzheimer’s Association (NIA-AA) 
research criteria [1–3]. As a marker for amyloidosis we used CSF Aβ1-42 or 
18F-AV-45-
PET and as marker of neuronal injury we used CSF tau or FDG-PET. If both modalities 
were present for a given subject, we used their PET measures because they are more 
commonly used in practice. Subjects with normal cognition were classified as preclinical 
AD when they had abnormal amyloid, without taking into account neuronal injury 
markers; as preclinical AD stage-1 if they had abnormal amyloid and a normal injury 
marker; and as preclinical AD stage-2 if both the amyloid and injury markers were 
abnormal. MCI subjects were similarly classified as prodromal AD if the amyloid marker 
was abnormal, without taking into account neuronal injury markers; as prodromal AD 
stage-1 if the amyloid marker was abnormal but the injury marker normal; and as 
prodromal AD stage-2 if both the amyloid and injury marker were abnormal. Figure 1 
gives an overview of classification of subjects according to these criteria.
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Figure 1. Schematic overview of the groups according to sub-classification, applying the research 
criteria.
Abbrevations: ADNI, Alzheimer’s Disease Neuroimaging Initiative; MCI, Mild Cognitive Impairment; AD, 
Alzheimer’s Disease. Subject classification based on AD biomarkers: Preclinical AD n= 146; 49 based 
on CSF measures only, 80 based on PET, and 17 subjects with both modalities present. Preclinical AD 
stage-1 n=110; 33 based on CSF measures only, 60 based on PET, and 17 with both modalities present. 
Preclinical AD stage-2 n= 34; 16 based on CSF measures only, 17 based on PET, and 1 with both modalities 
present. For two Cognitively normal subjects we did not have any information of their injury status so they 
could not be further classified into stage 1 or 2. Prodromal AD n= 420; 149 based on CSF measures only, 
148 based on PET, and 123 with both modalities present. Prodromal AD stage-1 n=216: 63 based on CSF 
measures only, 88 based on PET, and 65 with both modalities present. Prodromal AD stage-2 n=197: 85 
based on CSF measures, 59 based on PET, 53 with both modalities present. For seven MCI subjects we did 
not have any information of their injury status so they could not be further classified into stage 1 or 2.
Baseline assessment and longitudinal assessment
Subjects underwent a standardized assessment that included neurological, physical 
and neuropsychological examinations, collection of CSF and blood, and performance 
of MRI and PET scanning. For 32 cognitively normal and 23 MCI subjects amyloid 
assessment was performed at follow-up only and for these subjects we used the first 
follow-up assessment with this measure as the baseline visit. The protocols for data 
collection are described in detail at http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.
shtml. Cognitive measures were collected at baseline and at 6 monthly follow-up 
assessments; biomarkers were collected at baseline and annually.
CSF analysis
CSF samples were available at baseline for 174 subjects with normal cognition and in 
398 subjects with MCI. CSF samples were collected by lumbar puncture and shipped on 
dry ice to the Penn ADNI Biomarker Core Laboratory at the University of Pennsylvania, 
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Philadelphia for storage until further analysis. CSF was analysed using a multiplex xMAP 
Luminex platform (Luminex Corp) with immunoassay kit-based reagents (INNO-BIA 
Alzbio3; Innogenetics; www.adni-info.org) as described elsewhere [17]. Baseline and 
follow-up samples were analysed in the same batch. The cutoff-value for abnormal CSF 
aß1-42 levels was <192 pg/ml and for tau > 92 pg/ml.
Amyloid-PET analyses
Amyloid 18F-AV-45 PET was available for 286 cognitively normal and 485 MCI subjects. 
Data was acquired 50 minutes post-injection for 20 minutes. In case of motion artefacts, 
another 20 minutes of scanning was acquired. For each subject a florbetapir composite 
standard uptake valid ratio (SUVr) was created as a mean binding of 4 cortical regions 
(frontal, anterior/posterior cingulate, parietal and temporal cortex as determined with 
Freesurfer v4.5.0 and after co-registration of PET and MRI data with SPM5), divided 
by the reference region (whole cerebellum). An uptake in the measure above 1.11 was 
considered to be abnormal [18].
FDG-PET analyses
FDG-PET was available for 402 cognitively normal and 674 MCI subjects. FDG data was 
acquired 30 to 60 minutes post-injection. After preprocessing, images were spatially 
normalized in SPM5 to Montreal Neurological Institute (MNI) PET template. Meta-
analytically derived regions-of-interest (MetaROI’s) were calculated that includes FDG 
uptake in bilateral angular gyrus, posterior cingular and bilateral inferior temporal 
gyrus. Each MetaROI was normalised to a reference region composed of the pons and 
vermis. Total FDG uptake was calculated as a mean of the five individual MetaROI’s 
(www.adni-info.org). FDG uptake on PET below 1.21 was considered as abnormal [19].
MRI analyses
Whole brain structural scans were acquired with 1.5 or 3.0 Tesla MRI scanners. We 
analysed three MRI based outcome measures: whole brain, ventricular and hippocampal 
volume. For measurement of whole brain and ventricular volume the boundary shift 
integral (BSI) was used [20,21]. Hippocampal volumes were measured, using FreeSurfer 
version 4.3 for ADNI-1, and FreeSurfer 5.1 for ADNI-Go and ADNI-2 [22]. Each scan was 
segmented according to an atlas defined by FreeSurfer. For ADNI-Go and ADNI-2 two T1 
weighted images were acquired, of which we selected the non-accelerated acquisition 
scans. Hippocampal volume was measured bilaterally and the average volume over left 
and right was used for the present analyses. To correct for interindividual differences 
in head size, we used the total intracranial volume measure from FreeSurfer. From the 
ADNI database baseline hippocampal volume measures were available for 474 subjects 
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with normal cognition and 840 measures for subjects with MCI. Ventricular and whole 
brain grey matter volumes were available in 364 subjects with normal cognition and 
805 subjects with MCI.
Cognitive assessment
We used the CDR sum of boxes (CDR-sob), MMSE and Alzheimer’s Disease Assessment 
Scale-cognitive (ADAS-Cog 11 item)[23] to assess cognition. In addition we calculated 
the Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite 
(ADCS-PACC), which is a composite score of the total score of the delayed word recall 
on the ADAS-Cog subscale, the delayed recall score on the logical memory subscale 
II from the Wechsler Memory Scale, the digit symbol substitution test score from the 
Wechsler Adult Intelligence Scale-revised and the total MMSE score [24]. Because the 
digit symbol substitution test score was only available for ADNI 1 subjects, we also 
constructed a PACC-like score, without this test.
Data analysis
Statistical analyses were performed with SPSS version 20.0 for the Macintosh.
Linear mixed models (with covariates for age, sex and level of education) were used 
to test the following effects: 1) we tested whether baseline scores differed between 
preclinical AD stage-1 and 2 and between subjects with prodromal AD stage-1 and 2 
(i.e., differences in intercepts); 2) changes over time were assessed by testing whether 
slopes differed from 0 and whether they differed between subjects in preclinical AD 
stage-1 and 2 and between subjects in prodromal AD stage-1 and 2. For slope analyses 
we used an unstructured covariance matrix, assuming a random intercept and fixed 
slope, and used follow-up time as repeated measure. We assumed a linear change 
in time (time coded with a quadratic term was not statistically significant). Separate 
analyses were performed for each criterium used to classify predementia AD. Difference 
with a P-value <0.05 were considered to be statistically significant. Sample size was 
estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing 
an expected treatment effect of 25% reduction of decline in outcome measures with 
a power of 80%, a two-sided alpha of 5%, and a 10% annual dropout rate using the 
following formula [25]:
   n/arm= 2(z1-α/2+ z1-β)
2 (σε
2 ⁄ Σ(ti-tmean))
2 ⁄Δ2,           (1)
with Δ as the difference in mean rate of decline in treatment versus control, σ2e as the 
residual error variance of the mixed effects model, α as the type I error rate of a two 
sided test and 1-β as the power, ti as the times i at which measures were made and 
tmean as the average follow up time. The total sample size n required for a trial was then 
obtained by multiplying this estimation by two and adjusted for an annual drop out 
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rate of 10% over the course of three years (n/arm* 2 * 1.113). Finally, we calculated the 
numbers needed to be screened (NNS), which is the sample size needed in a specific 
subgroup divided by the prevalence of this group in subjects with the same cognitive 
status. All analyses were stratified for baseline diagnosis.
Results
Baseline characteristics and longitudinal change in outcome measures in 
subjects with normal cognition
Table 1 shows the baseline characteristics of the subjects with normal cognition 
according to different classification criteria. Subjects classified as preclinical AD stage-
2 were older (P=0.036), had smaller hippocampal volumes (P=0.014) and, by definition, 
higher CSF tau and lower FDG-PET binding (P<0.001) in comparison to preclinical stage-
1 subjects.
Table 2 shows the change in biomarkers and cognitive markers over time. In subjects 
with normal cognition, regardless of biomarkers status, all markers showed worsening 
over time, except for the ADAS-Cog, and both ADCS-PACC composite scores. Subjects 
with preclinical AD and preclinical AD stage-1 showed increases over time in amyloid 
PET, CSF tau levels, CDR-sob and ventricular volumes, and decreases in FDG pet, whole 
brain, and hippocampal volume. Subjects with preclinical AD stage-2 showed increases 
over time in ventricular volume and the CDR-sob, and decreases in CSF aß1-42 levels, 
whole brain and hippocampal volume. In subjects with preclinical AD, the rate of 
hippocampal volume loss, and increase in CDR-sob was faster for those classified as 
belonging to stage-2 than those to stage-1 (Table 2).
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Baseline characteristics and longitudinal change in outcome measures in 
subjects with MCI
Table 3 shows the baseline characteristics of subjects with MCI according to the 
different classification criteria. Subjects with prodromal AD stage-2 were more often 
apolipoprotein ε4 (APOEε4) positive (P=0.003), had higher amyloid binding on 18F-AV-
45PET (P=0.0001), smaller whole brain and hippocampal volumes (P=0.0001), worse 
scores on cognitive tests (CDR-sob and ADAS-Cog P=0.0001, MMSE P=0.001, ADCS-
PACC without digit symbol test P=0.029) and, by definition, higher CSF tau levels and 
lower FDG PET binding (P=0.0001) than subjects with prodromal AD stage-1.
Table 3. Baseline characteristics of subjects with mild cognitive impairment according to according 


















Age (years) 72.93 (7.6) 73.38 (7.22) 73.12 (7.25) 73.56 (6.99) 0.58
Females (%) 41% (0.5) 42% (0.5) 43% (0.5) 42% (0.5) 0.88
Years of education 15.9 (2.8) 15.91 (2.85) 15.90 (2.84) 15.83 (2.89) 0.82
1/2 APOE-ε4 alleles (%) (n=856) 338/93 (39/11) 210/63 (50/15) 95/31 (44/15) 114/31 (59/16) 0.003
CSF aß 1-42 (pg/ml) (n=398) 168.6 (54.2) 137.83 (27.3) 138.9 (31.8) 135.5 (21.9) 0.31
18F-AV-45(SUVr) (n=485) 1.2 (0.22) 1.35 (0.18) 1.33 (0.17) 1.40 (0.15) 0.0001
CSF tau (pg/ml) (n=382) 97.6 (57.3) 115.7 (59) 88.8 (39.7) 143.37 (62.1) 0.0001
FDG PET (SUVr) (n=674) 1.25 (0.13) 1.22 (0.14) 1.29 (0.12) 1.14 (0.1) 0.0001
Whole brain volume (cm3) (n=805) 1022 (59) 1023 (58) 1034 (61) 1011 (52) 0.0001
Hippocampal volume (mm3) (n=840) 3298 (517) 3241 (505) 3349 (532) 3140 (449) 0.0001
Ventricular volume (cm3) (n=805) 55.3 (50.4)) 56.2 (52.5) 55.0 (56.5) 57.3 (48.0) 0.77
CDR sum of boxes (n=873) 1.53 (0.89) 1.62(0.93) 1.45 (0.91) 1.82 (0.9) 0.0001
MMSE score (n=872) 27.57 (1.81) 27.4 (1.85) 27.6 (1.84) 27.13 (1.81) 0.001
ADAS-Cog (n=869) 10.27 (4.6) 11 (4.7) 10.27 (4.92) 11.96 (4.41) 0.0001
ADCS-PACC (n=372) -2.56 (2.28) -2.93 (2.09) -2.93 (2.23) -2.91 (2.00) 0.81
ADCS-PACC without digit symbol 
test (n= 869)
-1.20 (2.16) -1.57 (2.12) -1.07 (2.07) -2.16 (2.04) 0.029
Follow-up time (n=873) 2.62 (0.69) 2.64 (0.63) 2.60 (0.64) 2.65 (0.64) 0.42
Number of visits per subject (n=873) 5.94 (1.25) 6.18 (1.14) 6.15 (1.15) 6.14 (1.16) 0.92
Abbreviations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid 
ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia 
Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. 
ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. Data are mean (SD) 
unless specified otherwise.
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In the total group of MCI subjects, regardless of their biomarker status, all markers 
showed worsening over time (Table 4). In all subgroups of MCI patients, most markers 
became progressively worse over time, except for 18F-AV-45PET in the total prodromal 
AD and prodromal AD stage-2 subjects, and for CSF aß1-42 levels in prodromal AD 
stage-1 patients. Whole brain and hippocampal volume loss and worsening in cognitive 
test scores over time occurred faster in subjects with prodromal AD stage-2 than in 
subjects with prodromal AD stage-1 (Table 4).
Table 4. Annual change in outcome measures in subjects with mild cognitive impairment according 















CSF aß 1-42 (pg/ml) (n=187) -1.81 (0.66)** -1.66 (0.64)* 0.13 (1.02) -3.00 (0.82)** 0.13
18F-AV-45PET (SUVr) (n=234) 0.007 (0.003)* 0.01 (0.005) 0.014 (0.006)* 0.004 (0.01) 0.44
CSF tau (pg/ml) (n=185) 3.24 (0.88)** 4.11(1.15)** 3.69 (1.27)** 4.26 (1.83)* 0.89
FDG PET (SUVr) (n=388) -0.02 (0.002)** -0.027 (0.003)** -0.025 (0.003)** -0.029 (0.003)** 0.09
Whole brain volume (cm3) 
(n=731)
-11.46 (0.35)** -13.31 (0.49)** -11.64 (0.66)** -14.69 (0.72)** 0.007
Hippocampal volume (mm3) 
(n=804)
-86.22 (2.28)** -97.59 (3.78)** -86.06 (5.58)** -109.8 (5.10)** 0.006
Ventricular volume (cm3) 
(n=731)
4.54 (0.18)** 5.60 (0.30)** 6.04 (0.51)** 5.08 (0.34)** 0.08
CDR sum of boxes (n=811) 0.54 (0.02)** 0.68 (0.03)** 0.52 (0.05)** 0.82 (0.05)** <0.001
MMSE score (n=823) -0.73 (0.04)** -0.91 (0.06)** -0.63 (0.08)** -1.16 (0.08)** <0.001
ADAS-Cog (n=822) 1.14 (0.08)** 1.53 (0.10)** 1.09 (0.14)** 1.99 (0.15)** <0.001
ADCS-PACC (n=334) -0.81 (0.05)** -1.09 (0.08)** -1.10 (0.14)** -1.09 (0.10)** 0.89
ADCS-PACC without digit 
symbol test (n=782)
-0.46 (0.03)** -0.69 (0.05)** -0.45 (0.07)** -0.94 (0.07)** <0.001
Abbrevations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 
1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating 
scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-
PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. N after outcome variable 
indicates the number of subject from the total sample with at least 1 follow up measure available. Data are mean 
(SE). **p<0.01, *p<0.05 slope different from 0.
Sample size estimations
Sample size estimations for subjects with normal cognition
For subjects with normal cognition, sample size estimates ranged from 81-32750 (Table 
5). The smallest sample sizes were estimated for brain volumetric outcome measures, 
3.2
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irrespective of the inclusion criteria used. In preclinical AD stage-1, an intermediately 
small sample size was estimated with 18F-AV-45-PET as outcome measure (n=436). 
Cognitive outcome measures resulted in the largest sample size estimates, regardless 
of the inclusion criteria used. Numbers-needed-for-screening were 2-3 times larger for 
subjects with preclinical AD and preclinical AD stage-1 compared to cognitively normal 
subjects with unspecified biomarker status, when MRI measures, FDG-PET or CSF tau 
were used as outcome measures (Supplementary Table 1). Numbers-needed-for-
screening were smaller in subjects with preclinical AD and preclinical AD stage-1 when 
compared to subjects with normal cognition and unspecified biomarker status when 
18F-AV-45PET or cognitive measures were used as outcome measure. Numbers-needed-
for-screening increased 3-9 times in subjects with preclinical AD stage-2, regardless of 
the outcome measure used.
Table 5. Sample size estimates showing a treatment effect of 25% in a hypothetical 3-year trial in 











CSF aß 1-42 (pg/ml) 1205 (617-3311) - - 457 (153-6280)
18F-AV-45PET (SUVr) 2756 (1050-19103) 603 (256-2786) 436 (190-1853) -
CSF tau (pg/ml) 1440 (698-4532) 1121 (409-9444) 779 (274-7883) -
FDG PET (SUVr) 2425 (1327-5775) 2563 (914-24240) 1622 (623-10873) -
Whole brain volume (cm3) 304 (249-380) 169 (126-239) 226 (151-375) 86 (60-135)
Hippocampal volume (mm3) 361 (294-452) 279 (197-426) 514 (297-1095) 81 (58-123)
Ventricular volume (cm3) 310 (253-388) 271 (188-423) 324 (201-607) 191 (113-389)
CDR sum of boxes 2928 (1874-5206) 1280 (732-2791) 1745 (841-5580) 1046 (431-5342)
MMSE score 32730 (9837-1057708) 7317 (2373-122846) - -
ADAS-Cog - - - -
ADCS-PACC - - - -
ADCS-PACC without digit 
symbol test - - - -
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided 
alpha of 5%, and a 10% annual dropout rate. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 
1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical 
Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive. ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, Alzheimer Disease Cooperative 
Study Preclinical Alzheimer Cognitive Composite -, not calculated as slope is not significantly different from 0 (see 
Table 2). Data are mean (95%CI).
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Sample size estimations for subjects with MCI
In subjects with clinical MCI sample size estimates ranged from 165-9312 with the 
smallest sample size estimates when whole brain, hippocampal volume, and ventricular 
volume were used as outcome measures (Table 6). The use of 18F-AV-45PET, CSF aß1-42 
and CSF tau as an outcome measure resulted in the largest sample size estimations. In 
prodromal AD, sample size was the smallest for brain volumetric measures, the CDR-sob 
and ADCS-PACC. In this group, the largest sample sizes were estimated for the outcome 
measures CSF aß1-42 and CSF tau. For prodromal AD stage-1 and prodromal AD stage-2 
the smallest sample sizes were estimated when using brain volumetric measures as an 
outcome measure. Numbers-needed-for-screening were the smallest in clinical MCI, 
followed by subjects with prodromal AD, prodromal AD stage 2, and prodromal AD 
stage-1 (Supplementary Table 2).
Table 6. Sample size estimates showing a treatment effect of 25% in a hypothetical 3-year trial in 











CSF aß 1-42 (pg/ml) 6545 (2218-82165) 5257 (1705-88214) - 1469 (619-6964)
18F-AV-45PET (SUVr) 9312 (2850-251663) - 3925 (1074-500647) -
CSF tau (pg/ml) 3611 (1539-16455) 2760 (1148-13667) 1791 (634-17633) 3577 (1044-162076)
FDG PET (SUVr) 888 (662-1254) 447 (330-640) 486 (322-817) 396 (262-665)
Whole brain volume (cm3) 165 (147-187) 108 (94-126) 120 (97-152) 102 (85-125)
Hippocampal volume (mm3) 200 (178-227) 142 (123-167) 197 (155-259) 102 (85-123)
Ventricular volume (cm3) 274 (236-322) 231 (189-289) 260 (191-373) 185 (144-245)
CDR sum of boxes 636 (536-765) 443 (359-559) 603 (433-897) 355 (273-481)
MMSE score 992 (803-1256) 625 (488-830) 1263 (791-2328) 371 (283-507)
ADAS-Cog 1420 (1105-1893) 703 (548-933) 1346 (854-2431) 418 (318-573)
ADCS-PACC 745 (583-985) 433 (326-604) 488 (308-889) 395 (279-601)
ADCS-PACC without digit 
symbol test 1509 (1160-2043) 688 (528-932) 1576 (934-3203) 342 (262-465)
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided alpha 
of 5%, and a 10% annual dropout rate. Abbrevations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; 
CSF, cerebrospinal fluid; aß 1-42, amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, 
fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s 
Disease Assessment Scale-Cognitive; ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer 
Cognitive Composite. -, not calculated as slope is not significantly different from 0 (see table 4). Data are mean 
(95%CI).
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Discussion
Our main findings are that inclusion criteria, used to identify subjects with predementia 
AD, influenced the magnitude of change over time in observed outcome measures. 
Sample size estimates for a hypothetical 3-year clinical trial varied widely according 
to the combination of inclusion criteria and outcome markers applied. The smallest 
sample size needed to show a treatment effect was estimated for subjects with normal 
cognition or MCI who had both abnormal amyloid and injury markers at baseline using 
brain volumetric markers as outcome measure.
Subjects with normal cognition showed a worsening over time in all markers, except 
the ADAS-Cog, ADCS-PACC like composite score and ADCS-PACC without digit symbol 
test. When taking into account biomarkers, worsening was typically greater in subjects 
with preclinical stage-2 than in subjects with preclinical stage-1. In subjects with MCI, 
all markers became more abnormal over time. Worsening of outcome makers was 
greater for subjects with prodromal stage-2 than for subjects with prodromal stage-1. 
Our observation of larger effects in outcome measures for subjects at more advanced 
disease stages is in line with reports of previous studies [26–30]. Because subjects in 
stage-2 showed the most worsening over time in all outcome markers, the absolute 
difference between treated and nontreated groups in our hypothetical trial was the 
largest as well, and so subsequent sample size estimates were smaller for this group 
of subjects.
For all definitions of preclinical AD, brain atrophy outcome measures showed the 
most worsening over time and subsequently resulted in the smallest sample size 
estimates. This estimate was the smallest for preclinical AD stage 2. Amyloid markers 
showed some worsening over time, but acceptable sample size estimates based on 
amyloid were only obtained in preclinical AD stage-2 when CSF aß1-42 was used as 
an outcome measure and in preclinical AD stage-1 when 18F-AV-45-PET was used. In 
preclinical AD stage-2, when neuronal injury was defined based on CSF tau, no changes 
in FDG-PET were observed, which might reflect floor effects in this group of subject 
and this is in line with previous studies [31,32]. None of the cognitive measures showed 
decline over time.
Also, for all definitions of prodromal AD in MCI patients, brain atrophy outcome 
measures showed the most worsening over time and yielded the smallest sample size 
estimate. The smallest sample size estimate was observed for prodromal AD stage-2. 
In these subjects, amyloid measures and CSF tau levels showed limited change over 
time, which resulted in very large sample size estimates. FDG-PET showed some decline 
and this resulted in reasonable sample size estimates. Of the cognitive measures, the 
smallest sample size estimate was obtained with the CDR-sob and ADCS-PACC without 
digit symbol test, which became the most abnormal over a time.
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Across all predementia subjects, the inclusion criteria incorporating AD biomarkers 
considerably reduced sample size estimates. However, this was at the expense of an 
increase in the number of subjects needed-to-be-screened, since only a subset of 
subjects with normal cognition or MCI have abnormal AD biomarkers. Still, despite the 
large numbers-needed-to-be-screened, a previous cost-benefit analysis showed that 
enriching trials by refining inclusion criteria with the use of a CSFaß1-42/tau in MCI can 
reduce trial costs with 60%, because fewer subjects are needed to show an effect, and 
this outweighs the increased costs for screening [33].
The observation that both in subjects with preclinical AD and in subjects with 
prodromal AD CSF aß1-42 decreased in stage-2 but not in stage-1, while 18F-AV-45-PET 
changed in stage-1 but not in stage-2 suggests that these markers (in part) reflect 
different disease processes, although it should be noted that the slopes of change did 
not differ between stage-1 and stage-2 [34].
In our fictive trial we found reduced sample size estimates when enriching for AD 
biomarkers, and this is in line with sample size estimates from previous studies that 
used a similar fictive trial design approach. In preclinical AD, one study found that with 
CDR-sob and the MMSE score as outcome measure the use of an abnormal amyloid 
marker for inclusion reduced sample size relative to cognitively subjects unselected 
for biomarkers although sample size estimates in that study were twice as high as 
in our study [5,11]. Our observed lack of change on the PACC may limit its use as 
endpoint in preclinical AD trials with a 3-year duration. Longer trial durations are 
necessary to detect potential treatment effects on cognitive outcomes in preclinical 
AD (Supplementary Table 19). A recent study using a subset of ADNI subjects with 
normal cognition showed that when constructing a cognitive composite measure using 
information from cognitive tests scores of those subjects who show clinical decline, the 
power to detect changes might be improved [35]. However, in subjects with preclinical 
AD this optimised composite measure showed only minimal change over time. Two 
other studies reported similar to our results a reduction of sample size estimates 
for hippocampal, ventricular and whole brain volume and/or MMSE in prodromal AD 
compared to unspecified MCI [12,36]. While another study found that sample sizes were 
smaller for prodromal AD stage-2 than prodromal AD [9]. In addition, APOEε4 allele 
carriership as an additional risk marker might lead to even smaller size estimates [24, 
36, 37]. Although these previous studies show that AD biomarkers can decrease sample 
size estimates, none of these studies have compared the impact on these estimates of 
amyloid, injury, and clinical outcome markers over different preclinical and prodromal 
AD stages. Our study further extents these findings, as we covered all predementia 
stages of AD and demonstrated that also the stages influence sample size estimates.
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Methodological issues
For our power calculation, we made several assumptions that might have influenced 
our findings. We used linear mixed models with random intercepts and a fixed slope 
to assess changes over time in outcome measures. The use of a fixed slope might 
have underestimated sample sizes because it does not take into account variability in 
slopes between subjects [7,10]. In a post hoc analysis, we found that the use of random 
slope models indeed resulted in larger sample size estimates, although the model did 
not converge for several outcome variables (Supplementary Tables 3 and 4). Also, for 
the present analyses we used effect sizes of 25%, which can be considered to be an 
upper bound for a relatively small, but clinically relevant effect size. Larger effect sizes 
provide smaller sample size estimations, and lower numbers needed to screen. For 
example, with a hypothetical reduction of 35% sample sizes would be 45% smaller 
(Supplementary Tables 14–17). In addition, we did not correct for age effects in our 
slopes’ analyses, although these are likely to be present in cognitively normal subjects 
with normal AD markers [7,10]. It can be argued that one should not correct age effects 
because it cannot be excluded that even in cognitively normal subjects, with normal 
AD markers at baseline, the change in outcome effects is still reflecting (in part) AD 
and which might lead to an underestimation of treatment effects. Still, we performed 
additional post hoc analyses correcting for age, and this resulted in increased sample 
sizes or, in the case of preclinical AD stage-1, were often not estimable (Supplementary 
Tables 5 and 6). Of note is that sample size estimates for MCI subjects in stage-1 and 
stage-2 increased for neuronal injury outcome measures and remained comparable 
for cognitive outcome measures. A similar effect has been reported by a recent study 
in another study sample [36]. Possibly this difference reflects that brain structural 
changes are more intertwined with aging, making it difficult to detangle age from 
disease processes. Cognitive outcome measures seemed to be less affected by aging, 
but this might also reflect the much slower pace of decline in preclinical AD for these 
measures. In our design, we chose to model a hypothetical trial in which a treatment 
effect would result in a reduced change, to illustrate the effect of different inclusion 
criteria and outcome measure on sample size estimates. Other sample size estimates 
would be obtained in designs that assume that treatment might result in biomarker 
or cognitive improvements. In our analysis, we combined amyloid and injury markers 
either based on CSF or PET markers, which might have influenced our results because 
these modalities might reflect different processes. Post hoc analysis in subjects with 
markers for both modalities showed that the concordance for amyloid status was 85% 
for subjects with normal cognition and 92% for subjects with MCI (Supplementary 
Table 7), similar to previous studies [34,38–40]. Concordance for preclinical stage-1 and 
stage-2 classification in subjects who were amyloid positive on both CSF and PET was 
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85% for preclinical AD and 50% for prodromal AD (Supplementary Table 8). Additional 
exploratory analyses for the subgroup of prodromal AD with classification using only 
CSF measures provided slope and sample size estimates largely comparable to the 
total group of stage-1 and stage-2 subjects (Supplementary Table 18). We used FDG-
PET as a neuronal injury marker, if amyloid was measured with a PET tracer. However, 
using two PET markers may be impractical. We therefore repeated these analyses 
with hippocampal volume as a neuronal injury marker. We found a concordance of 
FDG-PET hypometabolism and hippocampal atrophy of 74% for subjects with normal 
cognition and of 64% for MCI patients (Supplementary Table 9). Slope and sample 
size estimates were largely similar (Supplementary Tables 10–13), suggesting that MRI-
based hippocampal volume can be used as a more practical alternative to FDG-PET 
for neuronal injury definition.
Our findings show that the definition of predementia AD influences the effects that 
can be found for outcome measures. This has important implications for trial design. For 
our hypothetical trial in subjects with preclinical AD, the estimated sample sizes were 
smallest in subjects at stage- 2, using volumetric markers as outcome measurement. 
In subjects with prodromal AD, the smallest sample size estimates were obtained when 
including subjects at stage-2, using brain volume and cognitive measures as outcome 
measurements. Although a change in cognition would be the most clinically relevant 
outcome, the estimated sample sizes required to demonstrate effects on such markers 
were about three to four times larger than estimates based on MRI markers. This 
highlights the need for novel cognitive tests that are more sensitive for cognitive decline 
in subjects with preclinical and prodromal AD [11,24].
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Supplementary data
Table 1. Numbers-needed-to-be-screened for cognitively normal subjects according to disease 












CSF aß 1-42 (pg/ml) 1205 - - 7017 (2344-96418)
18F-AV-45PET (SUVr) 2756 2156 (915-9961) 2067 (901-8791) -
CSF tau (pg/ml) 1440 4008 (1462-33764) 3695 (1300-37410) -
FDG PET (SUVr) 2425 9165 (3268-86666) 7699 (2956-51598) -
Whole brain volume (cm3) 304 604 (451-853) 1072 (715-1781) 1324 (917-2075)
Hippocampal volume (mm3) 361 999 (704-1525) 2439 (1411-5196) 1247 (886-1881)
Ventricular volume (cm3) 310 967 (671-1513) 1537 (954-2880) 2929 (1734-5974)
CDR sum of boxes 2928 4578 (2617-9978) 8280 (3989-26478) 16060 (6620-82012)
MMSE score 32730 26160 (8484-439217) - -
ADAS-Cog - - - -
ADCS-PACC - - - -
ADCS-PACC without digit 
symbol test
- - - -
Numbers indicate the number of subjects needed-to-be-screened in order to find the number of subjects listed in 
table 5 of the main manuscript. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid 
ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia 
Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. 
ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. -, not calculated as 
slope is not significantly different from 0. Data are mean (95%CI).














CSF aß 1-42 (pg/ml) 6545 10914 (3540-183149) - 6504 (2740-30828)
18F-AV-45PET (SUVr) 9312 - 15846 (4337-2021132) -
CSF tau (pg/ml) 3611 5730 (2383-28375) 7231 (2558-71186) 15835 (4619-717411)
FDG PET (SUVr) 888 928 (685-1329) 1962 (1300-3298) 1752 (1161-2944)
Whole brain volume (cm3) 165 224 (195-261) 483 (391-613) 452 (376-555)
Hippocampal volume (mm3) 200 296 (255-347) 797 (627-1048) 450 (378-546)
Ventricular volume (cm3) 274 480 (392-600) 1049 (773-1505) 818 (640-1084)
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Table 2. Numbers-needed-to-be-screened for MCI subjects according to disease stage 













CDR sum of boxes 636 919 (746-1160) 2433 (1746-3623) 1572 (1208-2130)
MMSE score 992 1298 (1014-1722) 5098 (3194-9400) 1641 (1252-2243)
ADAS-Cog 1420 1459 (1138-1937) 5435 (3446-9813) 1849 (1408-2536)
ADCS-PACC 745 900 (677-1254) 1970 (1243-3590) 1747 (1234-2660)
ADCS-PACC without digit 
symbol test
1509 1428 (1097-1934) 6361 (3772-12929) 1514 (1160-2058)
Numbers indicate the number of subjects needed-to-be-screened in order to find the number of subjects 
listed in table 6 of the main manuscript. Abbrevations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; 
CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, 
fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s 
Disease Assessment Scale-Cognitive; ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer 
Cognitive Composite. -, not calculated as slope is not significantly different from 0. Data are mean (95%CI).
Table 3. Sample sizes calculated with random slope, according to baseline diagnosis and outcome 













CSF aß 1-42 (pg/ml) * * * *
18F-AV-45PET (SUVr) * 949 * *
CSF tau (pg/ml) * * 908 *
FDG PET (SUVr) 3211 5476 3108 -
Whole brain volume (cm3) 457 241 376 *
Hippocampal volume (mm3) 495 431 559 92
Ventricular volume (cm3) 1316 1356 1672 748
CDR sum of boxes * * * *
MMSE score * 5955 * *
ADAS-Cog - - * -
ADCS-PACC - - - *
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42, amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive, ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite. *, not calculated because random slope could not 
be estimated, -, not calculated as slope is not significantly different from 0.
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Table 4. Sample size calculated with random slope, according to baseline diagnosis and outcome 





Prodromal AD stage 1
(N=216)
Prodromal AD stage 2
(N=197)
CSF aß 1-42 (pg/ml) 9793 5914 - *
18F-AV-45PET (SUVr) 20502 * * *
CSF tau (pg/ml) 6052 5139 - -
FDG PET (SUVr) 1577 731 1021 546
Whole brain volume (cm3) 431 285 350 222
Hippocampal volume (mm3) 409 255 283 225
Ventricular volume (cm3) 1108 960 1480 587
CDR sum of boxes 1797 1195 1861 747
MMSE score 1822 1205 2385 535
ADAS-Cog 2686 1618 3826 631
ADCS-PACC 1154 669 909 549
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42, amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive, ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite ,*, not calculated because random slope could not 
be estimated, -, not calculated as slope did not change.















stage 2 corrected 
for aging
CSF aß 1-42 (pg/ml) - 0.3 (2.53) - -
18F-AV-45PET (SUVr) 0.04 (0.01)** - 480 -
CSF tau (pg/ml) 2.4 (1.65) - - -
FDG PET (SUVr) -0.005 (0.005) - - -
Whole brain volume (cm3) -0.85 (1.16) -3.27 (1.56)* - 862
Hippocampal volume (mm3) 2.04 (8.75) -44.58 (11.86)** - 334
Ventricular volume (cm3) 1.42 (0.5) 2.12 (0.8)** - 677
CDR sum of boxes 0.05 (0.04) 0.18 (0.05)** - 1362
MMSE score - - - -
ADAS-Cog - - - -
ADCS-PACC - - - -
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite -, not calculated as slope did not change in previous 
slope analysis without age correction (listed in table 2 of the main manuscript). Data are estimate (SE). **p<0.01, 
*p<0.05 slope different from 0. Age correction was performed by substracting the slopes in cognitively normal 
subjects with both biomarkers normal from the slopes that changed significantly in the preclinical AD group.
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Table 6. Annual change in outcome measures corrected for age effects in subjects with prodromal 















stage 2 corrected 
for aging
CSF aß 1-42 (pg/ml) - 3.00 (1.39)** - 1459
18F-AV-45PET (SUVr) 0.013 (0.006)* - 4390 -
CSF tau (pg/ml) 1.43 (2.27) 1.64 (2.16) - -
FDG PET (SUVr) -0.016 (0.005)** -0.019 (0.005)** 1238 916
Whole brain volume (cm3) -4.54 (1.12)** -7.65 (1.12)** 782 374
Hippocampal volume (mm3) -39.57 (7.77)** -63.86 (7.87)** 934 299
Ventricular volume (cm3) 4.15 (0.57)** 3.21 (0.58)** 565 331
CDR sum of boxes 0.47 (0.08)** 0.77 (0.08)** 626 331
MMSE score -0.56 (0.13)** -1.15 (0.25)** 1375 362
ADAS-Cog 1.20 (0.24)** 2.08 (0.17)** 1091 378
ADCS-PACC -1.145 (0.19)** -1.135 (0.18)** 449 363
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42, amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive, ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite. -, not calculated as slope did not change. in previous 
slope analysis without age correction (listed in table 4 of the main manuscript). Data are estimate (SE). **p<0.01, 
*p<0.05 slope different from 0. Age correction was performed by substracting the slopes in cognitively normal 
subjects with both biomarkers normal from the slopes that changed significantly in the prodromal AD group.
Table 7. Number of subjects that show agreement/disagreement between CSFaß1-42 and PET 
based amyloid positivity.
Amyloid PET normal Amyloid PET abnormal
Cognitively normal CSF aß1-42 normal 34 5
CSF aß1-42 abnormal 3 13
MCI CSF aß1-42 normal 67 5
CSF aß1-42 abnormal 10 113
Abbrevations: MCI, Mild Cognitive Impairment; CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; PET, Positron 
Emission Tomography. Data are numbers
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Table 8. Number of subjects that show agreement/disagreement between CSF tau and FDG PET 
based positivity for neuronal injury.
FDG PET normal FDG PET abnormal
Cognitively normal (n=13) CSF tau normal 10 0
CSF tau abnormal 2 1
MCI (n=100) CSF tau normal 21 18
CSF tau abnormal 32 29
Abbrevations: MCI, Mild Cognitive Impairment; CSF, cerebrospinal fluid; aß 1-42 ,amyloid ß 1-42; FDG, 
fludeoxyglucose; PET, Positron Emission Tomography. Data are numbers.
Table 9. Number of subjects that show agreement/disagreement between MRI hippocampal 
volume and FDG PET based positivity for neuronal injury.
FDG PET normal FDG PET abnormal
Cognitively normal (n=358) MRI normal 248 51
MRI abnormal 41 18
MCI (n=647) MRI normal 248 87
MRI abnormal 147 165
Abbrevations: MCI, Mild Cognitive Impairment; MRI, magnetic resonance imaging; FDG, fludeoxyglucose; PET, 
Positron Emission Tomography. Data are numbers.
Table 10. Baseline characteristics for subjects with preclinical AD and prodromal AD according 
to disease stage classification at baseline with hippocampal atrophy instead of FDG-PET 
hypometabolism as neuronal injury marker.









Age (years) 74.6 (5.5) 75.6 (5.5) 73.79 (7.09) 73.56 (6.99)
Females (%) 62% (0.5) 46% (0.5) 39% (0.5) 42% (0.5)
Years of education 16.03 (2.7) 16.24 (2.68) 15.95 (2.97) 15.83 (2.89)
1/2 APOE-ε4 alleles (%) (n=410) 28/5 (28/5) 15/1 (46/3) 85/22 (46/12) 120/40 (55/18)
CSF aß 1-42 (pg/ml) (n=174) 158.9 (30.4) 146.00 (32.3) 141.3 (31.1) 134.0 (21.9)
18F-AV-45(SUVr) (n=286) 1.31 (0.18) 1.26 (0.15) 1.32 (0.15) 1.40 (0.18)
CSF tau (pg/ml) (n=172) 67.3 (33.6) 109.8 (43.4) 83.8 (38.5) 141.85 (62.1)
FDG PET (SUVr) (n=402) 1.32 (0.1) 1.27 (0.10) 1.24 (0.14) 1.20 (0.1)
Whole brain volume (cm3) (n=364) 1043 (51) 1038 (42) 1036 (60) 1012 (53)
Hippocampal volume (mm3) (n=474) 3763 (324) 3355 (338) 3522 (537) 3015 (328)
Ventricular volume (cm3) (n=363) 50 (42) 49.5 (39) 57.1 (58.4) 55.3 (46.8)
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Table 10. Baseline characteristics for subjects with preclinical AD and prodromal AD according 
to disease stage classification at baseline with hippocampal atrophy instead of FDG-PET 
hypometabolism as neuronal injury marker. (continued)









CDR sum of boxes (n=520) 0.0441 (0.16) 0.030 (0.12) 1.46 (0.90) 1.77 (0.9)
MMSE score 28.98 (1.04) 29.21 (0.93) 27.6 (1.87) 27.19 (1.81)
ADAS-Cog 6.09 (2.83) 6.95 (3.2) 10.54 (4.89) 11.57 (4.62)
ADCS-PACC 2.63 (1.81) 2.62 (1.56) -2.93 (2.23) -2.91 (2.00)
ADCS-PACC without digit symbol test 2.07 (1.34) 2.21 (1.53) -1.08 (2.12) -2.08 (2.01)
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite). Data are mean (SD) unless specified otherwise. 
Cutoff hippocampal volume <6732mm3 [1].
Table 11. Annual change in outcome measures for subjects with preclinical AD and prodromal AD 
according to disease stage classification at baseline with hippocampal atrophy instead of FDG-PET 
hypometabolism as neuronal injury marker.
Preclinical AD  Prodromal 
AD
Stage 1 Stage 2 Stage 1 Stage 2
CSF aß 1-42 (pg/ml) -1.04 (1.74) -5.56 (1.97)* 0.15 (1.03) -2.90 (0.81)**
18F-AV-45PET (SUVr) 0.03 (0.01)** -0.008 (0.009) 0.021 (0.006)** -0.006 (0.01)
CSF tau (pg/ml) 4.60 (1.59)** 3.03 (2.53) 4.48 (1.26)** 3.93 (1.83)*
FDG PET (SUVr) -0.014 (0.005)** -0.006 (0.007) -0.021 (0.003)** -0.032 (0.003)**
Whole brain volume (cm3) -7.80 (0.89)** -10.40 (1.04)** -12.00 (0.69)** -14.26 (0.70)**
Hippocampal volume (mm3) -48.63 (6.82)** -85.22 (9.20)** -84.21 (5.96)** -108.8 (4.77)**
Ventricular volume (cm3) 3.33 (0.45)** 3.93 (0.60)** 6.23 (0.53)** 4.94 (0.33)**
CDR sum of boxes 0.09 (0.02)** 0.32 (0.08)** 0.57 (0.05)** 0.75 (0.06)**
MMSE score -0.13 (0.07) -0.22 (0.12) -0.68 (0.09)** -1.13 (0.09)**
ADAS-Cog 0.052 (0.14) 0.13 (0.28) 1.09 (0.18)** 1.86 (0.16)**
ADCS-PACC -0.049 (0.089) -0.045 (0.166) -1.10 (0.14)** -1.09 (0.10)**
ADCS-PACC without digit symbol test -0.081 (0.064) -0.109 (0.129) -0.45 (0.07)** -0.89 (0.07)**
Analysis were performed in all subjects Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 
, amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical 
Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive. ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite Data are 
mean (SE). **p<0.01, *p<0.05 indicates a slope different from 0. Cutoff hippocampal volume <6732mm3 [1].
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Table 12. Comparison of sample size estimates in preclinical AD for effect size 25% according to 
disease stage classification at baseline with classification of stage 2 with FDG-PET hypometabolism 
or hippocampal volume.
Preclinical AD stage 1 Preclinical AD stage 2






CSF aß 1-42 (pg/ml) - - 457 (153-6280) 458 (153-6397)
18F-AV-45PET (SUVr) 436 (190-1853) 652 (3607-4121) - -
CSF tau (pg/ml) 779 (274-7883) 812 (280-9124) - -
FDG PET (SUVr) 1622 (623-10873) 2274 (754-32762) - -
Whole brain volume (cm3) 226 (151-375) 226 (151-375) 86 (60-135) 87 (60-136)
Hippocampal volume (mm3) 514 (297-1095) 415 (254-795) 81 (58-123) 102 (69-166)
Ventricular volume (cm3) 324 (201-607) 316 (197-585) 191 (113-389) 200 (117-419)
CDR sum of boxes 1745 (841-5580) 1589 (784-4777) 1046 (431-5342) 749 (343-2752)
MMSE score - - - -
ADAS-Cog - - - -
ADCS-PACC - - - -
ADCS-PACC without digit 
symbol test
- - - -
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided 
alpha of 5%, and a 10% annual dropout rate. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; 
aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, 
Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment 
Scale-Cognitive. ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. -, 
not calculated as slope did not change. Data are mean (95%CI). Cutoff hippocampal volume <6732mm3 [1].
Table 13. Comparison of sample size estimates in prodromal AD for effect size 25% according to 
disease stage classification at baseline with classification of stage 2 with FDG-PET hypometabolism 
or hippocampal volume.









CSF aß 1-42 (pg/ml) - - 1469 (619-6964) 1560 (646-7852)
18F-AV-45PET (SUVr) 3925 (1074-500647) 1293 (493-8967) - -
CSF tau (pg/ml) 1791 (634-17633) 1199 (494-6136) 3577 (1044-162076) 4213 (1141-682587)
FDG PET (SUVr) 486 (322-817) 698 (414-1419) 396 (262-665) 302 (213-458)
Whole brain volume (cm3) 120 (97-152) 118 (95-150) 102 (85-125) 105 (87-129)
Hippocampal volume (mm3) 197 (155-259) 218 (168-295) 102 (85-123) 98 (83-117)
Ventricular volume (cm3) 260 (191-373) 254 (186-365) 185 (144-245) 188 (147-248)
CDR sum of boxes 603 (433-897) 513 (371-755) 355 (273-481) 399 (305-543)
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Table 13. Comparison of sample size estimates in prodromal AD for effect size 25% according to 
disease stage classification at baseline with classification of stage 2 with FDG-PET hypometabolism 
or hippocampal volume. (continued)









MMSE score 1263 (791-2328) 1194 (740-2243) 371 (283-507) 422 (320-581)
ADAS-Cog 1346 (854-2431) 1277 (802-2344) 418 (318-573) 450 (343-617)
ADCS-PACC 488 (308-889) 488 (308-889) 395 (279-601) 395 (279-601)
ADCS-PACC without digit 
symbol test
1576 (934-3203) 1688 (960-3713) 342 (262-465) 376 (288-512)
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided 
alpha of 5%, and a 10% annual dropout rate. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; 
aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, 
Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment 
Scale-Cognitive. ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. -, 
not calculated as slope did not change. Data are mean (95%CI). Cutoff hippocampal volume 6732mm^3 [1].
Table 14. Sample size estimates showing a treatment effect of 35% in a hypothetical 3-year trial 











CSF aß 1-42 (pg/ml) 615 (315-1689) - - 233 (78-3204)
18F-AV-45PET (SUVr) 1406 (536-9746) 308 (131-1421) 222 (97-945) -
CSF tau (pg/ml) 735 (356-2312) 572 (209-4818) 397 (140-4022) -
FDG PET (SUVr) 1237 (677-2946) 1308 (466-12367) 828 (318-5547) -
Whole brain volume (cm3) 155 (127-194) 86 (64-122) 115 (77-191) 44 (30-69)
Hippocampal volume (mm3) 184 (150-231) 143 (101-218) 262 (152-559) 41 (29-63)
Ventricular volume (cm3) 158 (129-198) 138 (96-216) 165 (103-310) 97 (58-199)
CDR sum of boxes 1494 (956-2656) 653 (373-1424) 890 (429-2847) 534 (220-2725)
MMSE score 16699 (5019-539647) 3733 (1211-62677) - -
ADAS-Cog - - - -
ADCS-PACC - - - -
ADCS-PACC without digit symbol test - - - -
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided 
alpha of 5%, and a 10% annual dropout rate. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 
1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical 
Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive. ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, Alzheimer Disease Cooperative 
Study Preclinical Alzheimer Cognitive Composite. -, no change in slope . Data are mean (95%CI).
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Table 15. Sample size estimates showing a treatment effect of 35% in a hypothetical 3-year trial in 











CSF aß 1-42 (pg/ml) 3340 (1132-41921) 2682 (870-45007) - 750 (316-3553)
18F-AV-45PET (SUVr) 4751 (1454-128400) - 2003 (548-255432) -
CSF tau (pg/ml) 1842 (785-8395) 1408 (586-6973) 914 (323-8997) 1825 (532-82692)
FDG PET (SUVr) 453 (338-640) 228 (168-327) 248 (164-417) 202 (134-339)
Whole brain volume (cm3) 84 (75-95) 55 (48-64) 61 (49-77) 52 (43-64)
Hippocampal volume (mm3) 102 (91-116) 73 (63-85) 101 (79-132) 52 (44-63)
Ventricular volume (cm3) 140 (121-164) 118 (96-147) 133 (98-190) 94 (74-125)
CDR sum of boxes 324 (274-390) 226 (183-285) 308 (221-458) 181 (139-246)
MMSE score 506 (409-641) 319 (249-423) 644 (404-1188) 189 (144-259)
ADAS-Cog 725 (564-966) 358 (280-476) 687 (436-1240) 213 (162-292)
ADCS-PACC 380 (297-503) 221 (166-308) 249 (157-454) 201 (142-307)
ADCS-PACC without digit 
symbol test
770 (592-1043) 351 (270-475) 804 (477-1634) 175 (134-237)
Sample size was estimated for a hypothetical 3-year randomized-controlled trial with two arms, showing an 
expected treatment effect of 25% reduction of decline in outcome measures with a power of 80%, a 2-sided alpha 
of 5%, and a 10% annual dropout rate. Abbrevations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; 
CSF, cerebrospinal fluid; aß 1-42, amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, 
fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s 
Disease Assessment Scale-Cognitive; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, 
Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. -, not calculated as slope did not 
change (see table 6). Data are mean (95%CI).
Table 16. Numbers-needed-to-be-screened for cognitively normal subjects effect size 35% 












CSF aß 1-42 (pg/ml) 615 - - 3580 (1196-49193)
18F-AV-45PET (SUVr) 1406 1100 (467-5082) 1055 (459-4485) -
CSF tau (pg/ml) 735 2045 (746-17227) 1885 (663-19087) -
FDG PET (SUVr) 1237 4676 (1667-44217) 3928 (1508-26325) -
Whole brain volume (cm3) 155 308 (230-435) 547 (365-908) 675 (468-1059)
Hippocampal volume (mm3) 184 510 (359-778) 1244 (720-2651) 636 (452-960)
Ventricular volume (cm3) 158 493 (342-772) 784 (487-1469) 1494 (885-3048)
CDR sum of boxes 1494 2336 (1335-5091) 4225 (2035-13509) 8194 (3378-41843)
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Table 16. Numbers-needed-to-be-screened for cognitively normal subjects effect size 35% 












MMSE score 16699 13347 (4329-224090) - -
ADAS-Cog - - - -
ADCS-PACC - - - -
ADCS-PACC without digit 
symbol test
- - - -
Numbers indicate the number of subjects needed-to-be-screened in order to find the number of subjects listed in 
table 5 of the main manuscript. Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid 
ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia 
Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. 
ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite. -, not calculated as 
slope did not change. Data are mean (95%CI).
Table 17. Numbers-needed-to-be-screened effect size 35% for MCI subjects according to disease 
stage classification at baseline.











CSF aß 1-42 (pg/ml) 3340 5568 (1806-93443) - 3319 (1398-15728)
18F-AV-45PET (SUVr) 4751 - 8085 (2213-1031190) -
CSF tau (pg/ml) 1842 2923 (1216-14477) 3689 (1305-36320) 8079 (2357-366026)
FDG PET (SUVr) 453 474 (350-678) 1001 (663-1683) 894 (592-1502)
Whole brain volume (cm3) 84 114 (100-133) 247 (199-313) 231 (192-283)
Hippocampal volume (mm3) 102 151 (130-177) 407 (320-534) 230 (193-278)
Ventricular volume (cm3) 140 245 (200-306) 535 (394-768) 418 (326-553)
CDR sum of boxes 324 469 (381-592) 1242 (891-1849) 802 (616-1087)
MMSE score 506 662 (517-879) 2601 (1629-4796) 837 (639-1145)
ADAS-Cog 725 744 (581-988) 2773 (1758-5007) 943 (718-1294)
ADCS-PACC 380 459 (345-640) 1005 (634-1832) 891 (630-1357)
ADCS-PACC without digit 
symbol test
770 728 (560-987) 3245 (1925-6596) 773 (592-1050)
Numbers indicate the number of subjects needed-to-be-screened in order to find the number of subjects 
listed in table 6 of the main manuscript. Abbrevations: MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; 
CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, 
fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s 
Disease Assessment Scale-Cognitive; ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer 
Cognitive Composite. -, not calculated as slope did not change. Data are mean (95%CI).
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Table 18. Annual change in outcome measures for subjects with prodromal AD according to 
disease stage classification at baseline based on CSF only, with tau as neuronal injury marker 
and corresponding sample size estimates.
Slope estimates Sample size estimates
Stage 1 (N=108) Stage 2 (N=148) Stage 1 (N=108) Stage 2 (N=148)
CSF aß 1-42 (pg/ml) 0.097 (1.117) -2.798 (0.776) ** - 1638 (683-8035)
18F-AV-45PET (SUVr) 0.035 (0.017) 0.015 (0.021) - -
CSF tau (pg/ml) 4.896 (1.164)** 2.955 (1.779) 829 (383-2964) -
FDG PET (SUVr) -0.024 (0.004)** -0.031 (0.004)** 578 (316-1379) 373 (239-659)
Whole brain volume (cm3) -12.976 (0.913)** -14.471 (0.764)** 124 (95-167) 108 (88-134)
Hippocampal volume (mm3) -90.539 (6.774)** -111.544 (5.097)** 155 (118-214) 88 (74-106)
Ventricular volume (cm3) 7.733 (0.762)** 4.84 (0.358)** 242 (169-373) 210 (160-288)
CDR sum of boxes 0.848 (0.075)** 0.785 (0.052)** 290 (210-424) 286 (223-378)
MMSE score -1.007 (0.143)** -1.134 (0.09)** 721 (441-1388) 408 (305-574)
ADAS-Cog 1.798 (0.225)** 2.055 (0.165)** 654 (421-1150) 410 (306-578)
ADCS-PACC -1.099 (0.144)** -1.089 (0.105)** 488 (308-889) 395 (279-601)
ADCS-PACC without digit 
symbol test
-0.793 (0.105)** -0.918 (0.077)** 614 (385-1127) 383 (282-550)
Analysis were performed in all subjects Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 
, amyloid ß 1-42; AV-45, Florbetapir; PET, Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical 
Dementia Rating scale; MMSE, Mini Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-
Cognitive. ADCS-PACC, Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite Data are 
mean (SE). **p<0.01, *p<0.05 indicates a slope different from 0. Cutoff hippocampal volume <6732mm3 [1].
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Table 19. Annual change in outcome measures in subjects with normal cognition according to 
disease stage classification at baseline using all time points available, and sample size estimates 
for hypothetical trial of 5 years for effect size 25%.
Slope estimates based on all 
available time points
Sample size estimates for trial 












CSF aß 1-42 (pg/ml) (n=97) -3.086 (0.976)** -2.908 (0.96)** 1094 (410-8134) 585 (209-5526)
18F-AV-45PET (SUVr) (n=135) 0.022 (0.007)** 0.004 (0.008) 377 (145-2521) -
CSF tau (pg/ml) (n=97) 2.354 (1.053)* 0.95 (1.139) 2028 (564-188420) -
FDG PET (SUVr) (n=219) -0.0191 (0.003)** -0.003 (0.003) 343 (198-731) -
Whole brain volume (cm3) (n=346) -8.64 (0.808)** -9.931 (0.949)** 67 (48-101) 35 (24-53)
Hippocampal volume (mm3) (n=412) -44.246 (5.004)** -62.923 (6.373)** 243 (163-404) 123 (85-193)
Ventricular volume (cm3) (n=346) 3.204 (0.394)** 3.46 (0.543)** 116 (75-202) 93 (54-199)
CDR sum of boxes (n=98) 0.249 (0.026)** 0.241 (0.032)** 663 (456-1053) 453 (283-839)
MMSE score (n=486) -0.15 (0.036)** -0.204 (0.056)** 2523 (1175-8832) 2028 (852-9705)
ADAS-Cog (n=484) 0.513 (0.077)** 0.316 (0.112)** 920 (550-1845) 3169 (1099-34669)
ADCS-PACC (n=309) -0.033 (0.077) -0.13 (0.152) - -
ADCS-PACC without digit symbol 
test (n=394)
-0.168 (0.038)** -0.274 (0.061)** 1840 (876-6066) 1077 (518-3454)
Abbrevations: AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; aß 1-42 , amyloid ß 1-42; AV-45, Florbetapir; PET, 
Positron Emission Tomography; FDG, fludeoxyglucose; CDR, Clinical Dementia Rating scale; MMSE, Mini Mental 
State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive. ADCS-PACC, Alzheimer Disease 
Cooperative Study Preclinical Alzheimer Cognitive Composite. N after outcome variable indicates the number of 
subject from the total sample with at least 1 follow up measure available. Data are mean (SE). **p<0.01, *p<0.05 
indicates a slope different from 0.
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USE OF MILD COGNITIVE 
IMPAIRMENT AND PRODROMAL 
AD/ MCI DUE TO AD IN CLINICAL 
CARE: A EUROPEAN SURVEY  
Daniela Bertens, Stephanie Vos, Patrick Kehoe, Henrike Wolf, Flavio Nobili, 
Alexandre Mendonça, Ineke van Rossum, Jacub Hort, Jose Luis Molinuevo, 
Michael Heneka, Ron Petersen, Philip Scheltens, Pieter Jelle Visser
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Abstract
Introduction: The diagnosis of Mild Cognitive Impairment (MCI) refers to 
cognitive impairment not meeting dementia criteria. A survey among members 
of the American Association of Neurology (AAN) showed that MCI was 
considered a useful diagnosis. Recently, research criteria have been proposed 
for the diagnosis of Alzheimer’s disease (AD) in MCI based on AD biomarkers 
(prodromal AD/MCI due to AD). Aim of this study was to investigate the attitudes 
of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due 
to AD criteria. We also investigated whether the prodromal AD/MCI due to AD 
criteria impacted management of MCI patients.
Methods: Online survey in 2015 among 102 members of the European 
Academy of Neurology (EAN) and the European Alzheimer’s Disease Consortium 
(EADC). Questions were asked on how often criteria were used, how they were 
operationalized, how they changed patient management, and what were 
considered advantages and limitations of MCI and prodromal AD/MCI due to 
AD. The questionnaire consisted of 47 questions scored on a Likert scale.
Results: Almost all respondents (92%) used the MCI diagnosis in clinical practice. 
Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it 
helped to label the cognitive problem, involve patients in planning for the future 
and start risk reduction activities. These findings were similar to those reported 
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Introduction
The term mild cognitive impairment (MCI) was originally developed for research in non-
demented patients with objective memory impairment. These subjects were assumed 
to be at an increased risk of developing dementia, in particular Alzheimer-type dementia 
[1–4]. A survey among members of the American Academy of Neurology (AAN) showed 
that MCI was a common diagnosis and considered useful [5]. However, little is known 
about the clinical use of MCI outside Northern America, where attitudes towards MCI may 
be different. Moreover, since the introduction of the MCI concept, research criteria have 
been proposed to diagnose Alzheimer’s disease (AD) among subjects with MCI, referred 
to as prodromal AD and MCI due to AD [6, 7]. These criteria require, in addition to a 
diagnosis of MCI, the presence of biomarkers indicative for AD pathophysiology. Research 
criteria for prodromal AD were proposed by an International Working Group (IWG), and 
criteria for MCI due to AD by the National Institute on Aging–Alzheimer’s Association 
(NIA-AA). According to the IWG-1 criteria, prodromal AD is defined by abnormal amyloid, 
tau, or FDG-PET or by hippocampal atrophy, while according to IWG-2 criteria, prodromal 
AD is defined by abnormal beta amyloid 1–42 and tau in cerebrospinal fluid (CSF) or 
an abnormal amyloid PET scan [7, 8]. NIA-AA MCI due to AD is diagnosed with high 
likelihood in the presence of both abnormal amyloid and neuronal injury markers, and 
with intermediate likelihood, in case only an amyloid or injury marker is measured and this 
marker is abnormal [6]. Although these criteria are intended for research, they are also 
used in clinical practice [9]. However, it is unknown how often these criteria are used, how 
they are implemented, what is communicated to patients, how it affects the management 
of patients, and what are considered advantages and disadvantages of the criteria relative 
to the MCI diagnosis. Information on how MCI and the research criteria are perceived and 
in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used 
by 68% of the EAN/EADC respondents. The most common reasons to use the 
criteria were increased certainty of diagnosis (86%), increased possibilities to 
provide counseling (51%), facilitation of follow-up planning (48%), start of medical 
intervention (49%), and response to patients’ wish for a diagnosis (41%). Over 
70% of the physicians considered that a diagnosis of prodromal AD/MCI due to 
AD had an added value over the MCI diagnosis.
Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are 
commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were 
considered clinically useful and impacted patient management and communication.
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used is critical for the development and implementation of guide- lines for MCI in clinical 
practice, and to develop procedures to enable international standardization.
The survey on MCI among members AAN was performed in 2010. It showed that 
the term MCI was frequently used. Perceived benefits of the use of MCI included that 
the diagnosis facilitated planning for the future, motivated risk reduction activities, and 
financial planning. Drawbacks for using the term MCI were the difficulty to diagnose it 
and the fact that a diagnosis could cause un- necessary worry and that MCI could better 
be described as early Alzheimer’s disease (AD). Despite these critics, the benefits were 
thought to outweigh the drawbacks.
The aim of the present study was first to apply the AAN questionnaire to clinicians in 
Europe. The survey assessed the frequency of the use of the MCI diagnosis, implications 
for communication with and management of patients meeting criteria, and perceived 
strengths and limitations of the MCI concept. Secondly, we assessed the attitude towards 
the use of the preclinical AD/MCI due to AD criteria. We asked on the frequency of use of 
these criteria, how they were operationalized, what were reasons to use the criteria or not 
in clinical practice, whether a diagnosis of prodromal AD/MCI due to AD impacted patient 
management compared to MCI patient that did not meet prodromal AD/MCI due to AD 
criteria, and whether they provided added value over the MCI diagnosis without biomarkers
Methods
We conducted a European multicenter survey regarding the usefulness of MCI and 
prodromal AD/MCI due to AD and clinical practice (see Additional file 1), based on an 
adapted version of the MCI survey of Roberts and colleagues [5].
Survey development and contents
The first part of the survey was on MCI with sections on “terms and definitions,” 
“current practice,” and “attitudes” towards the use of the criteria in clinical practice. This 
part consisted of 26 questions scored on a Likert scale. It was the same as the AAN 
questionnaire with a few changes. We added questions on diagnostic investigations 
performed in patients with MCI and counseling on alcohol intake. We also rephrased 
the question on the disease codings according to European classification systems. In 
the second part of the survey, we explored attitudes towards criteria for prodromal AD/
MCI due to AD. The format of the questions was similar to part 1, except that we added 
2 questions on possible benefits (selection patients for trials, planning for follow-up) and 
deleted the statement “MCI is usually better described as early AD.” A steering group 
with both European and American representatives evaluated the survey content and the 
appropriateness of adjustments made. We pilot tested the survey in our center to check 
3.3
Daniela_VolledigBinnenwerk_final.indd   151 15-3-2021   10:08:50
152 Chapter 3.3
how much time it would take and if there were any suggestions. Next, we formatted the 
survey such that it could be administered online using the Bristol Online Survey system 
(https://www.onlinesurveys.ac.uk). The final version of the questionnaire consisted of 47 
questions (16 from Roberts in part 1, and 31 in part 2), and it took 15–20 min to complete it.
Participant identification and recruitment
We invited members of the European Academy of Neurology (EAN) and European 
Alzheimer’s Disease Consortium (EADC). The EAN unites neurologists across Europe 
and has members from 45 European national neurological societies and includes 800 
individual neurologists (https:// www.eaneurology.org/). The EADC is a network of over 
50 European centers that have a strong track record of clinical and biomedical research 
in AD and related dementias (http://www.eadc.info/sito/pagine/home.php).
We sent a link to the survey to members of the EAN scientific panel on Dementia 
and Cognitive Disorders (n = 74) and to EADC members (n = 140). We encouraged EAN 
and EADC members to share the survey to other colleagues working in the dementia 
field but who were not necessarily EAN or EADC members. We send our first mail on 28 
November 2014 and reminders on 12 and 19 December 2014. In addition, EAN members 
were invited to complete the survey via a web link that was provided in the November 
2014 EAN newsblog, which is sent to over 15,000 members of national neuro- logical 
societies in Europe. The survey was live between November 2014 and January 2015.
Analysis
Responses to survey items and demographics were expressed as percentages. We 
tested differences in responses between the EAN/EADC and the AAN respondents 
regarding the use of the MCI diagnosis. In a subgroup of respondents that used the 
diagnosis of “Prodromal AD” or “MCI due to AD” in clinical practice, we tested whether 
terminology, counseling, and management differed between patients with a diagnosis of 
prodromal AD/MCI due to AD and those without that diagnosis. Group differences were 
tested by the chi- square test. If a question had multiple responses, we used the chi-
square test for trend. A two-sided p value < 0.05 was considered statistically significant.
Results
Respondents
One hundred and two completed surveys were obtained, of which 38 from EADC members 
(response rate 27%), 53 from the EAN (including 16 members of the Spanish Association of 
Neurology), 3 from members of the Inter- national Psychogeriatric Association (IPA), and 8 from 
other or unknown sources. Demographic characteristics of the respondents are shown in Table 1.
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Table 1: Demographics
EAN/EADC AAN^
Age (mean (SD)* 50.0 (8.7) 54 (8.6)
Gender, n female/total (%) 26/84 (31%) 21%
Medical specialty n (%)
-  Neurology 74 (73%) 94.4%
-  Geriatrics  9 (8.8%) 3.1%
-  Psychiatry  9 (8.8%) 3.4%
- Neuropsychology  2 (1.9%) 4.4%
-  Combination of the above  7 (6.9%) NA
Subspecialty training, n yes (%) 65 (63.7%) 59.6%
Years of experience, n (%) NA
-  < 5 years  7 (6.9%)
-  5-10 years 15 (14.7%)
-  10-15 years 20 (19.6%)
-  15-20 years 20 (19.6%)
-  > 20 years 40 (39.2%)
Organization, n (%)
-  Solo practice 5 (4.9%) 30%
-  Group practice 57 (59.9%) 48.4%
 Single specialty group 1 (1.0%)
 Multispecialty group 6 (5.9%)
 University based group 50 (49%)
-  Hospital or clinic 38 (37.3%) 17.9%
 Health care centre 2 (2.0%)
 Government hospital or clinic 28 (27.5%)
 Other public or private hospital or clinical setting 8 (7.8%)
-  Other 2 (2.0%) 3.6%
Number of respondents within a country, n NA
 -  Turkey, Denmark, Finland, Georgia, Ireland, Israel, Luxembourg, Poland 1
 -  Austria, Belgium, Bulgaria, Norway, Slovenia, Portugal 2
 -  Sweden, Greece, Romania, Netherlands, France, Italy, United Kingdom 3-6
 -  Czech Republic, Germany 7-9
 -  Spain 33
* Response from 75 subjects. ^ Only percentages reported. NA=not available
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MCI
Terms and definitions of clinical diagnosis
Ninety-two percent of the respondents recognized MCI as a clinical diagnosis. Of these, 
85% differentiated between amnestic versus non-amnestic MCI forms and 65% used 
the subdivision of single versus multiple do- main MCI. A minority of respondents used 
cognitive impairment no dementia (CIND; 16%), age-associated memory impairment 
(AAMI; 13%), or other terms (8%).
Clinical practice
Ninety-three percent of the respondents saw patients with cognitive symptoms of 
mild severity routinely in practice. A small proportion (6%) saw them once or twice per 
month and 1% never. The most common terms to describe the cognitive impairment 
to patients were MCI (75%), memory problems (46%), and possibly early AD (45%). 
Laboratory assessment was performed routinely in 92% of patients with MCI, 
neuropsychological testing in 82%, magnetic resonance imaging (MRI) in 65%, and 
computed tomography in 42%. Less than 25% of respondents performed routinely 
lumbar puncture, electroencephalography (EEG), fludeoxyglucose positron emission 
tomography (FDG-PET), single-photon emission computed tomography (SPECT), or 
amyloid PET (Fig. 1).
Figure 1: Diagnostic investigations routinely performed in patients with MCI
Bars indicate frequencies (in %)
Abbreviations: AD=Alzheimer’s disease; CT= computed tomography; MRI= magnetic resonance 
imaging; EEG= electro-encephalogram; SPECT= single photon emission computed tomography; FDG-
PET= fludeoxyglucose positron emission tomography.
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Respondents routinely advised patients on mental and physical exercise. Less than 50% of 
the respondents discussed routinely diet and nutrition, alcohol intake, use of vitamins, and 
vascular risk factors (Table 2 and Additional file 2: Figure S1). Most respondents routinely 
discussed with patients the need for follow-up (89%) and the risk of AD in general terms 
(69%). Less than 40% of the respondents discussed routinely numeric estimates of AD, 
considerations in relation to driving, potential to undertake research studies, support service 
options available, potential benefits of advance planning, and referral to the Alzheimer 
Association or similar organizations (Table 2 and Fig. 2). A small proportion of the respondents 
routinely prescribed cholinesterase inhibitors (21%), memantine (13%), or other medications 
(e.g., vitamins or supplements, or antidepressants) (Table 2 and Additional file 2: Figure S1).
Figure 2: Topics that are routinely discussed with patients with MCI
Blue bars are frequencies (in %) of respondents of EAN/EADC who discuss routinely the above topics. Red bars 
are frequencies (in %) of respondents of the AAN survey. Abbreviations: EAN, European Academy of Neurology; 
EADC, European Alzheimer’s Disease Consortium; AAN, American Academy of Neurology. Differences 
frequencies between EAN/EADC and AAN members were tested using chi-square. *p<0.01 **p<0.0001.
Table 2: Usual practice when seeing patients with cognitive symptoms of mild severity
Never Rarely Sometimes Routinely p-value*
Patient counseling
-  Diet and nutrition EAN/EADC 9 (8.8) 11 (10.8) 32 (31.4) 49 (48) 0.17
AAN 57 (13.6) 69 (16.4) 132 (31.5) 162 (38.5)
-  Vitamins EAN/EADC 16 (15.7) 24 (23.5) 38 (37.3) 23 (22.5) 0.29
AAN 49 (11.6) 84 (20.1) 155 (36.9) 132 (31.4)
-  Mental exercise EAN/EADC 1 (1) 4 (3.9) 13 (12.7) 83 (81.4) 0.41
AAN 13 (3.0) 21 (5.1) 71 (17.0) 315 (74.9)
-  Physical exercise EAN/EADC 3 (2.9) 4 (3.9) 13 (12.7) 82 (80.4) 0.78
AAN 8 (1.8) 19 (4.5) 67 (15.9) 327 (77.8)
-  Alcohol EAN/EADC 18 (17.6) 14 (13.7) 32 (31.4) 36 (35.3) **
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Table 2: Usual practice when seeing patients with cognitive symptoms of mild severity (continued)
Never Rarely Sometimes Routinely p-value*
Patient education
-  Advance planning EAN/EADC 1 (1) 21 (20.6) 42 (41.2) 37 (36.3) 0.08
AAN 33 (7.9) 84 (20.0) 172 (41.0) 130 (31)
-  Driving EAN/EADC 3 (2.9) 16 (15.7) 42 (41.2) 41 (40.2) 0.82
AAN 11 (2.6) 52 (12.3) 186 (44.2) 172 (40.9)
-  Research studies EAN/EADC 2 (2) 12 (11.8) 47 (46.1) 40 (39.2) <0.0001*
AAN 27 (6.4) 109 (26) 199 (47.4) 85 (20.2)
-  Support services EAN/EADC 0 17 (16.7) 37 (36.3) 46 (45.1) 0.001*
AAN 18 (4.3) 92 (21.9) 195 (46.4) 115 (27.3)
-  Recommendations for follow-up EAN/EADC 0 1(1) 8 (7.8) 91 (89.2) 0.75
AAN 0 5 (1.3) 44 (10.4) 371 (88.3)
-  Risk of AD and related disorder 
(general terms)
EAN/EADC 1 (1) 5 (4.9) 25 (24.5) 70 (68.6) 0.55
AAN 4 (1) 37 (8.9) 113 (27) 265 (63)
-  Risk of AD and related disorders 
(numeric estimates)
EAN/EADC 7 (6.9) 24 (23.5) 47 (46.1) 22 (21.6) 0.17
AAN 47 (11.1) 125 (29.8) 150 (35.7) 98 (23.4)
-  Referral to Alzheimer’s 
association or similar association
EAN/EADC 15 (14.7) 34 (33.3) 35 (34.3) 16 (15.7) 0.22
AAN 82 (19.5) 153 (36.5) 146 (34.7) 39 (9.3)
-  Written summary letter of 
findings for patient
EAN/EADC 9 (8.8) 13 (12.7) 25 (24.5) 54 (52.9) <0.0001*
AAN 117 (27.8) 158 (37.6) 82 (19.6) 63 (14.9)
Medication prescribed
-  Cholinesterase inhibitors EAN/EADC 28 (27.5) 16 (15.7) 35 (4.3) 21 (20.6) 0.01*
AAN 60 (14.3) 67 (15.9) 189 (45) 104 (24.8)
-  Memantine EAN/EADC 64 (62.7) 14 (13.7) 7 (6.9) 13 (12.7) 0.0001*
AAN 147 (35.1) 108 (25.6) 129 (30.7) 36 (8.5)
-  Other EAN/EADC 26 (25.5) 7 (6.9) 28 (27.5) 9 (8.8) 0.89
AAN 140 (33.3) 45 (10.8) 169 (40.2) 66 (15.7)
All data are N(%)
Abbreviations: EAN, European Academy of Neurology; EADC, European Alzheimer’s Disease Consortium; AAN, 
American Academy of Neurology.
* Differences in replies between EAN/EADC and AAN members (chi square)
** Question not in AAN survey.
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Attitudes towards MCI
More than 80% of the respondents agreed strongly or somewhat with the statement that 
labeling cognitive problems as MCI was helpful for patients and family members and that 
labeling helps for future planning and helps to engage in risk reduction. Furthermore, 
more than 50% of the respondents agreed strongly or somewhat with the statement 
that labeling aids planning of insurance and finances and that certain medications can 
be helpful for some patients. More than 50% of the respondents disagreed strongly or 
somewhat with the statements that MCI is usually better described as AD, that diagnosing 
causes unnecessary worry for patients and family members, that it is too difficult to 
diagnose MCI accurately or reliably, and that it makes no sense to diagnose it because 
there is no approved treatment. In a free text section inviting open comment, the most 
common response was that MCI is a broad symptomatic diagnosis without a description 
of the etiology and needed further investigation (Table 3 and Additional file 2: Figure S2).













-  Labeling the problem 
is helpful for patients 
and family members
EAN/EADC 52 (51) 38 (37.3) 7 (6.9) 2 (2) 3 (2.9) 0.12
AAN 191 (45.5) 192 (45.7) 24 (5.6) 11 (2.7) 2 (0.5)
-  A diagnosis is useful 
so the patient can 
be more involved in 
planning for the future
EAN/EADC 44 (43.1) 41 (40.2) 8 (7.8) 5 (4.9) 4 (3.9) 0.15
 AAN 184 (43.8) 180 (42.8) 37 (8.8) 16 (3.9) 3(0.7)
-  A diagnosis can be 
useful in motivating the 
patient to engage in 
risk reduction activities
EAN/EADC 43 (42.2) 42 (41.2) 9 (8.8) 6 (5.9) 2 (2) 0.61
 AAN 148 (35.2) 207 (49.4) 39 (9.3) 21 (4.9) 5 (1.2)
-  A diagnosis helps the 
family with insurance 
planning
EAN/EADC 23 (22.5) 30 (29.4) 32 (31.4) 9 (8.8) 8 (7.8) 0.18
 AAN 90 (21.5) 143 (34.1) 143 (34.1) 31 (7.3) 12 (2.9)
-  A diagnosis helps the 
family with financial 
planning
EAN/EADC 25 (24.5) 41 (40.2) 27 (26.5) 4 (3.9) 5 (4.9) 0.35
 AAN 121(28.7) 183 (43.6) 93 (22.1) 15 (3.6) 8 (1.9)
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Certain medications can 
be useful for treating some 
patients
EAN/EADC 16 (15.7) 39 (38.2) 18 (17.6) 16 (15.7) 13 (12.7) 0.034





for patients and family 
members
EAN/EADC 8 (7.8) 12 (11.8) 11 (10.8) 28 (27.5) 43 (42.2) 0.000*1
 AAN 8 (2.0) 74 (17.6) 75 (17.8) 155 (36.8) 109 (25.9)
There is no approved 
treatment so it does not 
make sense to diagnose
EAN/EADC 6 (5.9) 0 6 (5.9) 25 (24.5) 65 (63.7) 0.02*
 AAN 11 (2.7) 24 (5.6) 33 (7.8) 130 (31.0) 222 (52.9)
It is too difficult to diagnose 
accurately or reliably
EAN/EADC 4 (3.9) 10 (9.8) 9 (8.8) 35 (34.3) 44 (43.1) 0.013*
 AAN 8 (2.0) 88 (21.0) 53 (12.7) 147 (34.9) 124 (29.5)
MCI is usually better 
described as early 
Alzheimer’s disease
EAN/EADC 8 (7.8) 13 (12.7) 23 (22.5) 30 (29.4) 28 (27.5) 0.91
 AAN 26 (6.1) 60 (14.4) 87 (20.8) 138 (32.8) 109 (25.9)
All data are N(%) Legend continues on next page
Abbreviations: EAN, European Academy of Neurology; EADC, European Alzheimer’s Disease Consortium; AAN, 
American Academy of Neurology.
*Differences between answers between EAN/EADC and AAN members were tested using chi square and are 
indicated with a p-value.
Comparison with results from the AAN survey
Age and gender were similar between AAN and EAN/EADC respondents. Compared 
to AAN respondents, EAN/EADC respondents were less often neurologist (73% versus 
94%) and worked less often in a solo practice (5% versus 30%) and more often in a 
hospital setting (37% versus 18% (Table 1)). EAN/ EADC respondents more often saw 
patients with cognitive symptoms of mild severity, discussed research studies, and 
provided a written summary letter of the findings than AAN respondents. EAN/EADC 
respondents less commonly prescribed cholinesterase inhibitors and memantine, and 
they less often agreed to the statement that a diagnosis “causes unnecessary worry to 
patients and family” (p < 0.0001 for all comparisons, Tables 2 and 3).
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Prodromal AD/MCI due to AD
Research criteria and clinical practice
Sixty-eight percent of the respondents used the research criteria for diagnosing 
prodromal AD/MCI due to AD (22% used the IWG criteria, 35% the NIA-AA criteria, and 
43% used both). Those who used the research criteria did not differ in demographics 
or membership of EADC or EAN, compared to non-users.
Reasons for the use of the research criteria were increased certainty of diagnosis 
in almost 90%. Around 50% of the respondents used the research criteria to increase 
possibilities to provide counseling and facilitation of follow-up planning and to start 
medical intervention. Less than 50% of the respondents used the criteria to respond 
to patients’ wish for a diagnosis and to facilitate selection for clinical trial selection or 
observational studies.
Thirty-two percent of the respondents did not use the research criteria. The most 
common reasons were lack of standardized measurements and cutoff values (42%), 
lack of treatment possibilities (42%), and lack of implication on a single-level case (33%). 
In less than 30% of the respondents, there was an inability to perform a biomarker 
measurement, a concern that the diagnosis might upset patients and their family; 
the lack of inclusion in national guidelines, or the lack of added value in diagnosing 
prodromal AD/MCI due to AD over a diagnosis of MCI.
Of the criteria users, 49% applied the research criteria only in a subset. This group 
applied criteria if they perceived a clinical need (38%) or if the patient wished to know 
(26%). Other reasons indicated in the open text field, were younger age, and selection 
of subjects for research. Seventy percent of the respondents always disclosed the 
diagnosis. The most common reason (50%) not to disclose diagnosis was the wish 
of patients not to know. Other reasons not to disclose the diagnosis were diagnostic 
uncertainty and fear that the diagnosis might upset patients or their family. When the 
diagnosis was not disclosed, information was still used to plan future care by 75%. 
Biomarkers always or often used to define prodromal AD/MCI due to AD were MRI 
measures of the medial temporal atrophy (MTA, 75%), CSF amyloid beta 1–42, or tau 
(52–55%). Less than 30% used FDG-PET, SPECT, or amyloid PET (Fig. 3). The use of 
research criteria appeared to influence the communication towards patients. The 
term “MCI” was less often used and terminology including “possible early AD” more 
often compared to the use of MCI as diagnostic label (p = 0.001). When patients met 
the research criteria, respondents more often used the term “possible early AD” and 
“early AD” (p < 0.0001) and less often patients were told they had “memory problems 
or difficulties” or “did not have dementia or AD” compared to patients not meeting the 
criteria (p < 0.0001).
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Figure 3: Use of biomarkers for scoring the research criteria
Bars indicate responders (in %) that often or always performed diagnostic assessment of the above- 
mentioned tests.
Abbreviations: MTA= medial temporal atrophy; MRI= magnetic resonance imaging; CSF= cerebrospinal 
fluid; abeta= amyloid beta; FDG-PET= fludeoxyglucose positron emission tomography; SPECT= single 
photon emission computed tomography; PET= positron emission tomography.
Counseling by respondents on diet and nutrition, vitamins, mental exercise, 
physical exercise, and alcohol did not differ between patients with or without criteria 
for prodromal AD/MCI due to AD. However, patients who met the criteria for prodromal 
AD/MCI due to AD respondents were more often counseled on the need for follow-
up, risk for AD in general terms advanced planning, driving, participation in research 
studies, availability of support services, and access to other support organizations and 
were more often prescribed cholinesterase inhibitors compared to patients who did 
not meet the criteria (Table 4 and Additional file 2: Figure S3).
Table 4: Usual practice when seeing patients with or without prodromal AD/MCI due to AD
Never Rarely Sometimes Routinely p-value*
Patient counseling
-  Diet and nutrition Prodromal AD 7 (11) 5 (8) 25 (38) 28 (43) 0.97
No Prodromal AD 8 (12) 6 (9) 24 (37) 27 (42)
-  Vitamins Prodromal AD 15 (23) 19 (29) 23 (35) 8 (12) 0.99
No Prodromal AD 14 (22) 19 (29) 24 (37) 8 (12)
-  Mental exercise Prodromal AD 2 (3) 2 (3) 7 (10) 56 (84) 0.45
No Prodromal AD 3 (4) 5 (8) 10 (15) 48 (73)
-  Physical exercise Prodromal AD 1 (1) 1 (1) 10 (15) 55 (82) 0.31
No Prodromal AD 1 (2) 4 (6) 15 (23) 46 (69)
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Table 4: Usual practice when seeing patients with or without prodromal AD/MCI due to AD 
(continued)
Never Rarely Sometimes Routinely p-value*
-  Alcohol Prodromal AD 10 (15) 13 (20) 22 (33) 21 (32) 0.95
No Prodromal AD 8 (13) 12 (19) 24 (38) 20 (30)
Patient education
-  Advance planning Prodromal AD 0 6 (9) 28 (41) 34 (50) 0.0001
No Prodromal AD 6 (9) 20 (30) 26 (39) 14 (21)
-  Driving Prodromal AD 0 5 (7) 27 (40) 36 (53) 0.0001
No Prodromal AD 5 (8) 18 (27) 28 (42) 15 (23)
-  Research studies Prodromal AD 0 5 (7) 32 (47) 31 (46) 0.0001
No Prodromal AD 6 (9) 25 (38) 26 (39) 9 (14)
-  Support services Prodromal AD 0 11 (16) 24 (36) 32 (48) 0.003
No Prodromal AD 4 (6) 25 (38) 19 (29) 18 (27)
-  Recommendations for follow-up Prodromal AD 0 2 (3) 4 (6) 61 (91) 0.0001
No Prodromal AD 0 10 (15) 15 (22) 42 (63)
-  Risk of AD and related 
disorder (general terms)
Prodromal AD 0 1 (2) 23 (34) 42 (64) 0.0001
No Prodromal AD 3 (5) 17 (27) 22 (34) 22 (34)
-  Risk of related disorders 
(numeric estimates)
Prodromal AD 9 (13) 19 (28) 27 (40) 12 (18) 0.33
No Prodromal AD 13 (20) 24 (38) 19 (30) 8 (12)
-  Referral to Alzheimer’s 
association or similar 
organization
Prodromal AD 6 (9) 16 (24) 30 (46) 14 (21) 0.0001
No Prodromal AD 29 (45) 20 (31) 12 (18) 4 (6)
-  Written summary letter of 
findings for patient and family
Prodromal AD 6 (9) 6 (9) 18 (27) 37 (55) 0.91
No Prodromal AD 6 (9) 8 (12) 19 (29) 33 (50)
Medication prescribed
-  Cholinesterase inhibitors Prodromal AD 9 (13) 8 (12) 26 (39) 24 (36) 0.0001
No Prodromal AD 40 (61) 18 (27) 6 (9) 2 (3)
-  Memantine Prodromal AD 44 (66) 13 (19) 7 (11) 3 (4) 0.30
No Prodromal AD 52 (79) 10 (15) 3 (4) 1 (2)
-  Other Prodromal AD 12 (32) 5 (13) 16 (42) 5 (13) 0.46
No Prodromal AD 13 (37) 2 (6) 18 (51) 2 (6)
All data are N (%)
*Differences in replies between regarding patients meeting criteria for prodromal AD/MCI due to AD and patients 
not meeting criteria for prodromal AD/MCI due to AD (chi square)
Abbreviation: AD, Alzheimer’s Disease.
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Attitudes towards prodromal AD/MCI due to AD
In the total group, over 80% of the respondents agreed strongly or somewhat to the 
statement that a diagnosis of prodromal AD/MCI due to AD was helpful for labeling 
the problem for patients and family members, was helpful for inclusion into clinical 
trials, aided physicians to plan for follow-up, involved patients in future planning, and 
motivated patients to engage in risk reduction activities. It was also frequently reported 
(62–76%) that a diagnosis could help family and patients with financial or insurance 
planning and could help in the decision to start medication.
The majority of all respondents strongly or somewhat disagreed with the statement 
that diagnosing prodromal AD/MCI due to AD has no added value over a diagnosis of 
MCI (70%). There was also considerable disagreement with the suggestions that it is 
too difficult to diagnose it accurately or reliably (69%), that it causes unnecessary worry 
for patients and family members (69%), and that there is no approved treatment so it 
does not make sense to diagnose it (73%) (Table 5 and Fig.4).
Figure 4: Topics of discussion in patients with and without prodromal AD
Frequency (%) of respondents that routinely discussed the above topics in patients with ‘prodromal AD’ 
(blue column) or ‘no prodromal AD’(red column).
Differences frequencies between ‘prodromal AD’ and ‘ no prodromal AD’ were tested using chi-square. 
*p<0.01 **p<0.0001
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-  Labeling the problem is helpful for patients 
and family members
53 (52) 33 (32) 6 (6) 4 (4) 6 (6)
-  A diagnosis is useful so the patient can be 
more involved in planning for the future
45 (44) 38 (37) 10 (10) 6 (6) 3 (3)
-  A diagnosis can be useful in motivating 
the patient to engage in risk reduction 
activities
43 (42) 40 (39) 10 (10) 5 (5) 4 (4)
-  A diagnosis helps the family with insurance 
planning
28 (27) 35 (34) 27 (26) 6 (6) 6 (6)
-  A diagnosis helps the family with financial 
planning
30 (29) 47 (46) 16 (16) 4 (4) 5 (5)
-  A diagnosis can be useful for including 
patients in clinical trials
71 (70) 23 (23) 5 (5) 3 (3) 0
-  Certain medications can be useful for 
treating some patients
26 (25) 39 (38) 13 (13) 10 (10) 14 (14)
-  A diagnosis is useful for the physician to 
plan the follow-up.
58 (57) 29 (28) 7 (7) 5 (5) 3 (3)
Drawbacks and limitations
-  Diagnosing causes unnecessary worry for 
patients and family members
4 (4) 14 (14) 14 (14) 36 (35) 34 (33)
-  There is no approved treatment so it does 
not make sense to diagnose
13 (13) 3 (3) 12 (12) 23 (23) 51 (50)
-  It is too difficult to diagnose accurately or 
reliably
4 (4) 21 (21) 7 (7) 30 (30) 40 (39)
-  A diagnosis has no added value over the 
diagnosis of MCI
8 (8) 9 (9) 14 (14) 21 (21) 50 (49)
All data are N(%)
Abbreviation: MCI, Mild Cognitive Impairment.
Discussion
According to this survey, the term MCI was widely used and considered to represent 
a useful clinical entity. MCI definitions, communication with patients, management, 
and attitudes towards the concept were, with a few exceptions, similar to that of AAN 
members in a previous study. The novel research criteria for prodromal AD/ MCI due 
to AD were used by 68% of the respondents, of whom 51% used the criteria in all 
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subjects with MCI. The use of the research criteria influenced the communication with 
and management of subjects with MCI. MCI was widely used as a clinical diagnosis and 
also referred to in communications with patients and their family. To diagnose MCI, 
respondents performed neuropsychological testing, while laboratory assessments, 
as well as MRI or CT imaging, were performed in the majority of the cases, which is 
in agreement with the EAN guidelines for the assessment of AD [10]. Respondents 
perceived that labeling the problem outweighed any negative effect but still 20% 
agreed with the statement that MCI would cause unnecessary worry for patients and 
family. Other reported benefits were a better planning for future and motivation of 
patients to engage risk reduction. Remarkably, prescription of cholinesterase inhibitors, 
memantine, vitamins, and supplements was relatively common, although there is no 
evidence of efficacy for these treatments in MCI.
The responses of the EAN/EADC members were generally similar to those of AAN 
members, despite the time interval of the studies. A major difference was that EAN/
EADC respondents less frequently prescribed cholinesterase inhibitors and memantine, 
compared to AAN respondents. Since such prescription of dementia medications in 
subjects with MCI is off-label use both in Europe and the USA, AAN members might be 
more convinced that these medications are of benefit. Despite being research criteria, 
the majority of respondents used prodromal AD/MCI due to AD criteria in clinical 
practice. The main reason given for this use was that the criteria increased the certainty 
of AD diagnosis. Only 55% often or routinely used an amyloid marker indicating that, 
in the majority of the cases, an injury marker was used for diagnosis. This is consistent 
with the NIA-AA criteria of intermediate likelihood and the IWG-1 criteria, but not with 
the IWG-2 criteria, as these consider amyloid markers as a core diagnostic feature. 
Yet, IWG-2 criteria were published only a few months before we performed our survey 
and therefore were unlikely to have been incorporated into clinical practice. The use 
of either an amyloid or injury marker may result in heterogeneity among subjects with 
“prodromal AD/ MCI due to AD” as there is only moderate overlap between amyloid and 
injury markers since they become abnormal in different stages of the disease and are 
supposed to reflect disease processes [11]. Not using amyloid markers may result from 
lack of awareness of the different diagnostic properties of amyloid and injury markers, 
lack of training of physicians to perform a lumbar puncture, or lack of possibilities 
to perform cerebrospinal assessment or amyloid imaging. Moreover, assessment of 
amyloid pathology is often not mentioned in national guidelines on dementia in Europe 
nor is it reimbursed. At the time of our survey in 2014, another survey showed that 
of the 19 countries that were included in our study only 8 had national guidelines 
that discussed CSF analysis in the assessment of cognitive disorders [12]. CSF analysis 
was reimbursed in 11 of the 19 countries. Forty-nine percent of the respondents who 
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applied the research criteria did assessments in a subset of patients depending on the 
clinical need and the wishes of patients. The latter criterion for selection underlines 
the importance for shared decision-making, since, in light of the lack of treatment 
possibilities, it is important to inform patients on the benefits and possible drawbacks 
of making a diagnosis [9]. In line with this, 15% of criteria users did not always disclose 
diagnosis if the patient or family members did not want to know.
Using research criteria had a major influence on the way patients were 
communicated with and their management, such as prescription of cholinesterase 
inhibitors. Despite of the fact that the criteria are meant for research use, respondents 
apparently found them clinically helpful. Irrespective of the application of the research 
criteria, all respondents perceived more benefits than drawbacks using the criteria in 
clinical practice.
This is in accordance with a previously performed EADC survey where respondents 
claimed to perceive high diagnostic confidence using AD biomarkers and clinical 
studies that use of amyloid biomarkers increased diagnostic confidence and impacted 
management [9, 13, 14].
In 2018, the NIA-AA consortium published an update to the NIA-AA criteria, referred 
to as a research framework [15]. It extends the NIA-AA criteria by basing the diagnosis 
of AD on amyloid, tau, and neuronal injury markers (ATN staging). Although conceptually 
the framework is similar to the NIA-AA and IWG-2 criteria as it defines amyloid pathology 
as necessary for the diagnosis of AD, the combination of both tau and injury markers 
may be more difficult to implement in clinical practice as the number of diagnostic 
categories increases.
A limitation of this comparative study was that the EAN/EADC survey was 
administered 5 years after the AAN survey. Nevertheless, the results were comparable 
across the two surveys but we cannot exclude the possibility that over time the 
attitudes towards MCI have changed among AAN members. Another possible 
limitation was the EAN/EADC survey was held among clinicians with a special interest 
in neurodegenerative disorders and mainly working at university hospitals, such that 
the responses may not be wholly generalizable to the broader community of clinicians. 
We sent our survey to members of the EADC and the EAN scientific panel on Dementia 
and Cognitive Disorders, which have a research interest in dementing disorders, which 
limits the generalizability of the findings. Because EADC and EAN members overlap 
and because we distributed the survey through the EAN newsletter, which is received 
also by neurologists not working in the dementia field, no response rate could be 
calculated. As we expanded upon the original AAN survey on MCI by including a second 
part focusing on the research criteria, this increased the length of the survey and 
may have increased levels of non-response. Another limitation that may argue against 
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representativeness is that 30% of our respondents were from Spain. However, post hoc 
analysis showed only a few differences between respondents from Spain compared to 
other respondents. Finally, questionnaires measured opinions and actual use of the 
criteria may be different. Our survey highlights that both the MCI and prodromal AD/
MCI due to AD criteria are considered clinically useful. Our survey indicated several 
barriers for the use of the criteria in clinical practice such as lack of standardized 
measurements and cutoff values of biomarkers [6–8, 15]. This will become even more 
problematic with the NIA-AA research framework as more biomarkers now can be used 
for the diagnosis, for which often no established cut-points are available, such as CSF 
neurofilament light. Moreover, there was variability in type of diagnostic tests used 
and patient management between clinicians. These findings highlight the need for an 
update of national and international guidelines on the diagnosis and management of 
predementia AD and communication to patients. This should take into account cultural 
background, the age, religious background, and education of patients [16].
In our study, we focused on the opinion of clinicians; however, it will be crucial to 
assess the opinions and needs of patients in future studies as well.
Conclusions
Our survey showed that both the MCI and prodromal AD/MCI due to AD criteria are 
considered clinically useful and that the diagnosis influenced the management of 
patients meeting these criteria. However, clinicians differed in the tests used to make 
the diagnosis and in the management of the patients. This highlights the need for 
standardized national and international guidelines for the diagnosis and management 
of predementia AD.
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Additional data
Figure S1: Counseling and medication prescription in patients with MCI
 
Frequency of response (%) in EAN/EADC survey (blue column) and AAN survey (red column) who routinely 
counsel on the above topics.
Differences frequencies between EAN/EADC and AAN members were tested using chi-square. *p<0.01
Figure S2: Benefits and drawbacks of MCI as clinical diagnosis
Blue bars are frequencies (in %)of respondents of EAN/EADC. Red bars are frequencies (in %) of 
respondents of the AAN survey. Frequency (%) of respondents that strongly or somewhat agreed on the 
above statements. Abbreviations: EAN, European Academy of Neurology; EADC, European Alzheimer’s 
Disease Consortium; AAN, American Academy of Neurology.
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Figure S3: Counseling and medication prescription in patients with and without prodromal AD
Frequency (%) of respondents that routinely counseled or prescribed treatment in patients with ‘prodromal 
AD’ (blue column) or no prodromal AD’(red column). Differences frequencies between ‘prodromal AD’ and 
‘ no prodromal AD’ were tested using chi-square. *p<0.01
3.3
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Introduction
The aim of the thesis was to investigate the use of biomarkers for trial design in non-
demented subjects with AD. In addition, we investigated the perceived usefulness of 
biomarkers in clinical practice. For this purpose, we examined in part I of this thesis, 
the pattern of disease progression of biomarkers and cognitive markers at different 
stages of AD, we investigated how the cutoff for CSF aß1-42 could be determined and 
investigated if amyloid levels were predictive for cognitive decline. In part II of this thesis 
we studied the use of biomarkers for clinical trials and the perceived usefulness of 
biomarkers in clinical practice among clinicians. We will now discuss our main findings, 
the implications for research, AD trials and clinical practice and our methodological 
issues. We will conclude with recommendations for future research.
Main findings
 I. Course of AD and assessment of amyloid biomarkers
In chapter 2 .1 we studied the temporal evolution of biomarkers and cognitive markers 
in different stages of AD. To this end we selected subjects with normal cognition, MCI and 
dementia with and without AD pathology at baseline, defined as abnormal levels of CSF 
Aß1-42. We then investigated differences at baseline and changes over time in biomarker 
and cognitive markers in the asymptomatic stage, MCI stage and dementia stage of AD (AD-
asymptomatic, AD-MCI, and AD-dementia). We also investigated whether these changes 
differed from subjects with normal cognition, MCI or dementia without AD pathology.
We found that biomarkers and cognitive markers showed a temporal order 
of change and that the markers showed different rates of decline in subjects with 
AD-asymptomatic, AD-MCI and AD-dementia (Figure 1). CSF Aß1-42 reached the 
maximum abnormality level in the asymptomatic stage and CSF tau in the MCI stage. 
The imaging and cognitive markers started to change in the asymptomatic stage and 
became abnormal in the MCI stage. The rate of change in these markers increased with 
increasing disease severity. The pattern of decline was distinct from that of subject 
without amyloid pathology, which showed a more benign pattern of change. Our results 
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are, with some exceptions, in accordance to the hypothetical model of dynamic changes 
and may be helpful to determine stage specific outcome measures for clinical trials.
As described in chapter 2.1 and other studies, abnormal CSF aß1-42 levels are indicative 
for Alzheimer’s disease and increase the risk for future AD-type dementia in non-
demented individuals. However, also a substantial part (15-35%) of non-demented 
patients with mild cognitive impairment and normal levels of CSF aß1-42, develop AD-
type dementia [1]. Possibly, these patients have borderline normal CSF aß1-42 levels or 
the clinical follow-up diagnosis may be incorrect. To address this issue, we performed 
two studies on the relation between normal aß1-42 levels and cognitive outcome in 
non-demented individuals and on the definition of abnormal aß1-42.
In chapter 2.2 we studied the association of CSF Aβ 1-42 in non-demented subjects 
with SCD or MCI. We found that lower CSF Aβ 1-42 levels within the normal range are 
predictive for faster clinical progression in non-demented memory clinic subjects. This 
effect was more evident in subjects with MCI. For both SCD and MCI subjects, the 
predictive value of CSF Aβ 1-42 levels was stronger than CSF tau or p-tau levels. These 
results suggest that low normal CSF Aβ 1-42 levels could reflect the earliest changes 
in the brain that are relevant for AD. Indeed, another study showed that individuals 
with low normal CSF Aβ 1-42 levels showed more decline in Aβ 1-42 levels and also 
more change in hippocampal volume and an increase in amyloid PET binding. Still, 
intermediate normal levels could also predict decline (chapter 2.2) and were also 
associated with decline in AD biomarkers, suggesting that the AD pathology starts 
before amyloid aggregation can be detected in CSF [2].
In chapter 2.3 we tested different ways to define abnormality of aß1-42 in CSF. Cutoff 
for abnormal CSF aß1-42 has typically been based on comparison between normal 
subjects and patients with AD. However, clinical diagnosis can be incorrect and 
cognitively normal subjects often have abnormal CSF aß1-42 [3], which underestimates 
the presence of amyloid pathology and incorrectly lowers the cutoff for abnormal CSF 
aß1-42 levels. As a result, subjects with borderline normal CSF aß1-42 levels could 
actually have abnormal levels depending on the used method to determine the cutoff.
In chapter 2.3 we defined a cutoff for CSF aß1-42 with the use of data driven 
Gaussian mixture modelling. With Gaussian mixture modelling one assumes that the 
data are a mix sampled from two different distributions, which represent a normal 
and an abnormal population. With this method we determined a cutoff for abnormal 
CSF aß1-42 levels at 680 pg/ml. This cutoff was independent of the cognitive stage 
and APOE genotype. The cutoff was higher in older than in younger subjects. The data 
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driven cutoff was higher than our clinical diagnosis-based cutoff and had a better 
predictive accuracy for progression to AD-type dementia in non-demented subjects 
(HR 7.6 versus 5.2, p<0.01). Our results suggest that mixture modelling is a robust 
method to determine cutoff for CSF aß1-42. Our new cutoff was similar to the amyloid 
PET derived cutoff for CSF aß1-42, implying a good correlation with amyloid pathology.
Taken together, the results suggest that clinical decline in non-demented 
individuals, with normal CSF aß1-42 can partly be explained by a conservative cut-point 
but also by early decline before aggregation can be detected by biomarkers.
II. Use of AD biomarkers for clinical trials and clinical practice.
In chapter 3.1 we reviewed how AD biomarkers have been used in clinical trials for 
inclusion and as outcome so far. We showed that previous clinical trials used biomarkers 
mainly as outcome measure. One of the possible explanations why trials with disease 
modifying treatment have failed is the inclusion of subjects with a clinical diagnosis of 
AD who did not have Alzheimer’s pathology in the brain. Another possible explanation 
is thought to be inclusion of subjects with advanced disease in which treatment is no 
longer effective. With the introduction of the research criteria it became possible to 
select subjects at an early stage of AD, using biomarkers. However, these biomarkers 
allow for different combinations of AD pathology biomarkers and it is unknown whether 
this has an impact on change in outcome measures. For trial design it is critical to 
understand how selection criteria influence change in outcome measures.
In chapter 3.2 we investigated the influence of different inclusion criteria for 
preclinical and prodromal Alzheimer’s disease (AD) on changes in biomarkers and 
cognitive markers and on trial sample size estimates. Inclusion criteria that we 
compared included: preclinical or prodromal AD (amyloid marker abnormal); preclinical 
or prodromal AD stage-1 (amyloid marker abnormal, injury marker normal); preclinical 
or prodromal AD stage-2 (amyloid and injury markers abnormal). Outcome measures 
were: amyloid, neuronal injury and cognitive markers. We found that sample size varied 
widely according to the combination of inclusion criteria and outcome markers applied. 
The smallest sample size needed to show a treatment effect was estimated for subjects 
with normal cognition or MCI who had both abnormal amyloid and injury markers at 
baseline, using brain volumetric markers as outcome measure.
As shown in chapter 3.1 and 3.2 the research criteria [4-9] for AD seem to be 
useful for selection of subjects with an early stage of AD. These research criteria 
are also increasingly used in clinical practice [10,11]. Still, it is not known how these 
criteria apply to a single patient and how communication towards patients should 
be whenever biomarkers are indicative for Alzheimer’s disease. There may also be 
different perceptions between clinicians. It is important to know any differences as 
4
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they may have implications for the implementation of diagnostic guidelines on MCI 
and research criteria in clinical practice. As a first step in chapter 3.3 we performed a 
survey among European neurologists with specialisation in neurodegenerative diseases 
and assessed the attitude towards the utility of the concept MCI and usefulness of 
research criteria in clinical practice. Most respondents used the term MCI for diagnosis 
and in communication with patients. A majority of responders also made a subdivision 
of amnestic versus non-amnestic MCI, and between single and multiple domain MCI. 
Counselling included mostly exercise and medication was prescribed in up to 21% of 
patients. The results were comparable to a survey performed among members of the 
American Academy of Neurology (AAN), except for prescribing drugs like cholinesterase 
inhibitors, which was higher among AAN members. The IWG and NIA-AA research 
criteria (2011) were used by almost 70% of the respondents. The main reason was the 
increase of certainty of diagnosis. Communication towards patients, topics of discussion 
and prescription of medication depended on whether or not a subject met criteria for 
prodromal AD/MCI due to AD. MCI was commonly used among European clinicians. 
The use of research criteria for prodromal AD/MCI due to AD was perceived useful and 
considerable influenced the management of and communication to patients with MCI.
Implications
I. AD pathophysiology
Our data are overall consistent with the amyloid cascade model of dynamic changes of AD, 
showing that the presence of abnormal amyloid precedes neurodegeneration and cognitive 
decline (chapter 2.1). We also showed that subjects with borderline normal levels of amyloid 
have an increased risk for development of Alzheimer’s dementia (chapter 2.2), indicating 
that there is a sliding scale for abnormality of amyloid rather than a fixed tipping point 
for initiation of disease. In addition to previous studies, we showed that, in the presence 
of abnormal amyloid, decline on neuronal injury markers and clinical measures is more 
severe than in individuals without amyloid abnormality (chapter 2.1). While individuals with 
abnormal aß1-42 but normal CSF tau showed decline on a range of biomarkers and cognitive 
markers this decline accelerated when they also had abnormal CSF tau (chapter 3.2). In 
other words, our data show that amyloid pathology is necessary to develop AD, and that 
tau pathology drives further degeneration. In addition to other studies, we also showed that 
biomarkers also differ in the stage in which abnormalities plateaus. For instance, CSF tau 
plateaus in a later stage, than CSF aß1-42 and that other injury markers show continuous 
increases in abnormality in the dementia stage. These findings are important as they may 
have implications for research and clinical trials (see below).
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Unlike the current model of AD progression our data show that cognitive markers 
change together with FDG-PET and atrophy imaging markers, rather than becoming 
abnormal after these injury markers (see figure 1 and chapter 2.1). This is in line 
with recent studies that have shown a tight relation between the magnitude of injury 
markers and the degree of cognitive impairment [12]. Moreover, our study, in line with 
other studies, showed that in individuals with abnormal amyloid and normal injury 
markers, cognitive complaints or impairment could already be present [13,14].
In order to study early AD it is important to have a reliable measure of amyloid pathology 
in vivo. In chapter 2.3 we showed that mixed modeling is a robust method to determine 
this cutoff. With this method we were better able to predict Alzheimer’s dementia in 
non-demented subjects than with the previously used clinical diagnosis-based cutoff. 
Also, our new defined cutoff was similar to a previous defined cutoff for CSF aß1-42 
derived with amyloid PET, suggesting a good concordance with amyloid plaques in vivo 
[15]. With this method further unravelling of AD pathology is possible and this method 
can be used to further study the concordance between CSF aß1-42 and amyloid PET at 
baseline and at follow-up. Still, it should be noted that AD pathology may already start 
before aggregation can be detected in CSF as low to intermediate normal levels could 
predict decline (chapter 2.2) and are also associated with decline in AD biomarkers [2].
Figure 1: Temporal evolution of biomarkers and cognitive markers in AD from the asymptomatic 
to the dementia stage.
Abbreviations: Tau, tau in cerebrospinal fluid; FDG, Fludeoxyglucose; ADAS-Cog, Alzheimer’s Disease 
Assessment Scale-Cognitive; NC, normal cognition; MCI, Mild Cognitive Impairment.
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II. Clinical trials (inclusion and outcome markers).
In chapter 3.1 we showed that biomarkers until 2010 were mainly used as outcome 
measure. The results presented in chapter 3.2 showed that the use of biomarkers can 
improve trial design in several ways.
Inclusion:
A major advantage of biomarkers for inclusion is that individuals can be selected with 
underlying AD pathology, which, in non-demented individuals cannot be diagnosed by 
clinical measures alone. Research criteria for AD using biomarkers, however, allow for 
different combinations of biomarkers. In our study subjects with both abnormal amyloid 
and injury markers at baseline, showed the fastest deterioration over time (chapter 
3.2). This would result in a larger effect size and therefore the need for a smaller sample 
size with a shorter follow up to find a treatment effect. However, subjects with abnormal 
amyloid and abnormal injury markers are thought to have a more advanced disease 
than subjects with amyloid abnormality alone. This may result in a lower treatment 
response, as treatment may be too late, in comparison to subjects with abnormal 
amyloid alone.
We found that subjects with prodromal AD showed more change in biomarkers and 
cognitive markers than subjects with preclinical AD. For clinical trials this would imply 
that a shorter follow-up is needed to reach endpoints. Still individuals with MCI are more 
advanced in the process of disease and may therefore be less responsive to treatment.
The choice of biomarkers would also dependent on the mode action of the intervention. 
For instance, it is critical to use amyloid pathology as inclusion criterion when 
intervention is focused on removal of amyloid.
Outcome:
Most trials in non-demented individuals used cognitive tests, cognitive decline or 
incident dementia as outcome. From a clinical perspective prevention of dementia 
would be the most relevant outcome. Still, a long follow-up would be needed to reach 
this endpoint both in preclinical (10-15 years) [16] and prodromal AD (5 years) [17] 
which makes outcome less feasible. As an alternative, change on cognitive tests could 
be used as outcome. In chapter 2.1 and 3.2 we showed that in preclinical AD cognitive 
measures did not change over time which limits the use of these cognitive tests as 
outcome measure. In prodromal AD cognitive tests did change but this decline was less 
than the decline observed in biomarkers, such that the sample size to detect a change 
would be 2-3 times higher for cognitive markers than biomarkers. Thus, biomarkers 
will have added value in both preclinical and prodromal AD.
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As discussed above, we showed in chapter 2.1 and 3.2 that biomarkers changed 
in different stages of the disease, such that different biomarkers should be used as 
endpoint in different stages. CSF aß1-42 levels did not change preclinical or prodromal 
AD. Amyloid PET and CSF tau changed substantially in preclinical and prodromal AD 
stage 1 only. FDG PET changed in prodromal AD only, while brain atrophy markers 
decreased in both preclinical and prodromal stage with a faster decline in stage 2 than 
in stage 1. Taken together, this means that CSF aß1-42 has limited value as outcome 
measure while amyloid PET could be used in preclinical and prodromal AD stage 1 
or for trials in which the mode of action is focused on eliminating amyloid. Similarly, 
CSF tau could be useful as outcome marker in preclinical and prodromal AD stage 1. 
Brain volumetric measures are useful as outcome across the whole predementia AD 
spectrum.
III. Clinical practice
Decreased CSF aß1-42 levels are indicative of Alzheimer’s disease and were therefore 
included in AD research criteria [5-9]. A limitation of implementation of CSF aß1-42 in 
clinical practice is the lack of a cutoff value to define abnormal CSF aß1-42. In chapter 
2.3 we showed that mixed modelling is a robust method to determine cutoff for 
abnormal CSF aß1-42. Some centres use amyloid PET to define amyloid pathology 
in non-demented subjects. Drawbacks for this method are requirement of a trained 
assessor to establish amyloid positivity. Amyloid PET is expensive and not available in 
every centre, let alone reimbursed. Mixed modelling appears to be just as sensitive as 
amyloid PET to define amyloid abnormality, is less expensive and does not show inter 
observer variability. Drawbacks for mixed modelling are that large samples of individuals 
with normal and abnormal amyloid are needed to define a reliable cutoff for CSF aß1-
42, which could be a difficulty for smaller centres. To overcome this problem, centres 
could send their samples to larger memory clinics where larger numbers of patients 
are present. For patients that have abnormal CSF aß1-42 levels clinical follow up is 
mandatory. In addition, a follow-up could also be considered in patients with low normal 
levels of CSF aß1-42 as these individuals are at risk for further cognitive decline as well 
(Chapter 2.2). In chapter 3.2 we showed that cognitive decline was faster in prodromal 
stage 2 than in stage 1, but it remains to be investigated whether this information can 
be used to make accurate predictions on rate of decline for individual patients.
To get more insight on clinical attitudes towards use of biomarkers we assessed the 
perceived usefulness of the clinical term MCI and the usefulness of biomarkers for the 
diagnosis of prodromal AD/MCI due to AD among European clinicians working in the 
Alzheimer field (chapter 3.3). We also assessed the implications for communication 
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with and management of patients meeting the criteria for prodromal AD/MCI due to AD. 
Of the respondents almost 70% claimed to use the research criteria in clinical practice. 
Main reason to do so was the increased certainty of diagnosis. The criteria were applied 
by these clinicians in around 49% of patients and the choice to do so was mostly driven 
by clinical need, wish of patients, younger age or research purposes. While not all 
respondents used the research criteria for diagnosis, 84% of respondents agreed to 
the statement that biomarkers have an added value over the clinical diagnosis of MCI. 
Applying the research criteria had a major influence on communication with patients, 
on management, follow-up and future planning. This is in accordance to other studies 
that showed that the use of amyloid biomarkers increased diagnostic confidence and 
influenced final diagnosis and management of clinicians [18,19]. So, using AD biomarkers 
can also be useful for clinical practice.
While we tested the opinion of clinicians, the opinion of patients is as important. Several 
studies have focused on the implementation of Alzheimer biomarkers in clinical practice 
and communication towards patients. One small study tested the effect of amyloid 
status disclosure in patients with MCI and their caregivers [20]. Most participants 
understood the information and found value in learning the results of amyloid imaging 
despite the lack of therapeutic options. In 2016 a workgroup was conducted to identify 
recommendations and best practice for delivering the MCI diagnosis, with amyloid 
imaging information [21]. The workgroup stated that some patients with a diagnosis of 
MCI, desire more information about their condition. Amyloid imaging may help improve 
prognostic information and reduce uncertainty associated with the diagnosis. Before 
amyloid assessment is performed, careful discussion is necessary to help patients 
decide whether to have the scan and to set expectations about how the results will 
affect clinical management. Also, patients should be educated about the possible scan 
results, implications and limitations. So, biomarker use in clinical practice can help the 
clinician and patients to narrow etiological diagnosis. But limitations of biomarker use 




Strength of several studies was the large sample and longitudinal data. This enabled us 
to test simultaneously a wide range of biomarkers and clinical markers longitudinally and 
to analyse cutoffs for CSF aß1-42 for different subgroups of patients. With stratification 
of clinical groups, according to amyloid status, we were able to study trajectories of 
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different markers in different AD stages relative to amyloid negative subjects. With the 
use of z-scores it was possible to compare score between different diagnostic groups 
and also between different markers, despite different units of measurements. Because 
we used z-scores relative to controls rather than relative to end-stage dementia, we 
could also compare the severity of the impairment on each marker.
One of our limitations was the relative old population in some of our studies. As the rate 
of decline may depend on age, our results may not apply to younger subjects. Second, 
to test the dynamic changes of AD, we selected our subjects cross-sectional across 
different stages rather than following subjects from the earliest stage of disease until the 
dementia stage. Although our findings suggest a continuum between the stages (figure 
1) findings need to be replicated in studies that follow subjects with asymptomatic AD 
until the dementia stage. Third, in chapter 3.2 we used both CSF aß1-42 as amyloid 
PET as marker for amyloid pathology. Some studies state that both markers show a 
good concordance [23], while others state that CFS aß1-42 changes before amyloid PET 
[24,25]. This may have resulted in an underestimation of an early stage AD diagnosis, 
depending on the modality used for diagnosis. In our cohort subjects with markers 
for both modalities showed a high concordance between CSF aß1-42 and amyloid 
PET, suggesting that CSF and PET are largely interchangeable as baseline measures. 
Fourth, in chapter 2.2 and 3.2 we used total tau as marker of Alzheimer’s disease 
at baseline, while the recent research criteria state that this a non-specific sign of 
neurodegeneration, rather than a sign of Alzheimer’s disease [6]. However, several 
studies have shown good correlation between phosphorylated tau and total tau [26] 
we do not think that this has had a major impact on our results. According to the 
research criteria, we used different modalities as sign of neurodegeneration, while we 
do not know if they all reflect the same pathophysiology and stage of disease. More 
studies are necessary to test this. In our studies the cognitive markers may not have 
been sensitive enough to find change in the earliest stage of disease although the tests 
used are well known and typically used in trials. Fifth, with our data we assumed a linear 
change of biomarkers and cognitive testes. This might not be the case in vivo and might 
have overestimated change, because it does not take into account variability in slopes 
between subjects. Furthermore, in chapter 3.2 we chose to model a hypothetical 
trial in which a treatment effect would result in a reduced change to illustrate the 
effect of different inclusion criteria and outcome measure on sample size estimates. 
Other sample size estimates would be obtained in designs that assume that treatment 
might result in biomarker or cognitive improvements (see also ‘Considerations and 
Recommendations for future research’). As regards the effect of CSF aß1-42 levels on 
cognitive decline, we found in chapter 2.2 that low normal levels of CSF aß1-42 were 
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predictive for clinical progression in non-demented subjects, whereas in chapter 2.1 
subjects with normal cognition and low normal levels of CSF aß1-42 did not show more 
decline than subjects with high normal levels of CSF aß1-42. This difference in findings 
can be attributed to several factors. First, subjects in chapter 2.2 were younger and 
second, they had subjective cognitive decline or MCI, while subjects in the latter study 
were older controls. Former studies showed that the rate of cognitive decline in subjects 
with abnormal CSF aß1-42, is age dependent showing slower decline in subjects with 
older age [27]. So, it is possible that asymptomatic subjects of older age and borderline 
CSF aß1-42 levels, will never show decline to MCI or dementia before the end of their 
life because of the slow decline, both in CSF aß1-42 as in cognition. Also, in chapter 2.2 
CSF aß1-42 levels were measured only at baseline and conversion to MCI or dementia 
was made clinically. So, it is not known if CSF aß1-42 levels declined after baseline.
Considerations and recommendations for future research
There is an increasing body of evidence supporting the hypothetical model of AD. What 
remains unknown is the timing and interval of biomarker-and cognitive change from the 
onset of amyloid abnormality. More studies are needed to test this. Furthermore, to find 
a treatment for Alzheimer’s disease it is crucial to know more about the pathophysiology 
of the disease for many factors are still not clear. For instance, what is the normal 
function of amyloid? What happens after it becomes abnormal? Is amyloid the cause 
of Alzheimer’s disease or a downstream product of another unknown cause? Is there 
one common pathway that leads to AD or are there several pathways? Is Alzheimer 
one disease or are there several subtypes as we see clinically in sporadic, autosomal 
dominant, early onset AD and late onset AD?
In the past decades several clinical trials have been conducted, mostly directed 
towards clearing amyloid, the hallmark of Alzheimer’s disease. Until now no trial has 
been successful in modifying or treat Alzheimer’s disease. Several factors have been 
mentioned as possible causes. First, subject selection without evidence of amyloid 
burden, hence inclusion of subjects without Alzheimer’s disease. Also, it is claimed that 
the clinical stage of subjects is too advanced to expect any benefit of intervention. At 
this moment clinical trials increasingly include subjects at an earlier clinical stage of 
disease in combination with presence of amyloid pathology. As regards intervention 
with anti-amyloid therapy, several monoclonal antibodies have been developed 
targeting different forms of amyloid aggregation (from monomers to plaques). The 
success rate may vary with the form of amyloid that is targeted. Since soluble oligomers 
are thought to be most toxic, clearing this form of amyloid might be most successful. 
Also, clearing plaques into oligomers might be dangerous in theory and may also be 
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a reason for failure of intervention. Furthermore, some trials that failed to show a 
treatment response claim that this might have been due to a too low dose. However, 
increasing the dose is also challenging as several monoclonal antibodies have shown 
dose related side effects of amyloid related imaging abnormalities (ARIA) with oedema 
or haemorrhages. Besides the limitations mentioned above there are more challenges 
that need to be addressed. First, as regards inclusion of subjects, most trials use 
amyloid PET for inclusion of non-demented subjects. Amyloid ligands for PET however, 
mostly bind to insoluble forms of amyloid, which is thought to be the end product of 
the abnormal amyloid processing. Since the soluble, earlier form of aß1-42 is thought 
to be most toxic [28,29], it cannot be excluded that subjects are still too far in the 
process to expect effect of treatment. Some studies state that decreased levels of 
CSF aß1-42 are an earlier marker for amyloid pathology compared to amyloid PET 
[24,25]. Second, as regards intervention, treatment is mainly focussed on amyloid, the 
main hallmark of AD, while other factors become abnormal during the disease process 
as well. AD therapy may be directed at multiple factors that are associated with the 
disease, like tau pathology. Third, the studies are needed to better understand the 
meaning of change in biomarkers upon treatment. For instance, when treating AD with 
anti-amyloid therapy, is a raise of amyloid in CSF a good sign? Is tau a good marker 
to use as sign of neurodegeneration, while our study showed that CSF tau measures 
stabilize in preclinical AD, while atrophy rates continue to increase? As regards cognitive 
outcome, more sensitive tests are needed to test if intervention is successful.
The use of biomarkers in clinical practice will depend on knowledge about the 
pathophysiology and treatment possibilities. As long as there is no therapy and as long 
as individual cognitive decline cannot be accurately predicted, well informed shared 
decision-making regarding use of biomarkers is crucial. More studies are needed to 
optimise this interaction based on easily accessible information on all biomarkers and 
combinations thereof, between clinicians and patients [20,21,30].
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Doel van het proefschrift
Het doel van dit proefschrift was om de waarde van het gebruik van Alzheimer 
biomarkers voor klinisch onderzoek en voor de dagelijkse praktijk te onderzoeken. 
Inleiding
De ziekte van Alzheimer (AD) is de meest voorkomende oorzaak van dementie. AD 
wordt gekenmerkt door klontering van het eiwit amyloid beta 1-42 (aß1-42) tussen 
hersencellen en de vorming van kluwen van het tau-eiwit in de hersencellen.  Het 
klonteren van deze eiwitten beschadigt hersencellen (“neurodegeneratie” of “neuronale 
schade” genoemd) leidend tot cognitieve problemen en uiteindelijk dementie. De 
klontering van deze eiwitten begint decennia voor het ontstaan van klachten en 
kan met verschillende tests (biomarkers) bepaald worden. Het amyloid-eiwit kan 
gemeten worden in hersenvocht (liquor), bloed en PET-scans. Markers die neuronale 
schade aantonen zijn een verhoogd tau in het hersenvocht of PET-scan, verminderd 
metabolisme op een FDG PET of atrofie op een MRI-scan van de hersenen. Met deze 
biomarkers is het mogelijk om AD in het vroegste stadium te diagnosticeren, nog 
voordat mensen klachten hebben. Omdat er nog geen behandeling beschikbaar is die 
AD kan afremmen of stoppen, worden deze biomarkers vooral voor onderzoek gebruikt 
in zogeheten onderzoekscriteria. 
Aangezien het amyloid-eiwit bekend staat als de initiator van AD, zijn onderzoeken 
er met name op gericht de productie van dit eiwit te remmen of dit eiwit te verwijderen 
uit de hersenen. Een eventueel effect zal waarschijnlijk het grootst zijn wanneer de 
behandeling in een vroeg stadium plaatsvindt, als er nog weinig cognitieve klachten 
zijn en er nog geen neuronale schade is.  Om patiënten in een vroeg stadium van AD 
te includeren voor klinisch onderzoek, zijn verschillende onderzoekcriteria opgesteld. 
Die criteria maken allen gebruik van biomarkers die onderliggende AD-pathologie 
aantonen en maken het mogelijk om patiënten in verschillende klinische stadia van 
AD te onderzoeken, te weten (i) preklinische AD, (ii) prodromale AD (of mild cognitive 
impairment (MCI) door AD) en (iii) dementie. In het vroegste, preklinische, stadium 
hebben patiënten onderliggende AD-pathologie, maar nog geen of niet-objectiveerbare 
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(subjectieve) klachten. In het prodromale stadium hebben patiënten duidelijke 
cognitieve problemen, maar functioneren zij nog zelfstandig. In het dementie stadium 
is zelfstandig functioneren niet langer mogelijk. 
De onderzoekscriteria lijken een goed hulpmiddel om patiënten in het vroege 
stadium van AD te identificeren. Echter, de criteria zijn feilbaar en er zijn nog allerlei 
onduidelijkheden.  Ten eerste is het nog onduidelijk hoe de biomarkers en cognitieve 
tests zich in verschillende klinische stadia van AD gedragen. Ook is er geen betrouwbare 
manier om een afkapwaarde voor abnormaal amyloid te bepalen en is het niet 
duidelijk of er cognitieve achteruitgang is bij personen met amyloidwaarden dichtbij 
het afkappunt. De onderzoekcriteria staan het gebruik van verschillende combinaties 
van biomarkers toe voor het vaststellen van AD. Het is echter niet bekend of deze 
biomarkers inwisselbaar zijn en of verschillende combinaties van biomarkers de 
uitkomst van onderzoek beïnvloeden. 
Hoewel het gebruik van biomarkers voor het vaststellen van AD bedoeld is voor 
klinische onderzoek, worden biomarkers in toenemende mate ook toegepast in de 
dagelijkse klinische praktijk. Het is echter onduidelijk in hoeverre de biomarkers en 
onderzoekscriteria hiervoor bruikbaar zijn.
In dit proefschrift zijn deze onduidelijkheden verder onderzocht. De volgende 
onderzoeksvragen zullen in twee delen besproken worden:
Deel I
·  Wat is het verloop van biomarkers en cognitieve tests in verschillende stadia van 
AD (hoofdstuk 2.1)?
·  Zijn aß1-42-waarden nabij het afkappunt voorspellend voor cognitieve achteruitgang 
(hoofstuk2.2)?
·  Hoe is de afkapwaarde voor aß1-42 in liquor betrouwbaar vast te stellen 
(hoofdstuk2.3)?
Deel II
·  Hoe worden biomarkers tot nu toe gebruikt voor inclusie en uitkomstmaat in 
klinisch onderzoek (hoofdstuk 3.1)?
·  Hoe beïnvloeden de verschillende combinaties van biomarkers, voor het vaststellen 
van AD, de uitkomst en de benodigde groepsgrootte om een effect aan te tonen 
in klinisch onderzoek (hoofdstuk 3.2)?
·  Zijn de biomarkers ook bruikbaar in de dagelijkse praktijk (hoofdstuk 3.3)? 




I Pathosfysiologie van de ziekte van Alzheimer en het gebruik van biomark-
ers om het ziekteverloop te vervolgen
In hoofdstuk 2.1 onderzochten wij hoe biomarkers en cognitieve tests veranderden 
na verloop van tijd bij patiënten met AD met een normale cognitie, licht cognitieve 
stoornissen (MCI) en dementie. De veranderingen in biomarkers en cognitieve tests 
werden vergeleken met die van patiënten zonder aanwijzingen voor onderliggend AD 
met normale cognitie, MCI en dementie. We vonden dat met het verstrijken van de tijd 
aß1-42 in liquor als eerste veranderde, gevolgd door tau en later atrofie en cognitieve 
maten. Deze volgorde was in grote lijnen overeenkomstig de heersende hypothese over 
het verbeloop van AD. Anders dan de heersende hypothese, ging de cognitie tegelijk 
met de neurodegeratieve markers achteruit in plaats van opvolgend. Wij toonden verder 
aan dat deze markers meer afwijkend werden met het verslechteren van de klinische 
situatie. De mate van verandering van biomarkers en cognitieve tests was minder 
uitgesproken bij deelnemers zonder aanwijzingen voor onderliggende AD met normale 
cognitie, MCI en dementie. Dit was de eerste keer dat met onderzoeksgegevens de 
heersende hypothese over het verloop van AD was getoetst.
In hoofdstuk 2.2 onderzochten we de voorspellende waarde van een normaal 
amyloid beta 1-42 (aß1-42) in liquor voor toekomstige ontwikkeling van prodromale-
AD en AD-dementie in personen met subjectieve klachten en MCI. We vonden dat 
lage - maar nog normale - waarden van aß1-42 voorspellend waren voor snellere 
klinische achteruitgang, met name in personen met MCI. De voorspellende waarde voor 
achteruitgang was sterker voor aß42-1 dan voor tau of p-tau in liquor. Met dit onderzoek 
toonden wij aan dat laag-normale waarden van aß1-42 in liquor een voorteken zijn van 
naderende AD en achteruitgang zou kunnen voorspellen naar MCI en dementie.  
Het bepalen van een afkapwaarde voor een biomarker is niet eenvoudig. Van 
oudsher werd de afkapwaarde voor abnormaal aß1-42 in liquor bepaald door de 
liquor van personen zonder cognitieve klachten te vergelijken met liquor van personen 
met klinisch vastgestelde AD-dementie. Deze methode is niet geheel betrouwbaar, 
omdat een klinische diagnose niet altijd betrouwbaar is en personen met een normale 
cognitie ook abnormaal aß1-42 kunnen hebben. In hoofdstuk 2.3 onderzochten wij 
de mogelijkheid om een betrouwbare afkapwaarde voor aß1-42 in liquor te bepalen 
middels ‘Gaussian mixture modelling’, een statistische methode. Deze methode 
gaat ervan uit dat amyloid-waarden in een populatie een mix zijn van abnormale en 
normale waarden. Met deze methode vonden wij een afkapwaarde van 680pg/ml voor 
abnormaal aß1-42 in liquor.  Deze afkapwaarde was hoger in personen met een hogere 
leeftijd, maar was onafhankelijk van klinische stadium of APOE-ε4 genotypering (een 
bekende risicofactor voor het ontwikkelen van AD). Ook correleerde de afkapwaarde 
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sterk met de amyloid-PET-bepaalde afkapwaarde voor liquor. De afkapwaarde was 
hoger dan de afkapwaarde bepaald middels klinische diagnose. 
II Gebruik van biomarkers voor klinisch onderzoek en de dagelijkse praktijk
In hoofdstuk 3.1 onderzochten wij hoe klinisch onderzoek tot dusver gebruik maakte 
van biomarkers voor (i) de selectie van personen met onderliggend AD en (ii) als 
uitkomstmaat. Wij vonden dat in de beginjaren met name gebruik werd gemaakt van 
biomarkers als uitkomstmaat. Met de komst van de onderzoekscriteria en de toepassing 
van biomarker-gerichte therapie (amyloid) werden biomarkers in toenemende mate ook 
gebruikt voor inclusie van patiënten met (een vroeg stadium van) AD. 
In hoofdstuk 3.2 onderzochten we of de verandering in uitkomstmaten afhankelijk 
was van de gebruikte inclusiecriteria voor het selecteren van personen met preklinisch 
en prodromale AD. Ook onderzochten wij welk effect de verschillende inclusiecriteria 
hadden op de benodigde groepsgrootte om een behandeleffect te meten. We vonden 
dat wanneer er zowel abnormaal amyloid als abnormaal neuronale markers gebruikt 
werden voor inclusie, biomarkers en cognitieve maten harder achteruit gingen. De 
benodigde groepsgrootte om een effect aan te tonen, werd hiermee kleiner.
In hoofdstuk 3.3 onderzochten wij middels een enquête (i) in hoeverre Europese 
clinici gebruik maakten van de term ‘MCI’ en de onderzoekscriteria in de klinische 
praktijk en (ii) in hoeverre het gebruik hiervan consequenties had voor besluitvorming. 
Informatie hierover is van belang voor de eventuele ontwikkeling en implementatie van 
richtlijnen voor het gebruik van MCI in de praktijk en de ontwikkeling van internationale 
standaarden. In ons onderzoek gebruikten de meeste respondenten de term MCI 
als diagnose en gebruikten zij die term ook naar patiënten en hun naasten. Een 
meerderheid maakte ook gebruik van de onderzoekscriteria. Voornaamste reden was 
het verkrijgen van diagnostische zekerheid. Wanneer patiënten AD-biomarkers bleken 
te hebben, had dat direct invloed op het vervolgbeleid zoals communicatie over AD, 
de mate van follow-up en het onderwerp van gesprek tijdens een dergelijke follow-up. 
Belangrijkste conclusies en implicaties
I Pathosfysiologie van de ziekte van Alzheimer en het gebruik van biomark-
ers om het verloop te vervolgen.
Onze data kwamen in grote lijnen overeen met de heersende hypothese over de 
pathofysiologie en het beloop van AD, waarbij aß1-42 veranderingen voorafgaan aan 
neurodegeneratie en cognitieve achteruitgang. Patiënten met abnormaal aß1-42 
vertoonden snellere neurodegeneratieve en cognitieve achteruitgang dan patiënten 
met normaal aß1-42. Patiënten met normale aß1-42 liquor waarden nabij het afkappunt 
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toonden echter ook een verhoogd risico op het ontwikkelen van AD-dementie. De 
afkapwaarde moet derhalve eerder als een glijdende schaal gezien worden dan een 
hard afkappunt.
Wanneer patiënten bij de eerste meting zowel abnormaal aß1-42 als abnormaal 
tau waarden hadden, vertoonden zij snellere cognitieve en neurodegeneratieve 
achteruitgang dan patiënten met alleen abnormaal aß1-42.
Hiermee toonden we aan dat amyloid nodig is voor het ontwikkelen van AD en tau 
verdere achteruitgang voortzet. 
Voor het betrouwbaar bepalen van een afkappunt van aß1-42 is ‘mixture modelling’ 
een robuuste manier gebleken. Met deze methode waren we, in vergelijking met de 
oude meetmethode, beter in staat om toekomstige ontwikkeling van AD-dementie te 
voorspellen bij niet-demente patiënten. Onze afkapwaarde kwam ook beter overeen 
met de met amyloid-PET-bepaalde afkapwaarde. 
II Gebruik van biomarkers voor klinisch onderzoek en de dagelijkse praktijk
Klinisch onderzoek:
Tot 2010 werden biomarkers met name gebruikt als uitkomstmaat bij interventie 
studies. Met de komst van de onderzoekscriteria en biomarker (met name amyloid) 
gerichte therapie, worden biomarkers in toenemende mate ook gebruikt voor inclusie 
in (geneesmiddel) onderzoek.  Onze studie toonde aan dat het gebruik van biomarkers 
op meerdere manieren klinisch onderzoek zou kunnen helpen. 
Inclusie: 
Het grootste voordeel van het gebruik van biomarkers voor inclusie is de zekerheid 
dat de juiste proefpersonen, met onderliggend AD, geselecteerd worden. Wij toonden 
aan dat wanneer deelnemers bij inclusie aanwijzingen hadden voor zowel abnormaal 
aß1-42 als tau, zij harder achteruit gingen dan deelnemers met alleen abnormaal aß1-
42. Dit heeft tot gevolg dat in de eerste groep minder deelnemers nodig zullen zijn 
om een effect van behandeling aan te tonen.  Anderzijds lijkt het erop dat deelnemers 
met zowel abnormaal aß1-42 als tau zich in een verder stadium van AD bevinden dan 
deelnemers met alleen abnormaal aß1-42. Het is niet ondenkbaar dat therapie in de 
eerste groep minder zal aanslaan dan in de tweede groep. De keuze patienten te 
includeren op basis van alleen aß1-42 of in combinatie met een neurodegeneratieve 
marker zal waarschijnlijk afhangen van verschillende factoren zoals het type interventie, 
het aantal benodigde deelnemers en de duur van de studie.
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Uitkomst: 
De meeste interventie studies in niet-demente AD-patiënten maken gebruik van 
cognitieve tests, cognitieve achteruitgang of dementie als uitkomstmaat. Vanuit 
klinisch perspectief lijkt dit een relevante uitkomst. Echter, bij selectie van preklinische 
of prodromale AD patienten, zullen deelnemers langzaam achteruit gaan. Er zal dus 
een lang vervolg nodig zijn om klinische uitkomstmaten te behalen (5-15 jaar).  In ons 
onderzoek toonden wij aan dat biomarkers de duur van studies twee tot driemaal 
kunnen verkorten. De mate van verandering van biomarkers over de tijd is erg 
afhankelijk van het klinische stadium van AD.  Zo is aß1-42 in liquor afwijkend in de 
preklinische en prodromale fase van AD, maar toont deze geen verdere verandering 
na verloop van tijd, terwijl amyloid PET en tau in liquor dat wel doen. Een abnormale 
waarde van aß1-42 in liquor is derhalve bruikbaar voor het opsporen van preklinische 
en prodromale AD, maar minder bruikbaar als uitkomstmaat, aangezien verdere 
verandering al van nature stagneert. FDG-PET-veranderingen waren zichtbaar in de 
prodromale fase en zijn daardoor bruikbaar in dat stadium. Toename van atrofie op een 
MRI-scan was in elk stadium zichtbaar en de verandering nam met het voortschrijden 
van de klinische stadia alleen maar toe. 
Klinische praktijk
In de klinische praktijk wordt ook in toenemende mate gebruik gemaakt van verlaagd 
aß1-42 voor de diagnostiek van AD. Een abnormale waarde kan bruikbaar zijn om 
meer zekerheid te krijgen over de onderliggende oorzaak van subjectieve klachten en 
MCI en om te bepalen welke patiënten verder vervolgd zouden moeten worden.  Als 
alternatief voor aß1-42 meting in liquor zijn er centra die amyloid–PET-scans gebruiken 
om stapeling van aß1-42 aan te tonen. Het behoeft echter een geoefend oog om 
amyloid-positiviteit vast te stellen. Ook is PET-onderzoek duurder dan bepalingen 
in liquor en hebben niet alle centra de mogelijkheid om een PET-scan te verrichten. 
Het bepalen van een betrouwbare afkapwaarde voor aß1-42 in liquor is echter ook 
uitdagend. Mixture modelling is hierbij een betrouwbare methode gebleken. Een nadeel 
van mixture modelling is echter dat grote groepen met normaal en abnormaal aß1-42 
nodig zijn om een betrouwbare afkap te kunnen berekenen. Dit kan voor kleinere centra 
lastig zijn. Als mogelijke oplossing hiervoor zouden kleinere centra hun liquor naar de 
grotere centra kunnen sturen waar de grote populatie aanwezig is. 
Naast abnormaal aß1-42 kunnen ook markers van neurodegeneratie gemeten 
worden. Wij toonden aan dat wanneer patiënten zowel abnormaal aß1-42 als tau 
hadden, zij harder achteruit gingen.  Te verwachten valt dat deze groep patiënten eerder 
het dementiestadium zal bereiken dan patiënten met alleen abnormaal aß1-42. Nader 
onderzoek en vervolg zal moeten uitwijzen of deze informatie gebruikt kan worden 
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om een betere prognostische voorspelling te doen op individueel niveau. Vanwege 
onzekerheden over de prognose en het gebrek aan behandelmogelijkheden, is het 
van belang patiënten en hun naasten mee te nemen in de beslissing of aanvullende 
diagnostiek gewenst is.  De gegeven informatie zou moeten gaan over de voor-en 
nadelen van aanvullende diagnostiek. Ook moet besproken worden wat een mogelijke 
uitslag is, wat de implicaties daarvan zijn, en wat de mogelijke beperkingen van een 
uitslag zijn. Uiteindelijk zal samen een weloverwogen beslissing genomen moeten 
worden. 
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En dan nu het deel dat door de meeste mensen wèl wordt gelezen.
Geachte professor Scheltens, beste Philip. Het is eindelijk af. Mijn ‘to do’ lijstje kan 
van jouw desktop verwijderd worden. Bedankt dat ik deel uit mocht maken van het 
Alzheimer Centrum. Je hebt een mooi centrum opgezet met een sterk team om je heen. 
Samen zorgen jullie voor een diepe footprint in het internationale Alzheimerveld. Jouw 
vertrouwen in de jonge onderzoekers werkt motiverend. En dat een goede leider ook 
humor mag hebben, laten jij en de andere neurologen binnen het centrum zien. Dit 
maakt de werksfeer ontspannen, zonder dat het afbreuk doet aan de kwaliteit. Kortom, 
een droomplek om te werken. 
Yo PJ! Bij onze eerste ontmoeting wisten wij volgens mij niet zo goed wat we aan elkaar 
zouden hebben en hoe het zou gaan lopen. Gaandeweg kwam ik erachter dat je een 
briljante wetenschapper bent die ook oog heeft voor (klassieke)muziek, funda en 
K3. De sprong in het wetenschappelijke diepe voelde in het begin onzeker, zonder 
duidelijke route. Maar achteraf is dat wat mijn tijd leuk heeft gemaakt. De vrijheid die 
jij mij gaf, maakte ook dat ik delen van mijn papers zelf vorm en inhoud heb mogen 
geven. Dankjewel. 
Dr. Tijms, lieve Betty. Wat leuk dat jij onderdeel bent geworden van mijn promotieteam. 
Met jou erbij zat het tempo er lekker in! Jij hebt de gave om van een moeilijk onderwerp 
iets simpels te maken. Jij en PJ vullen elkaar goed aan en zijn aan elkaar gewaagd. Naast 
de wetenschappelijke kant, vond ik het ook gezellig om over andere dingen in het leven 
te praten onder genot van een biertje. Hopelijk kan dat binnenkort weer. 
Leden van de leescommissie: prof dr. W.M. Van der Flier, prof. dr. C.E. Teunissen, dr. 
W.J. Jansen, prof. dr. C.W. Ritchie, prof. dr H.C. Weinstein, dr. N.D. Prins, dank voor het 
zorgvuldig lezen van mijn proefschrift en uw aanwezigheid tijdens mijn promotie-
ceremonie.
Geachte professor Van der Flier, beste Wiesje, dank voor de afgelopen jaren. Al waren 
wij niet direct bij elkaar betrokken, ik heb veel van je opgestoken. Volgens mij heb jij 
altijd honderden ballen in de lucht te houden, maar heb je het nooit druk. Je verliest 
nooit uit het oog wat je eigen promovendi doen en hebt daarnaast ook nog tijd voor 
die van anderen. 
Daniela_VolledigBinnenwerk_final.indd   198 15-3-2021   10:09:00
199Dankwoord
Geachte professor Teunissen, beste Charlotte. Ook voor jou geldt in mijn ogen dat je 
moeiteloos honderden projecten naast elkaar laat lopen en overal iets vanaf weet. Dank 
voor het kritisch meedenken en input bij het schrijven van ons stuk.
Dr. Jansen, beste Willemijn, jij bent mij voorgegaan in het PJ-team. Ondanks dat we 
beiden in Nederland onderzoek deden, zagen we elkaar met name op congressen in 
het buitenland. En dat is natuurlijk ook leuker. Fijn dat we dit samen kunnen afsluiten.
Prof Ritchie. Thank you for your time and effort in reading and evaluating this thesis. I 
am looking forward to discuss the content.
Professor Weinstein, beste Henry. Wat bijzonder dat je niet alleen mijn opleider bent, 
maar nu ook onderdeel uitmaakt van mijn promotie. Na een wat stroeve start, zijn we 
naar elkaar toe gegroeid met de cognitieve neurologie als gezamenlijke deler. Ook de 
gesprekken over de (klein)kinderen zijn waardevol. Ik bewonder je als persoon en als 
opleider van ons centrum. Knap hoe je het altijd voor elkaar krijgt om de leukste A(N)
IOS-groep samen te stellen. Onder jouw leiderschap zijn wij de beste opleidingsplek 
van Nederland. Iets om trots op te zijn! 
Dr. Prins, beste Niels, ook aan jou veel dank voor de fijne tijd in het Alzheimercentrum 
en het BRC. Jij bent een voorbeeld voor hoe ik als neuroloog zou willen zijn. Je bent 
respectvol en hebt altijd oog voor de patiënt. Doordat je daarin serieus bent, zou 
je bijna vergeten dat jij een heel sterk gevoel voor (droge) humor hebt. Ik heb veel 
met je gelachen. Ook veel dank voor je analytische blik en vernieuwende ideeën. Ons 
gezamenlijke stuk is daardoor mooi geworden.
Lieve AC bunkermatties; Welmoed (Krudop), Sofie (Saffie), Ineke, Argonde (Atanga), 
Marjolein en (collega, vriendin, paranimf) Hanneke. Het is al even geleden, maar ik 
heb hele warme herinneren aan de tijd in bunker 3. Dank voor alle foute grappen 
en goede gesprekken. Grappig hoe zulke verschillende persoonlijkheden een goede 
mix kunnen vormen en kunnen ‘samenwonen’! Buiten de bunker was het ook goed 
vertoeven. Christiane (Chrissie/Möller), Lieke (Smitsie), Marije, Marissa, Betty, Sietske, 
Maja, Rik, Willem, Jeroen, Flora, Astrid, Nicole, Aafke, Annelies, Astrid, Floor, Eva (en 
onderstaanden) en alle anderen die ik (wellicht) vergeet. Dank voor alle koffie en leuke 
tijden op congressen, reisjes en wintersport. En leuk dat ik met sommigen nog steeds 
contact heb. Elles, Nienke, Rosalinde, Annebet, Arno en Lisa dank voor jullie hulp en tips 
bij de laatste loodjes van mijn proefschrift. Pff tis nog best veel werk geweest. 
A
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Beste Yolande, Evelien, Niels en Femke, dank voor de begeleiding tijdens de 
screeningsdagen. Ik heb veel van jullie geleerd.
Inmiddels is er volgens mij weer een shift van personeel geweest, maar het AC zou 
niets zijn zonder Freek, Els (D), Anita, Karin en al het andere ondersteunend personeel, 
psychologen en verpleegkundigen. Dank daarvoor!
Lieve vrienden en vriendinnen. Velen van jullie ken ik al (bijna) mijn hele leven. Bij gebrek 
aan familie in Nederland zijn jullie een heel fijne vervanging hiervan gebleken!
Alida, Hanne (dank voor de mooie cover!), Elze, Lieke, Floris en Dario. Wij gaan heel 
ver terug (in willekeurige volgorde vanaf babytijd, peutertijd, kleutertijd en middelbare 
school). Heerlijk om vrienden en vriendinnen te hebben die je een reële blik op het 
leven geven en je met beide benen op de grond houden (mocht je willen gaan zweven). 
Inmiddels bouwen we geen hutten meer, klimmen wij niet meer op daken, bellen we 
minder vaak (ophangen, nu!), bouwen we geen torens van tosti’s meer en hoef ik niet 
meer thuis gebracht te worden. Maar als wij samen komen, lijkt er toch niets veranderd. 
Mooi hoe we ondanks de fysieke afstand (van sommigen), toch bij elkaar betrokken 
blijven. 
Mijn studietijd heeft mij behalve een bul, ook vriendschappen voor het leven gebracht. 
Dieuwertje, Hanneke, Willeke en Anke, bij jullie kan ik helemaal mijzelf zijn en jullie 
komen heel dichtbij het gevoel van familie. Ook leuk dat onze meiden ‘tantes’ hebben 
bij wie zij zich thuis voelen. En dan de ‘ooms’; lieve Marten, Jelle, Matthijs en Theo, jullie 
vieze en foute humor is onmisbaar. Dank daarvoor ;-). Lieve Nieke, Chiel, Tije, Abel, 
Felien, Nore, Mink, Nils en Jesper, sorry voor die humor.
Lieve Padamay (Pien, Dieuw, Mayo, Mark en Yvonne), mijn studententijd was een stuk 
minder interessant geweest zonder jullie. We hebben samen heel wat pieken en dalen 
meegemaakt, maar vooral heul veul gelachen. Dank daarvoor.
Lieve mama, ‘nadie hace por dinero lo que una mama hace gratis’. En dat geldt zeker 
voor jou. Dank dat je mij zo’n fijne jeugd hebt gegeven met heel veel vrolijkheid, liefde, 
vertrouwen en af en toe een liefdevolle schop onder mijn kont. Dankzij die schop ben 
ik gekomen waar ik ben. Je bent er altijd voor mij geweest en bent er nog steeds. Voor 
mij, voor Rik en voor de meiden. Gracias mamita. 
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Waeil en Abdul, lieve bonus broers, fijn om te zien dat we allemaal goed terecht zijn 
gekomen en mèt gezin! Dat we maar vele mooie herinneringen samen mogen maken. 
Het cliché is waar; liever een fijne buur dan een verre vriend. Ik had mij geen betere 
buurtjes kunnen indenken. Met name het afgelopen jaar heeft dat duidelijk laten zien. 
Dank daarvoor! 
A mi familia en Chile; ¡Gracias por ser parte de mi vida! Nunca voy a olvidar las visitas al 
Morro, los asados, los bailes y los viajes a las termas. Ahora que crecí, me da gusto ver 
que mis hijas también enriquecen su vida con ustedes. Gracias por las conversaciones 
sobre las cosas pequeñas y las cosas grandes de la vida. Aunque hemos tenido que 
despedirnos de algunos de nosotros, la familia sigue creciendo. Esta ‘mata sanos’ los 
quiere mucho.  
Lieve Bert en Ria. Bij jullie heb ik mij vanaf de eerste dag helemaal thuis gevoeld. Ik 
ben ook heel dankbaar dat jullie zo een grote rol in het leven van onze meiden spelen. 
En dat terwijl jullie nooit vast zouden gaan oppassen. Haha! Lieve Eliza, dank voor je 
vriendschap en luisterend oor (en alle abo’s die je uiteindelijk voor iedereen afsluit. 
Haha). Lieve Bert en Femke, dat we maar vele Schier weekendjes mogen houden en 
we samen mooie herinneringen kunnen maken. 
Lieve Rik, met jou ga ik dansend door het leven. Dank voor al je steun, liefde en 
zorgzaamheid. Ik had mij geen betere danspartner kunnen indenken. Jij leidt en 
adviseert waar nodig, maar laat mij ook vrij om mijn eigen moves te doen. Ik hou van 
je. Dat dansen in onze genen zit, is ook aan onze mini’s te zien. 
Lieve Mila, lieve Aylén wat ben ik trots op jullie! Mila, onze vrolijke meid met veel gevoel 
voor fantasie, ritme en mensen. Ik hoop dat je voor altijd zo blijft dansen! Aylén, vanaf 
dag één zagen papa en ik dat je een pittige meid bent die heel goed weet wat ze wil. 
Dat in combinatie met humor en compassie voor en interesse in anderen, maakt jou 
tot een bijzondere kleuter. 
Het leven met jullie is een feestje.  Mama hoeft voorlopig niet meer op zolder te 
vertoeven met haar laptop dus laat die discolamp maar draaien!
A
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Alzheimer’s disease (AD) is the major cause of dementia among patients 
over the age of 65, aecting around 50 million people worldwide 18% of 
persons above the age of 65 and approximately 25% of persons above the 
age of 85 will develop AD. In the Netherlands 280.000 patients currently 
suer from dementia and the number is expected to double in 2040. 
Dementia is the most expensive chronic disease costing our society
annually approximately 9 billion euros, which accounts for 9.5% of our total 
health costs. 70% of patients with dementia live at home with help from 
their caregivers. More than 50% of caregivers experience stress or are at 
increased risk to experience stress in the future. At present, there is no 
cure available. Results of clinical trials in AD dementia patients have been 
disappointing. This is, at least in part, due to the fact that treatment of AD
at the dementia stage is too late. Disease modifying therapy is probably 
most eective when given early in the course of the disease when neuro-
degeneration and cognitive impairment are limited. 
In the past years major advancements have been made in the develop-
ment of AD biomarkers that can be used to assess the key pathologies of 
AD in-vivo. These biomarkers will have a major impact on clinical practice 
and the design of trials for disease modifying treatments.  In this thesis we 
will investigate the implications of the availability of AD biomarkers for the 
design of AD prevention trials and management in clinical practice. Our 
focus is on the role of biomarkers in the diagnosis, prognosis, and disease 
tracking of non-demented subjects. 
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for clinical trial design and clinical practice
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